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This thesis follows the publication thesis format. In fact, chapter 3 comprises a 
manuscript, which is submitted for publication and currently under revision in the peer-
reviewed journal: Aging Cell. I, Noemi Gatto, am the first and primary author of the 
manuscript, and contributed (80%) to the experimental planning, execution, and 
preparation of the research data for publication.  
 
In this thesis, Chapter 1 is dedicated to giving a general introduction to amyotrophic 
lateral sclerosis (ALS), the mechanisms involved in this devastating disease and their 
involvement in ageing. Successively, Chapter 2 summarises the material and methods 
used in chapters 3 and 4. The first results chapter, Chapter 3, presents the results 
demonstrating that the cell model used in this study is able to retain ageing features 
from the human fibroblast donors without inserting any age-causing genetic 
manipulation. In fact, I have shown here that directly derived astrocytes from young 
and old donor skin fibroblasts diverge in a number of age-related signatures, including 
oxidative stress response and nucleocytoplasmic shuttling impairment. These cellular 
functions are particularly relevant when modelling ALS and its disease mechanisms. 
In fact, in chapter 4, I focused on investigating the role of SOD1, a key protein involved 
in the antioxidant response, and its link with nucleocytoplasmic transport in ALS 
patient derived astrocytes. 
Finally, Chapter 5 includes an overall discussion of both results chapters and how they 




ALS is a fatal neurodegenerative disorder, partly understood through studies on the 
first gene associated with familial ALS (fALS), SOD1. Several pieces of evidence 
indicate that misfolded wild-type SOD1 may also play a role in the pathophysiology of 
sporadic ALS (sALS), through different processes, such as misfolding, aggregation 
and prion-like pathogenic behaviour. Moreover, there is evidence indicating that SOD1 
could function as a transcription factor. 
The main risk factor for ALS is ageing; ageing and neurodegeneration share several 
pathways. Remarkably, it has been demonstrated that glial cells change their gene 
expression dramatically during physiological brain ageing. Thus, it is important to have 
these cells suitable for disease modelling, especially in neurodegenerative diseases 
like ALS, in which astrocytes actively contribute to motor neuron death. 
In my study, directly derived astrocytes from young and old donor fibroblasts preserve 
ageing signatures, representing a valuable model to study astrocytic function. To study 
the effect of wild-type SOD1 in fALS and sALS, induced astrocytes from control and 
patient fibroblasts were also generated. Staining for misfolded SOD1 showed nuclear 
aggregation of the protein in sALS astrocytes. This poses a question on the role of 
SOD1 in this cellular compartment. The nuclear presence of SOD1 in patient 
astrocytes was confirmed via cell fractionation, indicating that SOD1 might indeed act 
as a transcription factor or a co-activator. Furthermore, exportin-1 (XPO1) is able to 
shuttle misfolded SOD1 to the cytoplasm as a defence mechanism against toxicity. 
My data show that the expression levels of this protein naturally decrease with age. 
Its levels further decrease in sALS patients compared to controls, consistent with the 
finding of accumulation of misfolded SOD1 in the nucleus. I confirmed the interaction 
between XPO1-SOD1 through a proximity ligation assay. Moreover, a decrease in the 
interaction between XPO1 and misfolded SOD1 was detected in sALS and C9orf72 
ALS cases, in agreement with the higher levels of nuclear SOD1 observed in these 
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“I am among those who think that science has great beauty. A scientist 
in his laboratory is not only a technician: he is also a child placed before 
natural phenomena which impress him like a fairy tale. We should not 
allow it to be believed that all scientific progress can be reduced to 
mechanisms, machines, gearings, even though such machinery also has 
its beauty. 
Neither do I believe that the spirit of adventure runs any risk of 
disappearing in our world. If I see anything vital around me, it is precisely 
that spirit of adventure, which seems indestructible and is akin to 
curiosity” 
(Marie Curie 1867 – 1934)  
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1.1 Amyotrophic lateral sclerosis (ALS) 
ALS is the most common adult-onset motor neuron (MN) disorder. Motor neuron 
diseases (MNDs) are a heterogeneous group of neurological disorders that share the 
predominant loss of motor neurons. ALS accounts for approximately 85-90% of the 
total cases of MNDs and is characterised by loss of both upper and lower MN 
(Rowland and Shneider, 2001). In the United States and Canada, the disease is 
commonly called Lou Gehrig’s Disease, after the name of the famous baseball player 
who developed this disease (Lou Gehrig 1903-1941).  
The pathology is responsible for the loss of skeletal muscle innervation that leads to 
muscular atrophy and paralysis. ALS is a fatal disorder where death is usually caused 
by respiratory failure due to denervation of respiratory muscles within 3-5 years from 
diagnosis (Chiò et al., 2009; Andersen and Al-Chalabi, 2011).  
The vast majority of ALS cases (about 90%) are sporadic (sALS) with no family history 
of the disease, while in 5-10% of cases, the pathology is familial (fALS) and it is caused 
by specific inherited mutations (Kiernan et al., 2011). Remarkably, familial and 
sporadic ALS are for the most part clinically indistinguishable.  
ALS is a rare disease with an average incidence (number of new cases/year) of 1.5-
2.7 per 100,000 inhabitants and an average prevalence (proportion of individuals in a 
population having the disease) which varies from 2.7 to 7.4 per 100,000 (Beghi et al., 
2011; Silani et al., 2011; Chiò et al., 2013). However, its impact is greater, because it 
has been calculated that the life-time risk of ALS is 1 in 400 for women and 1 in 350 
for men (Kiernan et al., 2011). The incidence of ALS is the same worldwide, except 
for some Western Pacific areas where it peaks 50-100 times higher than elsewhere 
(Steele and McGeer, 2008). In fact, there are high incidence foci in the Kii peninsula 
of Japan and the Western Pacific island of Guam. The increased incidence of ALS in 
these areas has been associated with environmental causes, particularly the ingestion 
of a neurotoxic non protein aminoacid, β-N-methyl-amino-l-alanine (BMAA). BMAA is 
in cycad seeds and is produced by cyanobacteria. Furthermore, it is present in brain 
and spinal cord tissues from sporadic ALS and Alzheimer’s disease (AD) patients, but 
the precise involvement of BMAA in the disease is not totally understood (Vyas and 
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Weiss, 2009). This endemic form of ALS is associated with Parkinson's disease and 
dementia and is considered as a distinct disease compared to pure ALS.  
Apart from age (section 1.5), no risk factor has been consistently associated with ALS. 
However, physical trauma and sports activities have been investigated: a higher risk 
of developing ALS was found in Italian professional soccer players (Belli and 
Vanacore, 2005; Chiò et al., 2005), in American football players (Lehman et al., 2012) 
and in military personnel (Beghi and Morrison, 2005). It is hypothesised that in addition 
to physical stress, performance-enhancing drugs, and fertilizers used in playgrounds 
could have an important role (Al-Chalabi and Leigh, 2005; Harwood et al., 2016). 
Moreover, a hypothesis suggests that prenatal exposure to testosterone may play a 
role in the development of the disease (Wicks, 2012); however, the data produced so 
far are not conclusive. 
ALS is heterogeneous in age and site of onset, as well as prognosis. Such diversity 
may depend on genetic and hormonal influences as well as environmental risk factors. 
ALS mainly strikes in adulthood, with a mean age of onset between 55 and 65 years 
and a median onset of 64 years of age (Silani et al., 2011), but there are also rare 
cases of early onset characterised by a different disease course. Patients with an 
onset prior to 41 years show a survival rate three times higher than patients with onset 
after 60 years (Eisen et al., 1993). Clinical manifestations of the disease are indicative 
of degeneration and subsequent death of the motor neurons at all levels (upper and 
lower). The loss of these motor neurons leads to severe muscle atrophy defined as 
denervation atrophy. Early symptoms depend on the body region first affected by the 
disease. The onset is “bulbar” (25% of patients) in the case of speech and swallowing 
muscles being initially affected. When symptoms begin in the arms or legs (upper 
and/or lower extremities), it is referred to as “limb onset” ALS (75% of patients) 
(Kiernan et al., 2011). The degeneration of upper or lower MN leads to different 
symptoms in bulbar or limb onset patients. Limb onset disease is normally associated 
with weakness, lack of coordination and spasticity determined by upper MN 
alterations, while the loss of lower MN induces muscle wasting and fasciculation. In 
bulbar onset cases, the spastic dysarthria is attributed to upper MN degeneration, 
while dysphagia, atrophy of the tongue and fasciculation result from the loss of lower 
MN in the cranial nuclei of the brainstem.  
Two rating scales are used in clinical practice for assessing ALS disease progression: 
the revised ALS Functional Rating scale (ALSFRS-R) and the Appel ALS rating scale 
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(AALS) (Cudkowicz, Qureshi and Shefner, 2004).The most frequently used is 
ALSFRS-R. 
To date, there is no effective drug treatment for ALS. Riluzole and Edaravone are the 
only drugs approved by the US Food and Drugs Administration (FDA), providing 
modest benefits only in some patients (Petrov et al., 2017; Sawada, 2017). Riluzole 
may reduce the loss of MN (Kalra et al., 1998) and extend lifespan by about 3-6 
months (Miller, Mitchell and Moore, 2012). Its mechanism of action remains obscure 
since it has many different targets. Among its effects are inhibition of voltage-gated 
Na+ currents at the pre-synaptic terminal; inhibition of glutamatergic transmission both 
at presynaptic and postsynaptic levels; interaction with other types of ion channels 
(Ca2+ and K+) and increased production of brain derived neurotrophic factor (BDNF) 
(Bellingham, 2011). Edaravone is an intravenous drug approved in May 2017 after a 
Phase 3 clinical trial in Japan, that showed its ability to slow decline in the daily 
ALSFRS, potentially by reducing oxidative stress (Hardiman and van den Berg, 2017). 
More than 500 compounds with potential neuroprotective effects have been studied, 
which include: anti-oxidants, anti-excitotoxic agents, inhibitors of apoptosis, anti-
inflammatory agents, neurotrophins, chelators of metal ions and modulators of ion 
channels. Unfortunately several drugs, which showed some benefits in animal models 
of ALS, did not show efficacy in human clinical trials (Carrì, Grignaschi and Bendotti, 
2006). Various reasons can account for this lack of translation: the non-physiological 
levels of mutant protein overexpressed by the mouse model, the genetic and 
phenotypic heterogeneity of patients, the difficulty in establishing patient-relevant 
pharmacokinetic parameters in order to replicate the same biological activity in 
humans, the different disease time points at which the treatment was started, and the 
limitations of the mutant SOD1 model in reproducing the heterogeneity of the various 
ALS forms (Carrì, Grignaschi and Bendotti, 2006; Benatar, 2007; Oliveira and Pereira, 
2009).  
Furthermore, approximately 5% of patients with ALS fulfil the consensus criteria for 
definite or probable fronto-temporal dementia (FTD) (Kiernan et al., 2011) and up to 
50% may have some evidence of altered fronto-temporal function on detailed 
neuropsychological testing. Recent genetic discoveries, which have linked mutations 
in chromosome 9 open reading frame 72 (C9ORF72) and TAR DNA binding protein 
43 (TARDBP) to both ALS and FTD, have highlighted how these two pathologies 
belong to the same disease spectrum.  
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This further adds to the complexity of ALS and translation from animal models to 
patients. 
 
1.1.1 ALS genetics 
ALS is considered a multifactorial disease due to the interplay between genetic and 
environmental factors. Most ALS cases (about 90%) are sporadic (sALS) with no 
family history of the disease, while in 5-10%, the pathology is familial (fALS) and it is 
caused by specific inherited mutations (Kiernan et al., 2011). FALS is characterized in 
most cases by an autosomal dominant transmission with age dependent penetrance 
(Al Sultan et al., 2016), but recessive and X-linked forms have also been described 
(Chen et al., 2013). The clinical phenotype of fALS and sALS is usually 
indistinguishable, but fALS is usually characterized by an earlier age at onset 
compared to sALS. Moreover, familial patients show an equal male/female ratio and 
in general a longer disease duration; whereas sALS is commoner in males, with a 
male/female ratio of 1.5/1 (Manjaly et al., 2010; Ticozzi et al., 2011).  
  
1.1.1.1 Familial ALS (fALS)  
Each new gene (Table 1.1) that is linked to ALS aetiology provides important 
information on the involvement of specific pathogenic mechanisms, consequently 
attracting a lot of interest in the identification of new gene mutations.  
Molecular genetic techniques, such as genome-wide association studies and next-
generation sequencing, have contributed to the understanding of the genetic causes 
of fALS with approximately 60-70% of cases accounted for by variants in known ALS-
linked genes (Renton, Chiò and Traynor, 2014; Zou et al., 2017). The most frequent 
pathogenic variants are present in SOD1 (~20% fALS), C9ORF72 (~40% fALS), FUS 
(~4% fALS) and TARDBP (~5% fALS) (Boylan, 2015; Al Sultan et al., 2016). Given 
the central role of SOD1 in my thesis, the function of this protein in ALS is going to be 
described in section 1.3. C9orf72 genetic mutations were first observed in 2011 in 
patients with FTD, and subsequently in ALS patients (DeJesus-Hernandez et al., 
2011; Renton et al., 2011). This represents the most common inherited cause of ALS 
in European populations, approximately 34-40% of fALS cases (Zou et al., 2017). 
TDP-43 was identified by histological studies as a main component of cytosolic 
inclusions in FTD and ALS patients (Arai et al., 2006; Neumann et al., 2006) and it is 
now considered a pathological hallmark of ALS, being present in the majority of ALS 
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patients including cases without mutations in TARDBP (Giordana et al., 2010; 
Schipper et al., 2016; Takeuchi et al., 2016). To date, around 50 variants in TARDBP 
have been described in ALS (Lattante, Rouleau and Kabashi, 2013). Notably, 
dominant mutations were identified as a primary cause of ALS (Kabashi et al., 2008; 
Sreedharan et al., 2008; Yokoseki et al., 2008). FUS pathogenic variants were 
identified in 2009, in a subset of ALS patients (Kwiatkowski et al., 2009; Vance et al., 
2009). Interestingly, mutations in FUS often lead to an early onset form of ALS (Hübers 
et al., 2015; Gromicho et al., 2017; Zou et al., 2017). More details on aberrant 
pathogenic variants and their disease related mechanisms will be discussed in the 
following sections of this thesis. 
The genes associated with ALS can be linked into functional groups: such as RNA 
metabolism, protein quality control system (including autophagy, molecular 
chaperones and proteases) and endosomal trafficking. These main pathways have 
been found to be dysregulated not only in patients carrying specific mutations, but also 
in samples from sALS patients.  
 
Table 1.1 Altered pathways and genetic determinants identified so far in ALS and 
respective subtypes of ALS  
Autosomal dominant (AD); Autosomal recessive (AR), X-linked (XD) 
Pathway ALS type Gene (protein) Inheritance Reference 




AD or AR (Rosen et 
al., 1993) 
RNA metabolism ALS4 SETX (Senataxin) 
 
AD (Suraweera 
et al., 2007) 
ALS6 FUS (RNA-binding 
protein FUS) 
 
AD or AR (Kwiatkows




ALS9 ANG (Angiogenin) AD (Greenway 
et al., 2006) 
 6 




et al., 2008; 
Sreedharan 
et al., 2008; 
Kabashi et 
al., 2009) 







AD (Kim et al., 
2013) 
ALS21 MATR3 (Matrin 3) AD (Johnson, 




ALS-FTD1 C9orf72 (Guanine 
nucleotide exchange 
chromosome 9 open 

















ALS2 ALS2 (Alsin) 
 





AD (Chow et 
al., 2009) 













et al., 2004; 
Gkogkas et 
al., 2008; 







ALS12 OPTN (Optineurin) AD or AR (Maruyama 





















XD (Deng et al., 
2011) 














ALS18 PFN1 (Profilin 1) AD (Wu et al., 
2012) 
ALS22 TUBA4A (Tubulin 
a4A) 















ALS19 ERBB4 (Receptor 
tyrosine-protein 
kinase erbB 4) 
AD (Takahashi 
et al., 2013) 
Unknown ALS3 Unknown AD (Hand et al., 
2002) 
 
ALS7 Unknown AD (Sapp et al., 
2003) 
 
1.1.1.2 Sporadic ALS (sALS) 
Although the aetiology of sALS is largely unknown, genetic factors contribute to its 
pathogenesis. In some sALS cases gene changes highlighted in Table 1.1 can be 
found. Mutations in the genes listed in Table 1.2 can lead to ALS interacting with other 
genetic or environmental risk factors (Schymick, Talbot and Traynor, 2007) however, 
sALS cases bearing particular genetic variants represent only a small proportion of the 
sALS cases (20%). The reason may be attributable to an inheritance complex pattern 
of low penetrance; a high level of heterogeneity and/or the existence of other 
predisposing factors.  
 
Table 1.2 Susceptibility genes for sporadic ALS (sALS) 
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1.1.2 Pathogenic mechanisms 
ALS is a multifactorial disease, with involvement of several cell types and pathogenic 
mechanisms (Ferraiuolo et al., 2011). Although in vivo (Yamanaka et al., 2008; Hooten 
et al., 2015) and ex vivo (Ferraiuolo et al., 2007; Nardo et al., 2013) studies have 
indicated that not all pathways and cell types are involved in disease pathology at 
once, the exact sequence of events involved in disease onset, progression and end 
stages is yet to be unravelled. Nevertheless, it is clear that the interplay between 
various factors and cell types plays an important role in the presentation of disease 
symptoms and progressive degeneration of MN (Figure 1.1). In the following sections, 
I will give a brief overview of the main pathways associated with the pathophysiology 





Figure 1.1 Molecular mechanisms of motor neuron injury in ALS  
Several cell types and mechanisms are involved in ALS. Astrocytes contribute to motor 
neuron injury through different pathways: release of inflammatory mediators, reduced 
expression and activity of the glutamate reuptake transporter excitatory amino acid 
transporter 2 (EAAT2); reduced lactate release; and activation of pro-NGF–p75 
receptor signaling, while microglia activate an inflammatory response. Transcriptional 
dysregulation and altered RNA processing may occur in motor neuron themselves, 
that together with overproduction of reactive oxygen species (ROS) contributes to 
aberrant protein folding. This can lead to the formation of aggregates and 
subsequently to proteasome impairment and ER stress. Eventually autophagy and 
apoptotic pathways are activated. The activation of apoptosis is also determined by 
mitochondrial impairment and dysregulation of calcium homeostasis. Axonal transport 
is also impaired which may contribute to an energy deficit in the distal axon.  
 
ER, endoplasmic reticulum; IL, interleukin; MCP-1, monocyte chemoattractant protein 
1; NGF, nerve growth factor; NO, nitric oxide; PGE2, prostaglandin E2. 
  
(Ferraiuolo et al. 2011 Nature Reviews Neurology) 
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1.1.2.1 Oxidative stress 
One of the first pathways investigated in ALS was oxidative stress, due to the 
identification of ALS-causing mutations in SOD1, an anti-oxidant enzyme, in 1993 
(Rosen et al., 1993). ROS are produced by aerobic metabolism and they can 
potentially damage cells by oxidizing many biomolecules, such as DNA, proteins and 
lipids. It is well known that prevention of the activation of this deleterious pathway 
involves antioxidant agents in the removal of these reactive species. Biochemical 
markers of oxidative stress are present in post-mortem tissues from patients affected 
by several neurological diseases, including ALS (Islam, 2017). Oxidative stress results 
from an imbalance between the production of oxidant species, such as reactive 
oxygen (ROS), nitrogen (RNS) species and hydrogen peroxide (H2O2) and the cellular 
antioxidant mechanisms that remove them, including the SOD1 enzyme. An increase 
of oxidative damage markers has been reported in both sALS and fALS patients 
(Shibata et al., 2001; Nardo et al., 2009; Lopez-Gonzalez et al., 2016) as well as in 
mouse models of the disease (Casoni et al., 2005; Nardo et al., 2009). Oxidative 
damage has been observed not only in neurons, but also in glial cells in post-mortem 
tissues from ALS patients (Shibata and Kobayashi, 2008). Indeed, a recent study 
reported induced pluripotent stem cells (iPSC) derived astrocytes carrying C9orf72 
mutations to be toxic to MN through soluble factors, downregulating the secretion of 
various antioxidant proteins (Birger et al., 2019). Moreover, in a mouse study, 
conditioned medium derived from astrocytes expressing mutated SOD1 or TARDBP 
has been shown to induce rapid oxidative stress and extensive spinal MN death within 
few days (Rojas et al., 2014). This evidence suggests that the oxidative stress pathway 
may play a role in multiple disease genotypes. Indeed, oxidative stress may lead to 
loss of MN through several mechanisms, including mitochondrial damage, deleterious 
post-translational changes to proteins, cytoskeleton alterations, glial activation and 
release of pro-inflammatory cytokines and DNA/RNA oxidation (Banati et al., 1993; 
Crow et al., 2002; Rao, Yin and Weiss, 2003; Barber and Shaw, 2010).  
 
1.1.2.2 Dysregulation of proteostasis 
Protein misfolding is also one of the hallmarks of ALS. This process occurs 
physiologically in the cell, however, it is ameliorated through several mechanisms, 
such as the action of molecular chaperones, the ER-associated protein degradation 
(ERAD) and the ubiquitin-proteasome system (UPS). These and other mechanisms 
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work synergistically with each other and the impairment of one of these pathways may 
lead to protein accumulation. Extra and intracellular proteinaceous inclusions 
containing misfolded and abnormal ubiquitinated proteins are features of both sALS 
and fALS (Migheli et al., 1990; Kato, 1999) and they are also observed in the spinal 
cord of SOD1 G93A mice (Stieber, Gonatas and Gonatas, 2000; Cheroni et al., 2005, 
2009). Inclusions contain different proteins, such as SOD1, ubiquitin, chaperones 
(Watanabe et al., 2001), TDP-43 (Sanelli et al., 2007), dorfin (a ubiquitin ligase) 
(Hishikawa et al., 2003), neurofilaments and p38-MAPK (Bendotti et al., 2004). 
Alterations of the ubiquitin-proteasome system and insufficient levels of chaperone 
proteins in the ER contribute to protein aggregation (Cheroni et al., 2009) and protein 
aggregates may exert toxic effects by sequestering important key cellular elements.  
In this regard, in 2006, TDP-43 was identified as a key component of the insoluble and 
ubiquitinated inclusions in the brains of ALS and FTD patients (Arai et al., 2006; 
Neumann et al., 2006). Strikingly, aggregation of TDP-43 is present in ~97% of the 
ALS cases and ~45% of all FTD cases (Ling, Polymenidou and Cleveland, 2013; Tan 
et al., 2017). However, it is still controversial whether TDP-43 pathology occurs in 
SOD1-ALS (Arai et al., 2006; Mackenzie et al., 2007; Robertson et al., 2007; Turner 
et al., 2008; Shan, Vocadlo and Krieger, 2009; Mackenzie, Rademakers and 
Neumann, 2010). Several studies in SOD1 mice reported there is no redistribution of 
TDP-43 (Robertson et al., 2007; Turner et al., 2008), and only a few studies have 
reported a low number of SOD1-related fALS cases displaying TDP-43 cytoplasmic 
inclusions (Neumann et al., 2006; Tan et al., 2007). This evidence has led to the 
conclusion that patients with SOD1 mutations do not have the typical TDP-43 
proteinopathy which characterises most cases of ALS. Patients carrying SOD1 
mutations, in fact, display SOD1 cytoplasmic inclusions the pathological impact of 
which will be reviewed in more detail in section 1.3.2.2. 
 
1.1.2.3 Excitotoxicity 
Another pathway associated with ALS is excitotoxicity, caused by glutamate 
accumulation at the synapse. Glutamate is the main excitatory neurotransmitter in the 
central nervous system (CNS), through activation of ionotropic and metabotropic 
postsynaptic receptors. The excitatory signal terminates when glutamate is removed 
from the synaptic cleft by transporters, such as the excitatory amino acid transporter 
2 (EAAT2, SLC1A2 or GLT1). Excessive levels of synaptic glutamate cause 
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glutamate-induced excitotoxicity. Support for this toxic mechanism in ALS has been 
provided by human and animal studies (Trotti et al., 1999; Boillée, Vande Velde and 
Cleveland, 2006). In fact, increased glutamate levels in cerebrospinal fluid (CSF) were 
reported in ALS patients (Rothstein et al., 1991; Shaw et al., 1995) and reduced 
expression and activity of the astrocyte excitatory amino acid transporter 2 (EAAT2) 
were detected in post-mortem motor cortex and spinal cord of ALS patients (Lin et al., 
1998). In a transgenic SOD1 mouse model increased glutamate release from nerve 
terminals in mutant SOD1 mice  was observed (Trotti et al., 1999; Milanese et al., 
2011). Glutamate-mediated excitotoxicity leads to a cascade of cellular events and 
pathway dysregulation well characterised in ALS, including abnormal calcium influx in 
MN, Ca2+ overload of mitochondria and alteration of ER storage ability, activation of 
protein kinases, phospholipases and nitric oxide synthase and free radical production. 
Further supporting a pathogenic role of glutamate in ALS is the neuroprotective action 
of the anti-glutamate agent Riluzole (Miller et al., 2002). 
 
1.1.2.4 Mitochondrial dysfunction  
Mitochondrial dysfunction is also considered a potential pathogenetic factor involved 
in the aetiology of ALS. Mitochondria are important organelles playing a key role in the 
production of cellular energy as adenosine triphosphate (ATP), but they are involved 
in other essential functions such as regulation of calcium homeostasis, steroid 
metabolism and apoptosis regulation. Morphological and functional defects in 
mitochondria were found in both human MN from ALS patients (Sasaki, Horie and 
Iwata, 2007) and ALS cell and animal models (Hong et al., 2012; Magrané et al., 2014). 
In particular, in mice overexpressing mutant SOD1, it has been consistently found that 
mitochondria are less elongated and more spherical in MN (Higgins, Jung and Xu, 
2003; De vos et al., 2007; Vande Velde et al., 2011). Moreover, mutant SOD1 was 
found to be associated with mitochondria. In fact, SOD1 aggregates have been found 
in the intermembrane space of mitochondria in MN of various mouse models and in 
ALS patients (Higgins, Jung and Xu, 2003). Misfolded SOD1 protein aggregates impair 
mitochondrial function by firstly damaging the mitochondrial membrane and secondly, 
leading to the loss of mitochondrial membrane potential, swelling of the organelle and 
excess superoxide production (Pasinelli et al., 2004; Pickles et al., 2013, 2016). 
Another ALS-associated protein, TDP-43 has been shown to interact with 
mitochondria (Wang et al., 2016). Mutant TDP-43 accumulation occurs in 
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mitochondria, possibly mediated by internal mitochondrial targeting sequences in 
TDP-43 (Wang et al., 2016). In this organelle, TDP-43 may directly affect the 
regulation of mRNA coding for proteins involved in mitochondrial physiology, altering 
the mitochondria dynamics (Wang et al., 2013). Mitochondria produce ATP via 
oxidative phosphorylation, an essential substrate for cellular metabolism. Alteration in 
energy homeostasis and ATP deficits have been observed in skeletal muscle biopsies 
from ALS patients. Evidence confirmed a reduction in the activity of respiratory chain 
complexes I, II, III and IV in post-mortem spinal cord of sALS patients (Borthwick et 
al., 1999; Wiedemann et al., 2002), this is linked with defective energy metabolism 
(Pasinelli and Brown, 2006). Mutant SOD1 also affects the electron transport chain 
(ECT) (Vijayvergiya et al., 2005; Ferri et al., 2006), leading to a decreased production 
of ATP (Mattiazzi et al., 2002; Knott et al., 2008). Impaired mitochondrial respiration 
and ATP production have also been seen in models of non-SOD1 related familial ALS 
(Duan et al., 2009; Hong et al., 2012; Wang et al., 2013). Furthermore, mitochondria 
in MN are responsible for buffering cytosolic calcium levels. Calcium represents one 
of the main intracellular messaging systems, regulating synaptic transmission, 
neuronal development and metabolic pathways. It has been reported that mutant 
SOD1 affects calcium homeostasis and in general, intracellular calcium homeostasis 
is altered in ALS patients, with lower calcium buffering ability being a significant risk 
factor for MN damage (Alexianu et al., 2000; Beers et al., 2001; Jaiswal, 2013). Lastly, 
several studies confirmed the disruption of axonal transport of mitochondria in ALS 
patients (Borthwick et al., 1999; Mórotz et al., 2012). Indeed, axonal transport 
impairment alters the degradation and recycling processes of damaged mitochondria, 
leading to higher levels of disrupted mitochondria at the distal axon, with alterations in 
both anterograde and retrograde transport of mitochondria (De vos et al., 2007; 
Magrané and Manfredi, 2009; Shi et al., 2010). Conclusively, all these studies show 
that mitochondrial dysfunction is a critical feature of the pathophysiology in ALS. 
However, it is not clear whether mitochondrial dysfunction is a primary event or 
whether it occurs secondary to other cellular processes that lead to neuronal injury. 
 
1.1.2.5 Axonal and cytoskeletal dysfunction  
The transport of molecules and organelles in neurons is highly organized to be able to 
reach the axon terminus that might be located one metre away from the cell body in 
the case of motor neurons. Neurofilaments (Nf) are specific intermediate filaments of 
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neuronal cells that allow the transport of proteins synthesized in the cell body and 
directed towards the neuromuscular junction (NMJ) (anterograde transport) or 
substances, such as trophic factors, directed toward the cell body (retrograde 
transport). Nf accumulation in cell bodies and proximal axons of MN have been 
described in sALS and fALS patients (Hirano et al., 1984). Remarkably, cytoskeletal 
disorganization and inhibition of axonal transport due to the presence of SOD1 
aggregates was also found in SOD1 transgenic mice (Borchelt et al., 1998; Ligon et 
al., 2005). Furthermore, increased Nf levels are found in the CSF of ALS patients 
(Tortelli et al., 2012) and Nf accumulation in degenerating axons and an altered axonal 
transport are present in fALS mice (Ligon et al., 2005; Perlson et al., 2009; King et al., 
2012). Importantly, it has been shown that Nf heavy (NfH) and light (NfL) chain levels 
reflect neuronal injury and therefore can represent a valuable biomarker in ALS. In 
particular, in CSF the phosphorylated form of NfH level seems to be the most accurate 
diagnostic marker for ALS, while both phosphorylated and non-phosphorylated Nf in 
serum or plasma could predict survival and disease progression (Poesen and Van 
Damme, 2019). Overexpression of NfH provokes MN axonal defects with Nf inclusions 
in mice, which can be rescued by NfL overexpression (Meier et al., 1999), thus 
suggesting that an imbalance in the stoichiometry of Nf subunits may be important. 
Consistent with this hypothesis, decreasing NfL levels and overexpression of NfH 
levels in the SOD1 mouse model of ALS, increased the survival of these animals 
(Couillard-Després et al., 1998; Williamson et al., 1998). In this mouse model, MN 
degeneration is generally accompanied by a progressive increase in blood Nf levels, 
correlating with treatment responses (Boylan et al., 2009; Lu et al., 2012). A defect in 
axonal transport is one of the earliest events seen in ALS, though it still unclear if this 
is causative for disease. 
 
1.1.2.6 Aberrant RNA metabolism 
The identification of ALS-causing mutations in two RNA binding proteins: TDP-43 and 
FUS/TLS has led to hypothesis that alterations in the RNA processing pathway may 
represent an important pathogenic mechanism in ALS (Blitterswijk and Landers, 
2010). The specific role of these two proteins is not fully understood, but both are 
multifunctional proteins that are involved in different steps of gene 
expression/regulation including RNA splicing, transcription, translation and RNA 
transport. TDP-43 is a ubiquitous protein that contains two RNA-binding protein 
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domains, nuclear import and export signals and a glycine-rich domain (Lagier-
Tourenne, Polymenidou and Cleveland, 2010). Normally TDP-43 functions as a shuttle 
between the cytoplasm and nucleus (Ayala et al., 2008; Lagier-Tourenne, 
Polymenidou and Cleveland, 2010). Fused in sarcoma (FUS) mutations as a cause of 
ALS were discovered shortly after the identification of TARDBP (Kwiatkowski et al., 
2009; Vance et al., 2009). Similar to TDP-43, FUS/TLS is mainly nuclear but binds 
RNAs and shuttles between the nucleus and cytoplasm (Zinszner et al., 1997). 
The hypothesis was put forward that ALS-causing mutations in TARDBP and FUS 
lead to a toxic gain of function when their respective products form cytoplasmic 
aggregates (Lagier-Tourenne, Polymenidou and Cleveland, 2010). Moreover, TDP-43 
and FUS/TLS have been associated with stress granules, which are protein-RNA 
complexes that reversibly form under stress (Bosco et al., 2010; Liu-Yesucevitz et al., 
2010; Sama et al., 2013; Walker et al., 2013). In ALS pathology, stress granules act 
as hubs that may facilitate toxic protein aggregation (Chen and Cohen, 2019; 
Baradaran-Heravi, Van Broeckhoven and van der Zee, 2020). The other 
complementary, non-exclusive hypothesis, is that TDP-43 and FUS aggregates lead 
to a loss of function, as consequence of their nuclear depletion, this causes loss of 
correct splicing in the nucleus, aberrant transcripts and loss of normal shuttling 
between nucleus and cytoplasm (Ishigaki and Sobue, 2018; Prasad et al., 2019).  
 
The noncoding GGGGCC (G4C2) hexanucleotide repeat located in the first intron of 
C9orf72 has gained importance in ALS research. The repeat expansion counts for a 
significant percentage, around 40% of fALS, and around 25% of familial FTD cases 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011; Majounie et al., 2012). 
Moreover, it has been found that around 7% of apparently sALS cases in European 
populations carry mutations in C9orf72. Three competing but non-exclusive disease 
mechanisms have been proposed: loss of function of the C9orf72 protein, toxic gain 
of function from C9orf72 repeat RNA foci or from dipeptide repeat proteins (DPRs), 
poly-GA, poly-GP, poly-GR, poly-PA and poly-PR, produced by repeat-associated 
non-ATG (RAN) translation (Ash et al., 2013; Gendron et al., 2013; Mori, Arzberger, 
et al., 2013; Mori, Weng, et al., 2013; Zu et al., 2013). The reduction of C9orf72 protein 
level may cause inhibition of endosomal trafficking and the perturbation of 
endocytosis, leading to autophagy (Farg et al., 2014; Waite et al., 2014; Nassif, 
Woehlbier and Manque, 2017). Alterations in protein homeostasis are reviewed in 
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section 1.1.2.2. However, C9orf72 conditional knockout in mice does not cause motor 
neuron degeneration or motor deficits, indicating that a loss of C9orf72 function by 
itself was not sufficient to cause motor neuron disease (Koppers et al., 2015). 
Moreover, it has been reported that haploinsufficiency for C9orf72 activity contributes 
to neurodegeneration in C9orf72 ALS patients, this may be explained by the 
accumulation of glutamate receptors, causing excitotoxicity and impaired clearance of 
misfolded proteins and neurotoxic DPRs (Shi et al., 2018). This suggests a synergism 
between gain and loss of functions in C9orf72 ALS. 
Like the other repeat expansion diseases, RNA binding proteins (RBPs) can be 
sequestered by RNA foci, leading to downstream consequences. For example, the 
interaction with heterogeneous nuclear ribonucleoprotein hnRNP-H and multiple RNA 
transcripts, lead to important dysregulation of RNA processing (Lee et al., 2013). 
Additionally, this G4C2 expansion mutation can be transcribed in both sense and anti-
sense directions, generating DPRs identified in the p62-positive aggregates in the 
CNS of C9orf72-ALS patients (Gendron et al., 2013; Mann et al., 2013; Zu et al., 2013). 
The exact role of DPRs and RNA foci toxicity in C9orf72-associated pathophysiology 
remains controversial, but it is becoming clear that they have detrimental effects on 
nucleolar function and RNA metabolism (Barker et al., 2017). 
 
1.2 Non cell autonomous effects 
ALS is a "non cell autonomous" disease with evidence that other cells, such as 
astrocytes, oligodendrocytes, peripheral glial cells (i.e. Schwann cells) and cells of the 
immune system (macrophages, T lymphocytes), have an important role in the 
neurodegenerative process. Microglia and astrocyte activation and infiltrating T cells 
and dendritic cells have been extensively documented in post-mortem CNS tissues of 
ALS patients (Troost et al., 1989; Troost, van den Oord and Jong, 1990; Kawamata et 
al., 1992; Henkel et al., 2004). In addition, a substantial loss of interneurons has been 
reported in the spinal cord (Stephens et al., 2006), indicating that motor neurons are 
not the only neuronal population affected in this area of the CNS. Moreover, at the 
peripheral level, skeletal muscles are dramatically affected even at the earliest stage 
of the disease and undergo massive atrophy and several additional alterations (Léger 
et al., 2006; Yin et al., 2012). However, the involvement of the skeletal muscle in ALS 
is still controversial, as, despite early alterations, several studies suggest that these 
changes are only a secondary effect resulting from denervation (Miller et al., 2006; 
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Dobrowolny et al., 2008). In particular, the use of a deletable mutant gene to reduce 
mutant SOD1 from muscle did not provide any benefit in slowing disease onset or 
progression (Miller et al., 2006). Of relevance in this context, genetic studies focusing 
on expression or repression of mutant SOD1 in selected cell types have helped us 
understand the role and interplay between different non-neuronal cells. For example, 
gene mutations leading to human fALS, cause ALS-like disease in animal models only 
if expressed both in neurons and glial cells. Attempts to generate disease from 
selective mutant SOD1 expression only in MN failed. Furthermore, the silencing of 
mutant SOD1 only in MN induced a moderate effect on onset (delay of 20%) without 
interfering with the progression of the disease (Boillée et al., 2006), while silencing of 
mutant SOD1 selectively in glial cells affected disease progression without altering 
onset (Yamanaka et al., 2008).  
In vitro studies have clearly demonstrated that human astrocytes (Haidet-Phillips et 
al., 2011; Meyer et al., 2014; Re et al., 2014) and oligodendrocytes (Ferraiuolo et al., 
2016) from fALS and sALS cases, as well as primary murine microglia (Frakes et al., 
2014) not only are active players in disease progression in the presence of an injured 
neuron, but they can in fact actively induce death of healthy motor neurons. To date, 
how the non-neuronal cells induce toxicity remains incompletely understood. 
However, several hypotheses involving metabolic support, inflammation and 
glutamate toxicity, have been put forward. Due to the focus of this thesis, I will mainly 
concentrate on the contribution of astrocytes and microglia to the disease rather than 
other non-neuronal cells. 
 
1.2.1 Astrocytes  
Astrocytes are a large group of glial cells, necessary for homeostasis, defence and 
regeneration of the CNS (Burda and Sofroniew, 2014). The loss of neuroprotective 
functions and the gain of a neurotoxic function are two possible roles that astrocytes 
can assume in the pathophysiology of ALS. Astrocytes of spinal and cortical areas that 
show motor neuron degeneration, exhibit a selective loss or dysfunction of glutamate 
transporters, suggesting a contribution of glutamate-mediated excitotoxicity in 
neuronal death (Maragakis and Rothstein, 2006; Rattray and Bendotti, 2006). Indeed, 
one of the first pieces of evidence of glial dysfunction in human patients and in animal 
models of ALS came from observation of marked decrease in the expression of EAAT2 
(called GLUT-1 in rodents) in the motor cortex and spinal cord, in mouse models as 
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well as in both familial and sporadic ALS patients (Rothstein, Martin and Kuncl, 1992; 
Bruijn et al., 1997). Molecular knockdown of this astroglial protein also induced MN 
degeneration and paralysis (Rothstein et al., 1996). In this regard, β-lactam antibiotics 
have been identified as potential therapeutic molecules and they can stimulate the 
expression of glutamate transporters in astrocytes, thereby increasing the absorption 
and reducing the neurotoxic action of glutamate in animal models of ALS and 
ischaemia (Rothstein, Martin and Kuncl, 1992; Rothstein et al., 2005). Remarkably, it 
has been shown that transplantation of healthy astrocytes has neuroprotective effects 
in murine models of ALS, suggesting that this may represent a potential therapeutic 
strategy (Lepore et al., 2008). On the other hand, however, it can be observed that 
astrocytes may have a neurotoxic effects in ALS. It has been shown, in fact, that the 
expression of mutant SOD1 (mSOD1) exclusively in astrocyte cells accelerates the 
progression of the pathology (Yamanaka et al., 2008) through the production of soluble 
molecules that have a toxic effect on motor neurons, but not on the interneurons of the 
spinal cord. The molecular mechanisms of toxicity are not entirely clear (Nagai et al., 
2007; Di Giorgio et al., 2008). It has also been demonstrated that transplantation of 
glial precursors expressing mSOD1 into the spinal cord of wild-type mice, is able to 
induce the degeneration of motor neurons and activate the surrounding microglia 
(Papadeas et al., 2011). Astrocyte characteristics change in the presence of mSOD1 
and, as mentioned before, they contribute to motor neuron degeneration (Ferraiuolo 
et al., 2011). Noticeably, decreased metabolic support from lactate release and 
activation of the p75 receptor signalling pathway appear to be important players in 
astrocyte toxicity. Removal of the astrocyte toxicity could be obtained by increasing 
lactate provision to motor neurons, reducing NGF levels, or blocking the p75 receptor 
(Ferraiuolo et al., 2011; Madji Hounoum et al., 2017). When astrocytes encounter any 
biological risk in their immediate proximity, they become reactive and increase the 
expression of some astrocyte markers, such as the glial fibrillary acidic protein 
(GFAP), in a process termed astrogliosis. Astrogliosis has been detected both in 
human and rodent ALS models (Schiffer et al., 1996; Levine et al., 1999). Interestingly, 
downregulation or knockout of the master regulator of inflammation, NfκB, in 
astrocytes resulted in no significant beneficial effect in the mouse model of ALS 
(Crosio et al., 2011) or in in vitro assays (Frakes et al., 2014). On the contrary, both in 
vivo and in vitro studies have shown that inhibition of NfκB in microglia results in 
significant improvement in survival and delay in disease progression (Frakes et al., 
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2014). These results suggest that the timing and the inflammatory response of 
different cell types has a great impact on ALS disease progression and proposed anti-
inflammatory therapies will have to be carefully aimed in terms of timing. 
 
1.2.2 Microglia  
Microglia release a full range of pro-inflammatory versus anti-inflammatory cytokines 
and chemokines when encountering any potential hazard. They will react through the 
release of pro-inflammatory factors, e.g. interleukin 1beta (IL-1β), tumour necrosis 
factor alpha (TNFα), nitric oxide (NO) and interferon gamma (IFN-γ), which remove 
and/or confine biological risks. This phenotype is also called “classically activated” or 
M1. An alternative phenotype release anti-inflammatory factors, e.g. insulin growth 
factor 1 (IGF-1), interleukin 4 (IL-4) and IL-10, which repair and mediate recovery and 
is termed “alternatively activated” or M2 (Philips and Rothstein, 2014). Both pro and 
anti-inflammatory processes mediated by microglia are influenced by an intricate 
crosstalk with astrocytes as well as T-lymphocytes. Microglia do not solely express 
either M1 or M2 phenotypes. They can release several combinations of cytokines and 
chemokines according to the environment they are exposed to and their interplay with 
other cells. Thus, microglia may present different phenotypes at different time points 
and locations in the CNS. Microglial reaction is characterized by the upregulation of 
several markers that are used to identify these cells such as CD11b and Iba1 in 
addition to CD86, NO synthase and CD106 (Philips and Rothstein, 2014). Activation 
and proliferation of microglia were detected in the primary motor cortex, motor nuclei 
of the brainstem, corticospinal tract and the ventral horns in the spinal cord of ALS 
patients (Ince et al., 1996). Moreover, in animal models, an enhancement in microglial 
reactivity is detected in the ventral horn of the spinal cord that follows closely the 
denervation of the neuromuscular junction, one of the first pathological signs of MN 
degeneration (Alexianu, Kozovska and Appel, 2001; Saxena, Cabuy and Caroni, 
2009). Strikingly, deleting mSOD1 in microglia has a protective effect in the SOD1 
G93A mouse model, resulting in a slowing of disease progression and reduced motor 
neuron degeneration (Beers et al., 2006; Boillée et al., 2006). The elimination of 
proliferating microglia, expressing mSOD1 did not however have any impact (Gowing 
et al., 2008). This observation suggests that there may be a subpopulation of 
microglia, which exert a protective effect for motor neurons. Therefore, a positive effect 
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could be achieved through the selective depletion of neurotoxic microglia.  
In the CNS, myeloid cells of haematopoietic origin inhabit the perivascular spaces and, 
in terms of damage or inflammation, may penetrate the CNS parenchyma, which 
perform the function of macrophages. To date, there are no markers able to distinguish 
the microglia derived by macrophage infiltration (Durafourt et al., 2012; Shechter and 
Schwartz, 2013), but it is known that both are present in the sites of inflammation, as 
demonstrated in EAE models (Taupin et al., 1997; Ajami et al., 2011). Different studies 
have revealed the existence of different types of microglia, which reflect this model i.e. 
the polarization of peripheral macrophages (Gordon, 2003). It is hypothesized that, in 
ALS, polarized M2 microglia, active in the early stages of the disease, exert protective 
effects; while in the later stages, possibly induced by the accumulation of misfolded 
and aggregated mSOD1 and other toxic insults, this will cause a change in bias 
towards microglia with a cytotoxic M1 phenotype (Henkel et al., 2009; Appel, Beers 
and Henkel, 2010; Beers et al., 2011).  
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Figure 1.2 The roles of astrocytes and microglia in ALS 
Astrocytes and microglia contribute to ALS through several mechanisms. Microglia 
has a dual role, the anti-inflammatory (M1) and pro-inflammatory (M2) phenotype. The 
activated microglia induces the A1 phenotype in astrocytes, that become reactive, 
producing more pro-inflammatory molecules and leading to neuroinflammation. 
Moreover, reactive astrocytes express more GFAP. Dysregulation of glutamate 
transporters in astrocytes leads to glutamate accumulation and results in excitotoxicity. 
Protein aggregates, such as mSOD1, accumulate also in glial cells, leading to 
neurodegeneration.  
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1.3 SOD1 and its role in ALS 
1.3.1 SOD1 function and conformation of the wild-type (WT) protein 
SOD1 mutations are the best characterized genetic link to ALS, since they were first 
identified in 1993 (Rosen et al., 1993). SOD1 mutations constitute 20% of fALS cases 
(Bruijn, Miller and Cleveland, 2004), equivalent to 1-2% of the total ALS cases (Chiò 
et al., 2008; Kwon et al., 2012). More than 170 different mutations have been identified 
in SOD1 (http://alsod.iop.kcl.ac.uk). Various forms of mutant SOD1 have been widely 
used for the generation of transgenic animal models, which reliably mimic the human 
disease phenotype. 
The ALS1 locus is on the long arm of chromosome 21 (Siddique et al., 1991). The 
gene has a length of 9.3kb and consists of 5 exons and 4 introns. Its protein product 
is copper-zinc superoxide dismutase 1 (Cu/Zn SOD1), a ubiquitous homodimeric 
enzyme of 32 kDa, consisting of 153 amino acids. It is predominantly localized in the 
cytosol, but is also present in the mitochondrial intermembrane space (Lindenau et al., 
2000; Okado-Matsumoto and Fridovich, 2002), in the nucleus, lysosomes and 
peroxisomes (Chang et al., 1988). SOD1, which represents about 1% of total cytosolic 
proteins, is very abundant in CNS cells, particularly in motor neurons (Pardo et al., 
1995). Each monomer is formed by β sheet motifs and contains two important 
functional loops, referred to as the electrostatic loop and metal-binding loop (residues 
49-84) that surround the region dedicated to the bond with metals (Tainer et al., 1982). 
The metal-binding loop contains residues capable of Cu2+ and Zn2+ binding, while the 
electrostatic loop confers stability to the protein. They contribute in the determination 
of the conformation stability, a network of hydrogen bonds, welding the structure 
around metal ions (Strange et al., 2003). Copper is required for SOD1 enzymatic 
activity, while zinc probably has a role in maintaining the stability of the protein 
structure (Antonyuk et al., 2005). Human SOD1 contains four cysteine residues and 
two of them (Cys57 and Cys146) form a disulphide bridge (S-S). The maturation of the 
protein requires several steps, including copper insertion, zinc insertion, the formation 
of disulphide bridges and dimerization. The structural characteristics of SOD1 give it 
a high stability even under denaturing conditions, while the reduction of S-S bond 
weakens the bond between subunits and favours its aggregation (Furukawa and 
O’Halloran, 2005). The protein belongs to a dismutase family and plays an oxido-
reductant activity that catalyses the transfer of electrons from a reductant molecule 
(donor) to an oxidizing molecule (acceptor). Therefore, it plays an important 
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antioxidant action: it is able to transform oxygen free radicals, highly toxic for the cell, 
into less reactive intermediates. The SOD1 protein converts the superoxide anion (O2-
) into oxygen and hydrogen peroxide (H2O2), which is subsequently transformed into 
water by glutathione peroxidase and catalase. Catalysis is mediated, in two 
asymmetric steps, with the copper atom being alternately reduced and oxidized by 
superoxide (Cleveland and Liu, 2000). 
 
1.3.2 Potential mechanisms for SOD1 dysfunction in ALS 
1.3.2.1 Mutations and their effect on wild-type function 
To date, more than 170 different mutations have been identified in the 5 exons of 
SOD1 that give rise to ALS (http://alsod.iop.kcl.ac.uk). Most mutations are missense 
and they cause the substitution of a single amino acid in the protein, while deletions 
and nonsense mutations, which lead to a truncated form of the protein, are rare. In 
addition, 8 silent and 9 intronic mutations have been identified in SOD1 and, 
presumably, are not pathogenic (Al-Chalabi et al., 2012). The traditionally used 
numbering of the amino acids in SOD1 omits the start codon, whilst the modern 
numbering includes an additional codon. In general, pathogenic SOD1 mutations are 
inherited in an autosomal dominant fashion and individuals with two copies of the 
mutated gene display an anticipation of symptom onset (Boylan, 2015).  
An exception is represented by anomalous mutations, like D90A (first methionine 
excluded with the traditional numbering, p.D91A with the modern numbering). The 
D90A mutation is the most common mutation in Europe, accounting for 50% of all ALS 
cases in Sweden and Finland; it has a distinctive pattern of inheritance that shows 
both recessive and autosomal dominant patterns in different populations, with 
differences in the clinical phenotype, such as site of onset and disease progression 
(Andersen et al., 1996; Al-Chalabi, 1998).  
Mutations in SOD1 are located in all the regions of the primary structure and in all the 
functional domains of the protein. The mutated forms are differentiated by their various 
characteristics, such as the catalytic activity, charge, or the metal affinity. Two groups 
of mutants were identified: mutant forms which do not display changes in metal binding 
affinity (e.g. SOD1 G93A); and metal binding site mutated forms which, consequently, 
have a decreased affinity for copper and zinc ions (e.g. SOD1 G85R). Generally, the 
mutations may cause changes in the protein maturation steps and also, in metal 
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interaction. This leads to an unstable enzyme (Lindberg, Tibell and Oliveberg, 2002), 
characterized by abnormal folding with abnormal domain interactions not present in 
the native structure. These interactions can also be created with other proteins (heat 
shock proteins, the electron cascade proteins, etc.), making them unable to perform 
their functions, and inducing the formation of aggregates (Wang, Popko and Roos, 
2011). Some forms of mutant SOD1 are more sensitive to temperature variations 
(Hayward et al., 2002) and to the disulphide bond reduction than the native form 
(Lindberg, Tibell and Oliveberg, 2002). The disulphide bond reduction and the loss of 
metals from the active site induce the dissociation of two subunits and the balance 
shifting from the dimeric to the monomeric form (Lindberg et al., 2004).  
One of the hypotheses initially formulated to explain the mechanism by which mutant 
SOD1 causes ALS assumed loss of normal enzyme catalytic activity (loss of function 
hypothesis) (Deng et al., 1993). This hypothesis was supported mainly by the 
accumulation of free radicals in the cerebrospinal fluid of ALS patients. Several studies 
have shown an overall SOD1 activity reduction in SOD1 fALS patients, as measured 
in red blood cells, fibroblasts and lymphoblastoid cells (Saccon et al., 2013). 
Remarkably, indirect evidence suggests that SOD1 aggregation and misfolding 
reduces dismutase activity (Eun et al., 2009; Graffmo et al., 2013). Interestingly, in 
2007, Sau and colleagues tested the hypothesis that the reduced solubility of mutant 
G93A-SOD1 may reduce the nuclear protection normally exerted by this enzyme, 
which is necessary to block ROS-induced DNA damage. They showed that an altered 
cytoplasmic versus nuclear distribution of mutant SOD1 compared with wtSOD1 may 
lead to increased nuclear DNA damage after oxidative stress insult (Sau et al., 2007). 
However, a large body of evidence has indicated that motor neuron injury is caused 
by acquisition of new toxic functions by the mutated enzyme (gain of function 
hypothesis) (Watanabe et al., 2001; L. Wang et al., 2008). Transgenic mice 
overexpressing the mutated human SOD1, for example, develop a motor neuron 
disease similar to ALS, despite the presence of the corresponding wild-type murine 
enzyme (Gurney et al., 1994). In these models, the levels of dismutase activities are 
comparable, if not increased compared to those of non-transgenic mice. On the other 
hand, mice deficient in  murine SOD1 gene do not show motor neuron degeneration 
(Shefner et al., 1999), thus confirming that loss of function is not responsible for the 
pathologic phenotype. It has to be noted, however, that mice totally lacking SOD1 
develop a form of peripheral neuropathy and are more sensitive to motor neuron stress 
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compared to wild-type mice (Kondo et al., 1997; Shefner et al., 1999). Moreover, mice 
overexpressing wild-type SOD1 (wtSOD1) develop a modest neurodegenerative insult 
(Dal Canto and Gurney, 1994), indicating that overexpression per se might contribute 
to the overall disease phenotype.  
 
1.3.2.2 Oxidative stress, SOD1 Misfolding and Aggregation  
Generally, SOD1 behaves as an antioxidant enzyme by detoxifying superoxide (O2-) 
free radicals (Hayashi, Homma and Ichijo, 2016). Oxidative damage by mutated SOD1 
is mainly attributed to a gain of toxicity through ROS up-regulation rather than to a loss 
of function. ROS are produced via numerous mechanisms, including NADPH oxidase 
activity. In glia, NADPH oxidase 2 (Nox2) makes a complex with a GTPase Rac1, 
which in its GTP-bound activated state stimulates the production of ROS by Nox2. It 
has been reported that mutant SOD1 binds strongly to Rac1, which keeps Rac1 in its 
active state and leads to the persistent activation of Nox2 together with the 
overproduction of O2-(Harraz et al., 2008). Furthermore, the mitochondrial respiratory 
chain physiologically generates ROS and there are studies showing that the mutated 
form of SOD1 induces dysfunction of mitochondria. This evidence suggests that 
mutant SOD1 causes an increase in the production of ROS via modifications in 
electron transport chain complex activity or an excess of Ca2+ influx (Li et al., 2010; 
Tadic et al., 2014). In ALS, mitochondrial dysfunction has been demonstrated to 
contribute to disease, but it is not clear precisely when this occurs during the disease 
course. It is well known that mitochondria have several roles, including maintenance 
of the distal axonal. It also has been discovered that free radicals are accumulated in 
the intermembrane space of mitochondria that usually contained the lowest SOD1 
levels; this is followed by a slow gradual neuropathy (De vos et al., 2007). It is 
suggested that mitochondrial damage through higher levels of ROS in the 
intermembrane space may have an important consequence on distal axons of motor 
neurons. Recent studies in SOD1 G93A mice have shown an increase of markers of 
oxidative stress at the time of symptom onset. Moreover, it is reported that cellular 
respiration, intracellular ATP and mitochondrial elements (Cox, cytochrome c, 
complex I, enzyme activity) are decreased for the entire life of the affected mice (Irvin, 
Kim and Mitchell, 2015; Kaur, McKeown and Rashid, 2016). 
The protein misfolding mechanisms underlying the development of ALS are poorly 
understood. Oxidative damage is usually involved in the misfolding of SOD1 mutants 
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that cause fALS (Rakhit et al., 2002, 2004; Kerman et al., 2010) and accumulations of 
oxidized proteins appear during cell ageing (Brandes et al., 2013). In fact, the 
dismutase activity that produces H2O2 may make SOD1 more vulnerable to oxidative 
post-translational modifications (Valentine, Doucette and Zittin Potter, 2005). 
Interestingly, a study of ALS screening found a novel SOD1 mutation, c.352C>G 
(L117V), in two Syrian ALS families, that live in Europe. Synofzik et al., demonstrated 
that the structural stabilities of the pathogenic L117V mutant and wild-type SOD1 in 
denaturing conditions are similar. They have not reported differences in the content of 
misfolded SOD1 between extracts of fibroblasts from an L117V patient and from 
controls, using an ELISA specific for misfolded SOD1. Conversely, they found high 
levels of misfolded SOD1 in fibroblasts from ALS patients with seven other mutations 
in the Cu/Zn superoxide dismutase gene. Mutations in SOD1 resulting in a totally 
stable protein are linked with low disease penetrance and may be found in cases of 
sALS. Wild-type human SOD1 is relatively stable, and has been found to be within the 
stability range of ALS-inducing SOD1 variants, supporting the hypothesis that wild-
type SOD1 could be more generally involved in ALS pathogenesis through misfolding 
(Synofzik et al., 2012).   
In the past 10 years, several studies suggested that SOD1 could be pathogenic in both 
fALS and sALS, through either hereditary or non-hereditary modifications. Misfolded 
SOD1, in fact, has been found also in patients without SOD1 mutations (Bosco et al., 
2010; Ayers et al., 2016; Paré et al., 2018; Forsberg et al., 2019). A further link 
between wild-type SOD1 and ALS is provided by experiments showing that decreasing 
SOD1 levels in astrocytes derived from sALS patients inhibits astrocyte-mediated 
toxicity towards motor neurons (Haidet-Phillips et al., 2011). This suggests that wild-
type SOD1 may acquire toxic features analogous to fALS-linked mutated SOD1 
through post-translational alterations. Consistently, an experiment undertaken by 
Guareschi et al., utilising patient lymphoblasts, demonstrated that wild-type SOD1 is 
altered post-translationally in sALS and is oxidized in a subgroup of patients with 
bulbar onset. Through other analysis of oxidized carbonyl compounds on 
immunoprecipitated SOD1, the group has identified a form of oxidized SOD1 that is 
similar to mutated SOD1 in its characteristics including mitochondria dysfunction and 
the development of a toxic complex with Bcl-2 (Guareschi et al., 2012). Using a 
conformation-specific antibody that detects misfolded SOD1 (C4F6), it was observed 
that oxidized wild-type SOD1 and mutant SOD1 share a conformational epitope that 
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is not present in normal wild-type SOD1. In a subset of human sALS cases, motor 
neurons in the lumbosacral spinal cord were C4F6 immunoreactive, suggesting the 
presence of an aberrant wild-type SOD1 species (Bosco et al., 2010). Different studies 
have described the mutation-induced conformational changes of SOD1 as the cause 
of SOD1 toxicity. MS785 (mutant SOD1-specific antibody clone 785), a conformation-
specific antibody has shown that most SOD1 mutants share a common conformational 
property. Mutated SOD1 contains a N-terminal short region, that stimulates ER stress, 
by affecting an ER protein, Derlin-1 (Fujisawa et al., 2012). Moreover, mutated SOD1 
has an increased tendency to expose its hydrophobic faces in comparison to wild-type 
SOD1, and that the variable hydrophobicity within mutated SOD1 associates with its 
aggregation tendency (Münch and Bertolotti, 2010). More recently, a study using an 
immunoprecipitation assay and sandwich ELISA confirmed the presence of misfolded 
SOD1 in the cerebrospinal fluid (CSF) from patients with sALS as well as several other 
neurodegenerative disorders, suggesting that the misfolding of wild-type SOD1 in CSF 
is a common pathological process in ALS cases, even in the absence of SOD1 
mutations (Tokuda et al., 2019). Consistently, other studies have reported abnormal 
changes in SOD1 in Alzheimer’s Disease (AD) and Parkinson’s disease (PD) (Choi et 
al., 2005; Trist et al., 2017). 
Various experiments have shown that SOD1 aggregation reduces dismutase activity. 
The analysis of liver and muscle samples from transgenic mice, overexpressing wild-
type SOD1, revealed that aggregation was absent, while there was an increase of 
SOD1 protein levels and SOD1 activity (Graffmo et al., 2013). An increase in the SOD1 
protein was also found in the spinal cord and brain but, in these tissues, SOD1 
aggregation was marked and there was no increase in SOD1 activity. This suggests 
a strong relation between aggregation of the protein and overall decreased activity 
(Graffmo et al., 2013). An in vitro study of human neuroglioma cells co-expressing 
G93A SOD1 and amyloid-β, suggested that aggregate formation decreased SOD1 
activity (Eun et al., 2009). It is thought that aggregate accumulation of altered SOD1 
plays a role in disturbing cellular functions by damaging mitochondria, protein folding 
and proteasome function (Boillée, Vande Velde and Cleveland, 2006). SOD1 
aggregates are present not only in neurons, but also in the neighbouring glial cells 
(Tobisawa et al., 2003). Misfolded SOD1 within microglial cells and astrocytes can 
exacerbate neuroinflammation and this produces an amplified release of toxic factors 
(Boillée, Vande Velde and Cleveland, 2006). SOD1 protein inclusions have been 
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found in patients with SOD1 mutations and in SOD1 transgenic mice (Gurney et al., 
1994; Watanabe et al., 2001; Forsberg et al., 2010). Moreover, misfolded SOD1 
aggregation was detected in the nuclei of glial cells in ALS patients carrying or lacking 
SOD1 mutations (Forsberg et al., 2011) and recently, a study revealed misfolded 
SOD1 inclusions in motor neurons from patients with mutations in C9orf72 and other 
ALS/FTD-associated genes (Forsberg et al., 2019). Therefore, there is a body of 
evidence suggesting that the soluble form of SOD1 confers toxicity in the context of 
SOD1-mediated ALS. Supporting this idea, it has been demonstrated that the level of 
solubility of mutated SOD1 correlates with toxicity and that reduced aggregation of 
SOD1 in transgenic mice does not improve the disease course (Brotherton, Li and 
Glass, 2013; Parone et al., 2013). On the other hand, other studies have shown that 
the aggregation tendency correlates with the disease severity (Q. Wang et al., 2008; 
Prudencio et al., 2009).  
In conclusion, the presence of misfolded SOD1 inclusions found in ALS patients 
carrying SOD1 mutations as well as in sporadic and familial ALS patients lacking such 
mutations, suggests that misfolded SOD1 is involved in the pathogenesis of ALS; 
whereas, its presence in astrocytes, microglia and oligodendrocytes supports the idea 
of a pathological interplay between neurons and glial cells. 
 
1.3.2.3 Prion-like hypothesis and spreading mediated by extracellular vesicles 
It has been demonstrated that human SOD1 has prion-like characteristics that can 
activate its aggregation (Grad et al., 2011). Several studies suggest that a harmful 
property of SOD1 includes its prion-like propagation. This theory is explained by two 
properties of SOD1, one is cell-to-cell transmission and the other is the seeded 
aggregation. As an initial event underlying intercellular transmission, both mutant and 
wtSOD1 aggregates can be released from damaged cells (Grad et al., 2014). Mutated 
SOD1 can be also released through a principal secretory pathway which is controlled 
by chromogranin-A (CgA) and chromogranin-B (CgB), components of neurosecretory 
vesicles (Urushitani et al., 2006). Furthermore, oxidized wtSOD1 interacts with 
chromogranin-B (CgB) (Ezzi, Urushitani and Julien, 2007). Extracellular mutant or 
wild-type SOD1 aggregates are then absorbed by other cells via micropinocytosis 
(Münch, O’Brien and Bertolotti, 2011; Sundaramoorthy et al., 2013). Both mutant and 
wild-type SOD1 aggregates are shown to seed the aggregation of wtSOD1 in vitro 
(Grad and Cashman, 2014; Grad et al., 2014). There is other evidence which reports 
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that spinal cord homogenates from SOD1 G93A transgenic mice transformed the 
recombinant SOD1 G93A protein (self-seeding) and wtSOD1 protein (cross-seeding) 
into fibrillar species (Chia et al., 2010). Indeed, a recent study demonstrated this prion-
like propagation in transgenic mouse models of ALS (Ayers et al., 2014). In this 
experiment, Ayers and colleagues, injected directly spinal cord homogenates from 
paralyzed SOD1 G93A transgenic mice, into the spinal cord of neonatal SOD1 G85R-
SOD1:YFP (G85R-SOD1 mutant protein fused to the yellow fluorescent protein 
(YFP)), transgenic mice that expressed low levels of mutant SOD1 protein but did not 
manifest disease symptoms. Some of the SOD1 G85ReYFP transgenic mice that were 
inoculated with the spinal cord homogenate from SOD1 G93A transgenic mice 
developed the disease, indicating that ALS transmission is a strain-like property and 
that there is a factor able to induce the aggregation of SOD1.  
Pathogenic disease-causing proteins could also propagate by extracellular vesicles 
(EVs). EVs mediate the secretion of a variety of macromolecular cargo, including 
miRNAs, lipids, mRNAs and proteins (Pant, Hilton and Burczynski, 2012; C. C. Y. Li 
et al., 2013; Raposo and Stoorvogel, 2013), transmit their cargo from cell to cell and 
interact with neighbouring cells (Valadi et al., 2007; Pegtel et al., 2010; Colombo, 
Raposo and Théry, 2014). Recent evidence has shown that EVs from brains and 
spinal cords of the SOD1-G93A ALS mouse model, as well as from human SOD1 fALS 
patient spinal cord, contained abundant misfolded and non native disulfide-cross-
linked aggregated SOD1. These findings suggest that CNS-derived EVs from an ALS 
animal model contain pathogenic disease-causing proteins and indicate that 
astrocytes and neurons produce these EVs (Silverman et al., 2019). Therefore, in 
conclusion, exploring the molecular mechanism of prion-like and EVs propagation may 
provide insights to develop novel therapeutic strategies for ALS. 
 
1.3.2.4 A newly discovered function: SOD1 as a transcriptional regulator 
Ataxia telangiectasia mutated (ATM) is a human kinase that behaves like an oxidative 
sensor, directly activated by H2O2 (Guo, Deshpande and Paull, 2010). A study has 
demonstrated that there is a relationship between SOD1 and Mec1, a yeast 
homologue of ATM (Carter et al., 2005), and this MEC1 pathway is dependent on 
SOD1. Several studies on the role of Mec1 found that inactivation of the temperature-
sensitive Mec1-1 allele nullifies the ability of ROS to induce SOD1 nuclear localisation. 
Moreover, through yeast proteomic mass spectrometry, it has been demonstrated that 
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SOD1 forms a potential protein complex with Dun1 kinase (Ho et al., 2002) that is a 
Mec1 effector (Zhou and Elledge, 1993; Zhao and Rothstein, 2002). SOD1 is bound 
to Dun1 and their interaction is increased by oxidative stress, whilst the deletion of 
Dun1 stops ROS-induction of SOD1 nuclear localisation. Since Dun1 is a kinase, it is 
thought that SOD1 is regulated through Dun1-mediated phosphorylation, thus leading 
to its nuclear localisation. Furthermore, it has been shown that nuclear SOD1 controls 
the expression of a group of oxidative response genes (Tsang et al., 2014). If H2O2 
levels increase, SOD1 associates with the promoters of the target antioxidant genes, 
that SOD1 controls at the transcriptional level. Experiments in yeast have confirmed 
that oxidative stress promotes SOD1 nuclear translocation. These suggest that SOD1 
responds to oxidative stress and is probably regulated by endogenous ROS (Tsang et 
al., 2014). Tsang et al., in fact, measured the level of genomic DNA damage through 
Comet assay in different yeast strains after inducing oxidative stress and showed that 
nuclear SOD1 plays a critical role against oxidative DNA damage caused by 
environmental and endogenous ROS. Moreover, COMET assay was previously 
utilized to test SOD1 toxicity in the nuclei of NSC34 cells (Sau et al., 2007). 
 
Following from the evidence of SOD1 as a transcription factor or potentially as a 
transcription regulator, SOD1 nuclear localisation has been reported in the literature. 
In fact, in 1992 Crapo et al. described SOD1 primarily as a cytosolic protein in human 
cells and tissues; but, using different antibodies, they could also detect a small 
percentage of SOD1 in the nucleus (Crapo et al., 1992). This nuclear localisation had 
previously been reported also in rat hepatocytes (Chang et al., 1988).  
In 2012, Gertz et al., confirmed the nuclear localisation of human SOD1 (hSOD) in 
transgenic (tg) mice expressing mutated forms of hSOD1. In particular, they used tg 
mice expressing hSOD1-G93A, hSOD1-G37R, and hSOD1-wild-type to investigate a 
new subcellular pathology involving mutant hSOD1. Moreover, they reported the 
disruption of the nuclear architecture, looking at the survival motor neuron protein 
(SMN) complex. SMN was in fact disrupted in motor neuron nuclei prior to disease 
onset in hSOD1-G93A and -G37R mice; whilst age-matched hSOD1-wild-type mice 
did not show SMN disruption despite the presence of SOD1 in the nucleus. Their data 
suggest new mechanisms involving hSOD1 accumulation in the cell nucleus and 
mutant hSOD1-specific disruption of the SMN complex in ALS mouse models and a 
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potential overlap of pathogenic mechanisms with spinal muscular atrophy (Gertz, 
Wong and Martin, 2012).  
The nuclear presence of SOD1 described above poses the questions of how it gains 
access to the nucleus and its subcellular function in this location. Bidirectional 
movement of small proteins occurs via passive diffusion through the nuclear pore 
complex, whilst proteins larger than ~40 kDa normally require specific transportation 
(Terry, Shows and Wente, 2007). In rat hepatocytes, nuclear SOD1 can be depleted 
by dialysis. The size of the native SOD1 dimer is 32 kDa, and it should therefore be 
able to move freely between the nucleus and the cytosol, through nuclear pores 
(Chang et al., 1988). Its function could be to catalyse the dismutation of superoxide 
radicals produced by nuclear membrane cytochromes P450 and b5 and NADPH 
oxidase (Chang et al., 1988; Li and Shah, 2002). Interestingly, SOD1 is essential for 
viability in DT40 cells, and it has been reported that nuclear SOD1 functions as a 
guardian of the genome by mitigating the accumulation of  DNA lesions formed directly 
or indirectly by superoxide generated in or near the nucleus (Inoue et al., 2010). Of 
great relevance in this context, another study showed that mutant Gly93 → Ala (G93A) 
SOD1 is present in the nucleus of human neuroblastoma cells in association with DNA. 
In this study, the cells were transfected to achieve low-level expression of either wild-
type or G93A fALS mutant SOD1. Their findings indicate that the G93A SOD1 
association with DNA could induce DNA damage and activate apoptosis by inducing 
p53. This toxic activity of mutant SOD1 in the nucleus may have a critical role in the 
complex interplay of pathways associated with motor neuron death in ALS (Barbosa 
et al., 2010).  
In addition, also the misfolded form of SOD1 was detected in the nucleus of 
motoneurons and glial cells in spinal cord tissue from ALS patients, considering the 
nucleus as a potential site of SOD1 toxicity (Forsberg et al., 2011). 
More recently, a report has shown that misfolded SOD1 and wtSOD1 expose a 
normally buried nuclear export signal (NES)-like sequence. NES-like sequence 
exposure is only a feature of ALS-linked SOD1 mutants and misfolded wtSOD1. The 
nuclear export carrier protein is XPO1 (Chromosomal Maintenance 1, CRM1 or 
Exportin 1), which recognizes this NES-like sequence and exports misfolded SOD1 to 
the cytoplasm. This indicates that SOD1 mutants are removed from the nucleus by 
XPO1 likely as a defence mechanism against toxicity of nuclear misfolded SOD1 
(Zhong et al., 2017). 
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1.4 Ageing as a risk factor for ALS: common pathways involved in ageing and 
ALS 
Ageing is a major risk factor for neurodegenerative diseases (Khan, Singer and 
Vaughan, 2017), in particular for the development of ALS (Alonso et al., 2009). In fact, 
a number of ALS/FTD causing genes are involved in ageing pathways. Autophagy, 
inflammation, nuclear cytoplasmic transport and splicing of RNA are common 
dysregulated pathways in both ageing and ALS, thus this overlap could explain why 
ageing is the main risk factor for this disease (Niccoli, Partridge and Isaacs, 2017). 
Interestingly, several studies have proposed ALS as a multi-step process (Al-Chalabi 
et al., 2014), thus ageing may facilitate some aspects of its development (Niccoli, 
Partridge and Isaacs, 2017). 
 
1.4.1 Protein degradation and autophagy 
The maintenance of the proteome involves a complex network of molecular 
chaperones and protein degradation pathways. Chaperones promote the folding of 
proteins or refolding of misfolded protein. Newly folded proteins are directed to the 
endoplasmic-reticulum (ER)-Golgi pathway for post-translational modification and 
secretion. Proteins non-correctly folded are recognized by ER-associated degradation 
(ERAD), targeted for ubiquitin-proteasome system (UPS) degradation or autophagy. 
Autophagy is normally classified into three types: microautophagy, macroautophagy 
and chaperone-mediated autophagy (CMA). All of these processes involve lysosomal 
degradation but they have different mechanisms. Microautophagy is the direct 
invagination of small parts at the lysosome surface, followed by vesicle degradation in 
the lysosomal lumen and release of breakdown products into the cytoplasm. 
Macroautophagy, generally referred as autophagy, involves multiple proteins 
coordinating vesicle formation through different steps, followed by fusion with 
lysosomes to form the so-called autolysosomes. CMA is a selective and direct 
elimination system for a particular group of soluble cytosolic proteins containing the 
pentapeptide KFERQ as recognition sequence. These are targeted to lysosomes and 
directly translocated across the lysosome membrane for degradation, without the 
formation of additional vesicles. 
It is been reported that the ability to maintain a stable and functional proteome declines 
with age, thus, as consequence, misfolded and damaged proteins accumulate, 
 35 
impairing cell function and tissue homeostasis (López-Otín et al., 2013). ALS, like 
other neurodegenerative disorders that are age-related diseases, is characterized by 
the presence of misfolded protein aggregation, suggesting that the protein quality 
control is affected. In fact, several mutated proteins associated with ALS, are involved 
in protein degradation pathways (see Table 1.1) and can also be found as aggregates. 
In particular, ageing might contribute to genetic mutations that dysregulate these 
pathways. For example, it has been reported that partial loss of function of TBK1, a 
major genetic cause for ALS/FTD, leads to age-dependent neurodegeneration. TBK1 
is an endogenous inhibitor of RIPK1, a mediator of neuroinflammation and apoptosis. 
TAK1 is another endogenous RIPK1 inhibitor and decreases in expression in ageing 
human brains. In 2018, a study showed that the embryonic lethality of Tbk1−/− mice 
is dependent on RIPK1 kinase activity. Moreover, in Tbk1+/− mice, the reduced 
myeloid TAK1 expression induces all the key hallmarks of ALS/FTD, which are 
rescued by inhibition of RIPK1 (Xu et al., 2018). Therefore ageing enables RIPK1 
activation by decreasing TAK1 expression, which cooperates with genetic risk factors 
to promote the onset of ALS/FTD. 
 
1.4.2 Nucleocytoplasmic transport and RNA metabolism  
A key-player in the nucleocytoplasmic transport, powered by a RanGTP-gradient 
(Schmidt and Görlich, 2016), is the nuclear pore complex (NuPC), that regulates the 
communication between the nuclear and the cytoplasm compartments. The NuPC is 
a defined structure of evolutionary conserved proteins, called nucleoporins (Nups). 
Nups are vulnerable to age-related damage and, importantly, ALS-causing mutations 
have been identified in these proteins. For example, loss-of-function mutations in 
GLE1 lead to defects in mRNA export (Nousiainen et al., 2008; Kaneb et al., 2015). 
Proteins are imported or exported through the NuPC via nuclear transport receptors 
(NTRs), members of the karyopherin β family, known as importins and exportins 
(Cautain et al., 2015; Soniat and Chook, 2015). The NTRs are characterized by a 
conserved Ran-GTP-binding motif at the N-terminal, while at the C-terminal they vary 
and are involved in substrate recognition (Görlich et al., 1997). Impaired 
nucleocytoplasmic shuttling has recently emerged as mechanism contributing to ALS 
pathology and other neurodegenerative diseases, as well as being present in 
physiological ageing (Kim and Taylor, 2017). The main pathological hallmark in 
neurodegenerative diseases is the aggregation of protein that forms cytoplasmic 
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inclusions. In most cases of ALS, both sporadic and familial, the nuclear protein TDP-
43 (Ayala et al., 2008) is depleted from the nucleus and accumulates in the cytoplasm 
(Neumann et al., 2006), where it can interfere with nucleocytoplasmic transport of 
protein and RNA (Woerner et al., 2016). Several studies also reported impaired 
nucleocytoplasmic transport as consequence of several ALS mutations, such as 
mutations in the nuclear localisation signals (NLSs) of FUS and hnRNPA1 (Dormann 
et al., 2010; Gal et al., 2011; Q. Liu et al., 2016). Furthermore, evidence of 
dysregulation in this mechanism has been observed in C9Orf72 ALS/FTD cases 
(Freibaum et al., 2015; Jovičić et al., 2015; Zhang et al., 2015; Boeynaems et al., 2016; 
Shi et al., 2017). Thus, in conclusion, ageing could have impact on disease. The 
disruption of NuPC and changes in expression of transport factors could potentially 




Neuroinflammation has also a role in ALS pathophysiology. Neuroinflammation 
associated with neuronal loss is characterised by activation of microglia and 
astrocytes, production of pro-inflammatory cytokines and infiltration of T lymphocytes 
(Endo, Komine and Yamanaka, 2016). Multiple studies have confirmed the activation 
of microglia in ALS (Turner et al., 2004; Corcia et al., 2012). As mentioned in section 
1.2.2, when microglia encounter any potential hazard, they release a full range of pro-
inflammatory versus anti-inflammatory cytokines and chemokines. This may induce 
the neurotoxic activation of astrocytes that could contribute to the death of neurons 
and oligodendrocytes (Liddelow et al., 2017). Astrocytes, as described in section 1.2.1, 
are responsible for homeostasis, defence and regeneration of the CNS (Burda and 
Sofroniew, 2014). Therefore, a body of evidence (section 1.2) indicates that 
inflammation is a crucial mechanism for neuronal injury and ALS progression. 
Nevertheless, also the human ageing brain displays elevated inflammatory markers 
(Janowitz et al., 2019). Thus, the imbalance between anti-inflammatory and pro-
inflammatory cytokines in ageing increases the risk for neurodegenerative diseases. 
 
1.5 Modelling ALS  
In order to investigate the disease mechanisms that lead to MN degeneration, several 
models have been created. The development of animal models represented a crucial 
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point in ALS research. Different model systems have contributed to the knowledge of 
ALS disease mechanisms. Small in vivo models, such as C.elegans, drosophila and 
zebrafish are widely used for genetic screening; while rodent models should mimic the 
disease more closely and are used to investigate pathogenic mechanisms and for 
proof of concept therapeutic studies (Van Damme, Robberecht and Van Den Bosch, 
2017). Moreover, through the use of animal models it is possible to follow the 
pathology, monitoring the pathogenetic events, from pre-symptomatic stages to the 
end stages, and to study the early mechanisms that trigger the development of the 
disease. Numerous SOD1 and other genetic mutation mouse models have been 
created since 1994, to better understand the mechanisms involved in the 
pathogenesis of ALS, and with the aim of producing reliable animal models that mimic 
the clinical phenotype of ALS (Van Damme, Robberecht and Van Den Bosch, 2017). 
Indeed, SOD1 models have been invaluable to understand some of the disease 
mechanisms, but the translation of findings from model systems to the clinic has been 
unsuccessful so far (Mitsumoto, Brooks and Silani, 2014). Despite the differences in 
the number of copies of the transgene, in the expressed protein levels, in the 
dismutase activity and in some neuropathological features, all the introduced 
mutations cause, in the same way, degeneration and death of motor neurons, leading 
to progressive muscle atrophy and paralysis, typical ALS symptoms. Moreover, these 
animals display the same histopathological features associated with ALS in humans, 
such as the presence of aggregates containing SOD1 and ubiquitin in degenerating 
motor neurons, astrogliosis and microgliosis. The differences in the onset and 
progression of the pathology observed between the different mutations, but also in the 
context of a single mutation, may depend not only on the different number of copies 
of the transgene (Alexander et al., 2004), but also on gender and the genetic strain of 
the mouse. This suggests an important effect of the background and other genetic 
factors in the development of the disease (Heiman-Patterson et al., 2005; Mancuso et 
al., 2012; Nardo et al., 2013). Also, TDP-43, FUS and C9orf72 models were created 
but they only partially recapitulate the disease phenotype and the disease hallmarks 
observed in post-mortem tissues. Finally, the rodent mouse models only represent a 
small portion of familial cases.  
A powerful tool for ALS modelling is represented by induced pluripotent stem cells 
(iPSCs). This implies generating models from patient-derived stem cells, thus having 
the most important advantage that they remove the need to overexpress transgenes 
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containing pathogenic ALS gene mutations. This type of in vitro model has greatly 
contributed to the understanding of ALS pathogenic mechanisms, although it does 
display some limitations. First of all, iPSCs present clonal variability; this in ALS 
research was shown in a study using iPSC lines of ALS patients, carrying a TARDBP 
mutation. Differentiated motor neurons of individual clones from the same patient 
showed variations in TDP-43 expression, aggregate formation and oxidative stress 
induced cell death (Egawa et al., 2012). Secondly, another important limitation relating 
to the induction of pluripotency in adult fibroblasts is that this reverts cellular age to an 
embryonic status (Lapasset et al., 2011; Patterson et al., 2012), which is retained even 
after conversion into neurons, thus erasing ageing-associated signatures (Miller et al., 
2013). To circumvent this limitation, recent studies have shown that neurons directly 
reprogrammed from fibroblasts without the use of pluripotency factors, retain ageing 
signatures compared to iPSCs-derived neurons (Mertens et al., 2015; Huh et al., 2016; 
Tang et al., 2017; Victor et al., 2018). 
 
1.5.1 Cell Reprogramming 
The discovery of reprogramming fibroblasts into induced pluripotent stem cells (iPSCs) 
(Takahashi et al., 2007) allowed to model in vitro not only fALS, but also sALS, the 
majority of ALS cases. In 2008, the reprogramming of human fibroblasts to a 
pluripotent state, using transcription factors led to the first ALS-patient iPSCs, that 
were then successfully differentiated in motor neurons (Dimos et al., 2008). Since 
then, many different techniques have been used to produce iPSC lines via genetic 
reprogramming of several somatic cells types, including keratinocytes and adipocytes 
(Aasen et al., 2008; Taura et al., 2009). Moreover, the production of induced neural 
progenitor cells (iNPCs) (Meyer et al., 2014) and motor neurons (Son et al., 2011) was 
possible through direct conversion technology. Originally, the transcription factors 
were introduced by lentiviral or retroviral constructs, leading to the random integration 
of the transgene into the target genome, which can alter the expression of endogenous 
genes. Recently, less invasive approaches have been developed, such as non-
integrating viral vectors, like plasmids, adenoviruses, microRNA (miRNA) and Sendai 
virus (Myszczynska and Ferraiuolo, 2016).  
Using iPSCs has allowed to ALS research to investigate disease mechanisms not only 
linked to mutations in the familial cases. Since iPSCs recapitulate various aspects of  
disease pathophysiology, such as the aggregation and/or mis-localisation of proteins 
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(Matus, Medinas and Hetz, 2014) it was also possible to produce many results from 
sporadic ALS patients-derived cells to better characterise pathways that contribute to 
disease (Table 1.3). Furthermore, ALS iPSCs represent a valuable tool to design novel 
therapeutic strategies, such as targeting the degradation of sense and antisense 
C9orf72 RNA foci (Lagier-Tourenne et al., 2013; Sareen et al., 2013), and also to 
perform compound screening (Egawa et al., 2012). 
 




Functional phenotype identified References 
Motor neurons Mutant TDP-43 induces selective cell-
specific vulnerability 
(Bilican et al., 2012) 
Motor neurons Mutant SOD1 induces neurofilament 
disorganization 
(Chen et al., 2014) 
Neurons C9orf72 disrupts nucleocytoplasmic 
transport 
(Zhang et al., 2015) 
Motor neurons Changes in excitability (Kiskinis et al., 2014) 
Oligodendrocytes Involvement in MN death through a 
SOD1-dependent mechanism 
(Ferraiuolo et al., 
2016) 
Astrocytes Non-cell autonomous toxicity to MN (Meyer et al., 2014) 
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1.6 Hypothesis and aims 
Ageing is considered a key primary risk factor for ALS. Moreover, ageing is linked to 
several pathways, altered in ALS, such as protein misfolding and mis-localisation, and 
changes in nucleocytoplasmic transport. This led to the hypothesis of this doctorate 
work, investigating whether: 
 
1.  Ageing has impact in our directly reprogrammed iNPC-derived astrocytes 
(Meyer et al., 2014) modelling neurodegenerative disease; 
 
2. SOD1 nuclear presence affects the nucleocytoplasmic transport in the context 
of fALS and sALS astrocytes.  
 
A set of aims was established creating the basis of this thesis:  
 
1. To determine the ability of our model to retain ageing features and to understand 
the astrocytic contribution to human health and disease in the human CNS, 
examining pathways involved in neurodegeneration, i.e. oxidative stress 
response, inflammatory response and nucleocytoplasmic transport changes;  
 
2. To investigate the localization of wild-type and misfolded SOD1 in astrocytes 
from ALS patients and its link with the alteration of nucleocytoplasmic transport, 





 Material and Methods  
 
2.1 Materials 
All cell culture reagents and chemicals were purchased as described as follow: 
 
2.1.1 Cell culture media and reagents 
• iNPC medium 
ü B27-Supplement (Gibco Life technologies) 
ü DMEM/F-12 (1:1) (1X) + GlutaMAX (Gibco Life technologies) 
ü N2-Supplement (Gibco Life technologies) 
ü bFGF (Peprotech) 
• Hu Plasma Fibronectin (Millipore) 
• StemPro® Accutase (Gibco Life technologies) 
• iAstrocyte medium 
ü Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
ü Foetal Bovine Serum (FBS) (Life Science Products) 
ü N2-Supplement (Gibco Life technologies) 
ü Penicillin/Streptomycin (Lonza BioWhittaker) 
• Formaldehyde (Fischer Scientific) 
• Triton™ X-100 (AppliChem) 
• DEPC (BioChemica) 
• Hoechst 33342, Trihydrochloride, Trihydrate (Life Technologies) 
• Phosphostop (PS) (Roche) 
• Proteinase Inhibitor Cocktail (PIC) (Roche) 
• ProtoGel 30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock Solution 
(GeneFlow) 
• Ammonium persulphate (APS) (Sigma) 
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• Tetramethylethylenediamine (TEMED) (Sigma) 
• Bradford protein assay dye reagent (Bio-Rad Laboratories) 
• PMSF (Phenylmethanesulfanyl) 
• Pre-stained protein ladder (GeneFlow) 
• Dried Skimmed Milk (Marvel) 
• Bovine Serum Albumin (BSA) (Fisher Scientific) 
• EZ-ECL kit (Geneflow) 
• RNAeasy Mini kit (Qiagen) 
• High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
• 2x SYBR Green/Rox PCR Master Mix (Bimike.com) 
• CellROX® Reagent (Life Technologies) 
• Duolink® In Situ Orange Starter Kit Mouse/Rabbit (Sigma-Aldric) 




Table 2.1 Solutions used in the study 
Solution Components 
PBS 1X 137mM NaCl, 2.68mM KCl, 10.14mM Na2HPO4 
(anhydrous), 1.76mM KH2PO4 (anhydrous) made up to 
volume with deionised water 
DEPC treated PBS 0.2% v/v of diethyl pyrocarbonate (DEPC) in PBS solution 
autoclaved 
DEPC treated water 0.2% v/v of diethyl pyrocarbonate (DEPC) in water 
autoclaved 
IP lysis buffer 150mM NaCl, 50mM HEPES, 1mM EDTA, 1mM DTT, 
0.5% (v/v) Triton™ X-100, 20µL/mL PIC, pH 8.0 
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IP T/N Lysis Buffer 150mM NaCl, 50mM HEPES, 1mM EDTA, 1mM DTT, 1% 
(v/v) Triton™ X-100, 1% Sodium deoxycholate, 20µL/mL 
PIC, pH 8.0 
Hypotonic Lysis Buffer 10mM HEPES, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 
20µL/mL PIC 
Resolving buffer 1.5 M Trizma®, 13.9 mM SDS, pH 8.8, filtered 
Stacking buffer 0.5 M Trizma®, 13.9 mM SDS, pH 6.8, filtered 
4x Laemmli buffer 228mM Tris-HCl, 38% (v/v) glycerol, 277mM SDS, 0.038% 
(w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol pH 
6.8 
Running buffer 25mM Tris, 3.5mM SDS, 20mM glycine 
Transfer buffer 47.9mM Tris, 38.6mM glycine, 1.38mM SDS 
Tris Buffered Saline, 
with Tween® 20 
(TBST) 
20mM Tris, 137mM NaCl, 0.2% (v/v) Tween® 20, pH 7.6 
Oxidised RNA pull 
down Lysis Buffer 
DEPC PBS, 0.1% Triton, PIC (20 µL/mL), DNase (1 
µL/mL), RiboSafe RNase Inhibitor (1 µL/mL, Bioline) 
Binding buffer 20mM Tris-HCl, 1M NaCl, 1% SDS, 0.2mM EDTA up to 
400mL of DEPC water 
Total RNA pull down 
Lysis Buffer 
50mM Tris-HCl pH7.5, 100mM NaCl, 2mM MgCl2, 1mM 
EDTA pH8, 0.5% Igepal C9-630 (NP40), 0.5% Na-
deoxycholate in DEPC water, 20μL PIC/mL and 1μL/mL 
RNase Inhibitor 
Elution buffer 10mM Tris, pH7.5, 1mM EDTA up to 200mL DEPC water 




5% horse serum (Dako), 0.05% Triton in PBS 
 
2.1.3 Cell culture 
2.1.3.1 Induced neural progenitor cells (iNPCs) 
Human skin fibroblast samples were obtained from different sources (Table 2.2). Prof. 
Pamela Shaw (PJS) and Dr Daniel Blackburn (DB) provided the fibroblast samples 
 44 
from the University of Sheffield (Study number STH16573, Research Committee 
reference 12/YH/0330 and MODEL-AD research study number STH19080 Research 
and Ethics Committee number: 16/YH/0155 respectively). Prof Stephen J. Kolb (SJK) 
provided the fibroblast samples from the ALS/MND Clinic, Department of Neurology, 
The Ohio State University (OSU), Wexner Medical Center, Columbus, OH (Ethics 
number 04304AR). Five fibroblast lines (including underaged donors) were purchased 
from the biorepository Coriell under material transfer agreement (MTA). Informed 
consent was obtained from all subjects before sample collection.  
 
Table 2.2 Summary of the information on the astrocytes and fibroblast lines used in 
this study 
ID Cell line Biobank Phenotype Age at biopsy 
collection 
Gender 




5 months Male 




3 years Male 




3 years Male 
CTR_1 
(O3) 
155 PJS Non-ALS 
control 
42 years Male 
CTR_2 
(O2) 
3050 PJS Non-ALS 
control 
55 years Male 
CTR_3 
(O1) 
MAD14 DB Non-ALS 
control 
56 years Male 
CTR_4 AG08620 Coriell Non-ALS 
control 
64 years Female 
sALS_1 PAT009 SJK sALS 61 years Female 
sALS_2 PAT12 SJK sALS 29 years Male 
sALS_3 PAT17 SJK sALS 47 years Male 
C9_1 PAT78 PJS C9Orf72 66 years Male 
C9_2 PAT183 PJS C9Orf72 50 years Male 
C9_3 PAT201 PJS C9Orf72 66 years Female 
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SOD1_1 PAT100 SJK SOD1 (A4V) Not known Female 
SOD1_2 PAT102 SJK SOD1 (A4V) Not known Female 
SOD1_3 PATND Coriell SOD1 (D90A) 56 years  Male 
 
2.1.4 Primers 
All primers were ordered from Sigma-Aldrich®. 
 
Table 2.3 Primer sequences used for qPCR 
(Fw=forward, Rv=Reverse)  




















2.1.5.1 Primary antibodies 
Table 2.4 Primary antibodies used in the study  
(ICC=immunocytochemistry, WB=western blot, PLA=Proximity Ligation Assay, 
IP=immunoprecipitation) 
Primary antibody Species Assays Working 
Dilution 
Supplier 
Nestin Mouse ICC 1:1,000 Abcam, 
ab18102 
Pax6 Rabbit ICC 1:1,000 Abcam, ab5790 
CD44 Rabbit ICC 1:200 Abcam, 
ab157107 
GFAP Rabbit ICC 1:1,000 Dako, Z0334 
 
Vimentin Chicken ICC 1:1,000 Millipore, 
ab5733 






































SSRP1 Mouse WB 1:500 Abcam, 
ab26212 
b-actin Mouse WB 1:10,000 Abcam, ab6276 
b-tubulin Chicken WB 1:1,000 Millipore, 
ab9354 
NRF2 Rabbit WB 1:1,000 Abcam, 
ab31163 
GAPDH Rabbit WB 1:1,000 Cell Signalling, 
21185 
XPO1/CRM1 Rabbit WB 1:2,000 Abcam, 
ab180144 
XPO1/CRM1 Rabbit PLA 1:1,000 Cell signalling, 
46249 
IPO5 Rabbit WB 1:1,000 Abcam, 
ab88695 
RANBP17 Rabbit WB 1:2,000 Abcam, 
ab168842 
Histone H3  
(tri methyl K9)  
Rabbit ICC 1:800 Abcam, ab8898  
Lamin A/C Mouse ICC 1:800 Abcam, 
ab40567 
 
2.1.5.2 Secondary antibodies 
 
Table 2.5 Secondary antibodies used in the study  
(ICC=immunocytochemistry, WB=western blot) 
Secondary antibody  Source Assay Dilution 
used 





















a-Rabbit IgG (H+L), HRP 
Conjugate 
Promega   
W401B 
WB 1:5,000 














2.2.1 Direct Reprogramming of Skin Fibroblasts to iNPCs 
Direct conversion was conducted as described previously in Meyer et al., 2014. 
Fibroblasts were seeded in a well of a six-well plate (Greiner-Bio) and treated with 
retroviral vectors for OCT3, Sox2 and KLF4 (Meyer et al., 2014). The medium was 
switched to NPC conversion medium, consisting of DMEM/F12, 1% N2, 1% B27, EGF 
(40ng/ml) and FGF (20 ng/mL). After 2-4 days the cells changed shape to look smaller 
and rounded. These were collected or lifted using accutase and, depending on the 
density and their growth rate, they were expanded in multiple wells of a six-well plate 
or a 10cm dish (Thermo Scientific) coated with human fibronectin (5 μg/mL). The cells 
were stained for Nestin and PAX6 to establish that iNPC conversion was successful. 
Staining was repeated every 5 passages to confirm retention of neural progenitor 
characteristics. The efficiency of the conversion ranged between 98%-100%. The 
reprogramming and quality control work were performed by Dr Laura Ferraiuolo, Dr 
Simon Bell and Mr Allan Shaw. iNPC maintenance was carried out by myself, Miss 
Monika Myszczynska and Mr Allan Shaw. 
 
2.2.2 Differentiation of iNPCs into iAstrocytes 
To induce astrocyte differentiation, about 500,000 iNPCs were plated in medium made 
up of DMEM, 10% Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin, 0.2% N2-
supplement in a 10-cm dish coated with human fibronectin (2.5 μg/mL). Astrocytes 
were allowed to differentiate for 7 days with a medium change at day 3-4 (Figure 2.1). 
These cells were stained with typical cell biomarkers, including vimentin, CD44, 





Figure 2.1 Schematic depicting the iAstrocyte differentiation protocol. 
  
(Modified from Meyer et al., 2014 PNAS) 
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2.2.3 Treatment for stress response assessment and cell collection 
Serum starvation experiments were carried out by washing the cells with PBS twice 
and changing the culture medium to fresh media without FBS at day 6.  
On day 7 iAstrocytes were washed twice with PBS to remove residual medium and 
harvested by cell scraping. The cell pellets were stored at -80°C until processed for 
RNA or protein extraction. 
 
2.2.4 SOD1 knock-down treatment 
SOD1 knock-down treatment was achieved by using a commercially available 
adenovirus expressing a short hairpin RNA (shRNA) against SOD1 (Ad-h-SOD1-
shRNA, cat# 1859, Vector Biolabs). The cells were transduced 24h post-seeding 
(MOI, Multiplicity of infection=5-7). 
 
2.2.5 Microarray analysis 
Microarray analysis of human fetal astrocytes (purchased from Sciencell), post-
mortem (PM) astrocytes laser-captured from brain samples and iAstrocytes (iA) 
reprogrammed from fibroblast donors was performed at SITraN, University of 
Sheffield, at different time points and for different studies (Table 2.6). Fetal astrocytes 
were run on GeneChip™ Human Gene 2.0 ST Array; while post-mortem astrocytes 
and iAstrocytes were run on GeneChip™ Human Genome U133 Plus 2.0 Array. The 
U133 arrays have their probe sets located at the 3'UTR of the gene, whilst the 1.0 ST 
arrays have probe sets across the entire transcript. 
 
Table 2.6 Summary of the information on microarray data 
ID Origin Age Gender GEO accession number 
Fetal_1 Sciencell - M/F 10.15131/shef.data.12162282  
Fetal_2 Sciencell - M/F 10.15131/shef.data.12162282  
Fetal_3 Sciencell - M/F  10.15131/shef.data.12162282  





















Old iA_1 Direct 
reprogramming 






Old iA_2 Direct 
reprogramming 



















from skin fibroblasts 






from skin fibroblasts 
















All the included data were already available and had in place relevant ethical approval. 
The quality of array data CEL files was assessed using the Affymetrix Expression 
Console software. Normalisation: all the transcripts were normalised against beta-
tubulin, and harmonisation across Chip files was obtained using the Robust Multi-
Array (RMA) algorithm. Differential gene expression between samples was 
determined using Qlucore Omics Explorer after normalisation. The software was used 
also for Principal Component Analysis (PCA) and hierarchical clustering. To access 
the functions of genes found in the meta-analysis, the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) and 
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IMPaLA: Integrated Molecular Pathway Level Analysis (http://impala.molgen.mpg.de/) 
software tools were used. The website Human Genomic Resources (HAGR, 
http://genomics.senescence.info/) was used to identify ageing-related genes. 
 
2.2.6 qPCR primer design 
Genomic DNA sequences were imported using Ensembl.org (www.ensemble.org), 
and primers were designed using the online tool Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools  /primer-blast/). Each primer pair (Table 2.3) was 
diluted in water to a 100µM stock. 
 
2.2.7 RNA Isolation and quantitative polymerase chain reaction (qPCR) 
RNA was extracted using the RNAeasy Mini kit from the astrocyte pellet as per 
manufacturer’s instructions. Total RNA was reverse-transcribed with a High Capacity 
cDNA Reverse Kit according to the manufacturer’s instructions. 
  
2.2.7.1 Reverse transcription 
A master mix from the High Capacity cDNA Reverse Transcription Kit was prepared 
using the components described in the table below: 
 
Table 2.7 Components of the master mix 
Component Volume 
10 x RT Buffer 2.0 µl 
25 x dNTP Mix (100mM) 0.8 µl 
10 x RT Random Primers 2.0 µl 
MultiScribeTM Reverse Transcriptase 1.0 µl 
Nuclease-free H2O 3.2 µl 
Total per Reaction 10.0 µl 
 
The master mix was mixed on ice before adding 10 µl to each 0.2 reaction tube. 10 µl 
of RNA sample (12.5 ng/μl per well) was added to each tube and mixed. The tubes 
were spun briefly and placed in the DNA Engine PTC-200 thermocycler (MJ Research) 
with a heated lid at 80°C, running the following program: 
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Table 2.8 qPCR cycle programme 
Temperature Time 
25°C 10 min 
37°C 120 min 
85°C 5 min 
4°C - 
 
Samples were used immediately or stored at -20°C and were loaded at a concentration 
of 12.5 ng/μl per well. qPCR was performed using 2x SYBR Green/Rox PCR Master 
Mix and forward and reverse primers (5μM), to a total volume of 20µL.  
 
Table 2.9 Components of the PCR Master Mix 
Component Volume 
SYBR green 10 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
dH2O 7 µl 
cDNA Template 1 µl 
Total per Reaction 19 µl 
 
The reaction was run on a Stratagene MX300P machine, using the programme in 
Table 2.10. At the end, a dissociation curve was created to ensure amplification of a 
single product and absence of primer dimers. 
 
Table 2.10 qPCR programme 
Step Temperature Time Cycles 
Initial Denaturation 95°C 10 min 1 
Denaturation 
Annealing 
95°C 30 secs 40 
60°C 60 secs 
Extension 
Final extension 
95°C 60 secs 1 
55°C 30 secs 
95°C 30 secs 
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GAPDH was tested against other housekeeping genes, i.e. beta-actin, RLP13A and 
U1. GAPDH showed the most consistent and stable expression across samples of 
different ages as well as between fibroblasts and astrocytes. Hence, GAPDH was 
amplified on each plate to normalize expression levels of target genes between 
different samples using the ΔΔCt calculation (ABI) and to assess assay reproducibility. 
 
2.2.8 Seeding iAstrocytes 
At day 5/6, a 96 well tissue culture treated black plate (Griener Bio-One) was coated 
with fibronectin diluted 1:400 in PBS. iAstrocytes were first washed with PBS before 
incubating with accutase for 5 minutes at 37°C. The accutase was neutralised in an 
appropriate volume of iAstrocyte medium and cells were collected in a 15ml falcon 
and centrifuged at 200g for 4 minutes. The obtained pellet was resuspended in an 
appropriate volume of medium and the cells were counted using a 0.100 mm Burker 
hemocyctometer (Marienfeld). The cells were seeded at the desired density (usually 
6,000/well for staining) and were left for 24 hours to adhere.  
 
2.2.9 Oxidative-stress assay  
7,000 iAstrocytes were plated per well in 96-well plates at day 5 of differentiation in 
complete astrocyte medium. On day 6, medium was replaced either with complete or 
with serum-free astrocyte medium for 12 hours. After 12h, medium was replaced in all 
conditions with complete astrocyte medium and CellROX baseline measurements 
were collected, using the Opera Phenix Imaging System (Perkin Elmer). A time-course 
experiment was also performed, in which CellROX measurements were collected 
every 2 hours for 6 hours. CellROX® Reagent (Life Technologies) was used at a final 
concentration of 2.5 μM as per manufacturer’s instructions and incubated with cells for 
30 minutes at 37°C. CellROX® Reagent was then removed, cells were washed three 





Cells were plated in 96-well plates (Griener Bio-One) and fixed 24h after seeding with 
4% paraformaldehyde (PFA) for 10 min and washed 3 times with PBS before the 
blocking solution consisting of PBS with 5% horse serum, 0.05% Triton X-100, was 
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applied for 1 h. All primary antibodies were diluted in blocking solution and their dilution 
and provider are listed in Table 2.4. Incubation of the primary antibody was performed 
overnight at 4°C. The next day, cells were washed 3 times in PBS before the 
secondary antibody (Table 2.5) in blocking solution was applied for 1 h at room 
temperature. Hoechst reagent diluted 1:6,000 was added for 5 minutes to visualise the 
nucleus. Cells were then washed twice with PBS and imaged using the Opera Phenix 
high-content imager (Perkin Elmer). 
 
2.2.11 Columbus Analysis 
Columbus Software was used in the image analysis setting to measure different 
parameters including nuclei numbers, nuclear size (μm2) (mean per well), CellROX 
intensity/cell area, Lamin A/C distribution, H3K9me3 intensity and SOD1-XPO1 
interaction. CellROX, Lamin and H3K9me3 quantifications were carried out by Dr 
Ferraiuolo and Mr Shaw. In iAstrocytes stained for PLA the number of nuclei were 
identified and segmented using the Hoechst nuclear stain. Nuclear PLA foci were 
identified using the built-in spot analysis script using Hoechst-created masks and 
factoring in relative focus intensity as well as a splitting coefficient for accurate focus 
discrimination. 
 
2.2.12 Western Blotting 
2.2.12.1 Protein extraction 
Medium was removed and the plate was washed twice with PBS. The cells were 
scraped using a cell scraper (VWR®), collected in a 1.5 Eppendorf tube and spun at 
16,000g for 1 minute to obtain the pellet, which was stored at -80°C until use. 
PhosSTOP was added to the IP lysis buffer if specific phosphorylated protein isoforms 
were probed for by immunoblotting. 20-60 µl of IP lysis buffer were added per pellet, 
depending on the sizes, and then they were left for 15 mins on ice. The lysate was 
then centrifuged at 17,000g for 5 mins at 4°C. The lysate supernatant was reserved 
whilst the pellet of debris was discarded. 
 
2.2.12.2 Bradford Assay  
Bradford assay was used to quantify the protein concentration of cell lysates. Firstly, 
the protein assay dye reagent concentrate (Bio-Rad) was diluted in dH2O in a 1:4 ratio 
to make a working concentration of Bradford reagent. 1µL of cell lysate was added to 
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1mL Bradford reagent, and mixed. The Bradford reagent and protein sample was 
loaded into a polystyrene cuvette with 1cm path length, and the optical density shift at 
A595nm (OD595nm) of the sample relative to a blank control was measured using a 
WPA S1200 Diode Array Spectrophotometer (Biochrom®). The concentration of the 
protein lysate was then calculated and converted to µg/mL using the Beer-Lambert 
law (OD595nm = εcl; where ε = 1/15, and l = 1cm). 
 
2.2.12.3 SDS-Polyacrylamide Gel Preparation  
The separation of proteins was carried out on the basis of the molecular weight by a 
polyacrylamide gel under denaturing conditions. Resolving gels of the required 
acrylamide % (w/v) (Table 2.11) were prepared by mixing reagents described in Table 
2.12. Spacer plates with 1.0 mm integrated spacers (Bio-Rad) and short plates (Bio-
Rad) were assembled on the Mini-PROTEAN® Tetra Cell Casting Stand and clamps 
(Bio-Rad) with gaskets (Bio-Rad). Gels were poured into glass plates, and a layer of 
isopropanol was placed on top of the gels. The gels were left for at least 15 minutes 
to set and the isopropanol was removed. 5% stacking gels were prepared by mixing 
reagents described in Table 2.12, and then poured onto the set resolving gels in the 
glass plates. 1.0 mm 15-well Mini-PROTEAN® Combs (Bio-Rad) were then inserted 
into the stacking gels, and left for at least 15 minutes to set. 
 
Table 2.11 Appropriate gel percentage based on protein size 
Protein size (kDa) Gel Percentage (%) 
12-45 kDa 15% 
10-70 kDa 12% 




















2.2.12.4 Polyacrylamide Gel Electrophoresis  
Cell lysates were mixed with 4X Laemmli buffer (See Table 2.1) and boiled for 5 
minutes at 95°C to denature the proteins. 12% or 15% SDS-Polyacrylamide gels were 
loaded into a Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-Rad), and the 
apparatus was filled with running buffer (see Table 2.1). Typically, 20µg of denatured 
protein was loaded per well onto the SDS-polyacrylamide gels. 2μL pre-stained protein 
ladder (BLUeye, Geneflow) was loaded as a molecular weight marker in one well per 
gel. Gel electrophoresis was performed at 50V for 30mins, then 150V for 
approximately 1.3h until the dye front reached the bottom of the gel.  
 
2.2.12.5 Transfer on nitrocellulose membrane  
Gels were then removed from the electrophoresis cell, and assembled with transfer 
buffer (see Table 2.1)-saturated Whatman paper, and transfer buffer-saturated 
nitrocellulose membrane in a semi-dry transfer apparatus (Biometra) (Figure 2.2). 
Electrophoretic transfer of the proteins from the gels to the membranes was performed 
at 0.15A/gel transferred for 1h. Membranes were then stained with Ponceau stain 
0.1% (w/v) Ponceau S, 5% (v/v) acetic acid, and trimmed. 
  
dH2O 5.8 mL 4.2 mL 3.5 mL 2.5 mL 
30 % (w/v) Acrylamide 1.7 mL 3.3 mL 4.0 mL 5.0 mL 
Resolving buffer  - 2.5 mL 2.5 mL 2.5 mL 
Stacking buffer  2.5 mL - - - 
10 % (w/v) APS 50 μL 50 μL 50 μL 50 μL 




Figure 2.2 Semi-dry transfer apparatus and gel/membrane setup 
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2.2.12.6 Immunoblotting  
For general immunoblotting, membranes were blocked in 5% (w/v) milk/Tris buffered 
saline, with Tween® 20 (TBST) for 1h at room temperature on a roller. The 
membranes were incubated with primary antibody (Table 2.4) in 5% milk (w/v)/TBST 
over-night at 4°C on a roller.  
The following day membranes were washed 3 times in TBST for 15 minutes at room 
temperature. The membranes were then incubated with secondary antibody (Table 
2.5) conjugated to horseradish peroxidase (HRP) in 5% milk/TBST for 1h at room 
temperature on a roller. The membranes were then washed 3 times in TBST for 15 
minutes at room temperature and were then incubated with ECL for 1 minute and 
imaged using a G:BOX (Syngene). 
 
2.2.12.7 Quantification of protein levels  
Quantification of proteins was performed by densitometric analysis of bands obtained 
by immunoblotting using GeneTools (Syngene) image analysis software. The semi-
quantitative assay was obtained by correlating the densitometric value of the band 
obtained for the protein of interest to the value of a normaliser, employing a 
housekeeping gene like b-actin. Statistical analyses were made using Prism software 
(GraphPad). 
 
2.2.13 Nuclear and Cytoplasmic Fractionation 
Cell fractionation was used to assess the presence of SOD1 in the nucleus of 
iAstrocytes. 
Total fraction One 10cm plate was used for the total fraction. The medium was 
removed, and the cells washed once with PBS. The cells were then lysed with 250µL 
of IP T/N Lysis Buffer (See Table 2.1), scraped, collected in a tube and left 10 minutes 
on ice. After this incubation, the lysates were spun down at 13,300rpm, for 4 minutes, 
at 4˚C and the supernatant was collected in a fresh tube as total fraction. 
Cytoplasmic Fraction Two plates were used for the nuclear and cytoplasmic fraction. 
After one wash with PBS, 1mL of accutase was added and the plates were incubated 
at 37°C for 2 minutes. Accutase was neutralised with media and the cells were 
collected in a tube and spun at 200g for 4 minutes. The media were removed and the 
pellet was washed twice with PBS and then left to dry. 400µL of hypotonic lysis buffer 
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(See Table 2.1) was added to the pellet, re-suspending it with a cut tip, to avoid 
shearing cells. At this point the lysate was passed through a 19g needle 10 times, left 
for 10 minutes on ice and then, spun down at 4,000rpm for 3 minutes at 4°C to 
separate the nuclear fraction from the cytoplasmic. The supernatant was transferred 
to a fresh tube, and spun again at 6,000rpm for 8 minutes at 4°C. The supernatant 
was collected into a new tube and spun down at 13,300rpm for 1 minute at, 4°C. The 
final supernatant was the cytoplasmic fraction. 
Nuclear Fraction To the pellet (from the cytoplasmic fraction) 250µL of IP lysis buffer 
with 60µL of PMSF were added. At this point the lysate was passed through a 25g 
needle 10 times and then left for 30 minutes on ice. It was spun at 13,300rpm for 4 
minutes at 4°C. The supernatant was the nuclear fraction. Bradford assay and 
Western Blot were performed as described in section 2.1.12. Equal loading was done 





2.2.14 Pull-down  
2.2.14.1 Oxidised RNA 
30µL of Protein G Sepharose beads (GE Healthcare) were taken as a slurry for each 
sample/condition, using a 1ml pipette tip cut at the bottom to enlarge the point. The 
beads were washed once with DEPC PBS and then diluted in 1ml DEPC PBS, 
centrifuged for 1 minute at 500g, then the supernatant was removed. 1mL 2% BSA in 
DEPC PBS was added and the tubes were left rotating at 4°C for 1 hour to block the 
beads. The tubes containing the beads were spun down at 500g for 1 minute at 4°C. 
1mL of DEPC PBS with 0.5% Triton was added. 2 µL of antibody, 8hydroxyguanosine 
was added to each tube, and then they were left rotating at 4°C overnight. The 
following day, on ice, the media were removed from cells that were washed once with 
DEPC PBS. 1mL of DEPC PBS was added to the 10cm dish and UV-crosslinked with 
300mJ/cm2. The cells were scraped and transferred to a pre-chilled 1.5mL tube. The 
lysate was passed through a 19G needle 10 times and left on ice for a further 
10minutes. Subsequently the preparation was centrifuged for 10min, 17,000g at 4°C 
and the supernatant was transferred to a new tube, and the protein concentration was 
measured through a Bradford assay, as previously described. The sample was diluted 
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to 2mg/mL. The beads were centrifuged for 1min at 500g and the supernatant was 
removed. The same volume of lysate was added to the beads and the 1:1(v:v) of PBS 
plus 1M NaCl was added. The samples were incubated rotating at 4°C overnight. 
The tubes were centrifuged for 1 minute at 500g and the supernatant was removed. 
The pellet was washed once with PBS+1M NaCl+0.1% Triton and twice with Lysis 
buffer (PBS + 0.5% Triton). The supernatant was removed and 50µL of elution buffer 
and 1µL of RNase A (10mg/ml) were added. The tubes were vortexed slowly and then 
incubated at 37°C for 30 minutes, flicking them every 5 minutes. After this incubation 
they were centrifuged for 1min at 17,000g. The supernatant containing RNA-bound 
proteins was collected. On SDS-PAGE the input and eluted protein (output) were 
processed as described before in the western blot analysis section 2.1.12. 
 
2.2.14.2 PolyA RNA precipitation 
For this assay 4 dishes per cell line were used. The medium was removed from cells, 
which were washed with DEPC PBS. Half samples were treated with UV to crosslink 
proteins and RNA, while half were not crosslinked as a negative control.  
For the “no UV” samples: PBS was removed, 500μL of lysis buffer was added, and 
then, the cells were scraped and transferred into pre-labelled tubes.  
For UV samples: PBS was removed, 1mL of DEPC PBS was added to cover the cells. 
The plates were placed on ice without lids and UV crosslinked at 0.3 J/cm2 (3,000x100 
μL/cm2). The PBS was removed and 500μL lysis buffer was added. The cells were 
scraped and transferred to pre-labelled tubes. All of the samples were incubated on 
ice for 5 minutes and then spun for 10 minutes at maximum speed at 4°C. While 
spinning, 50μL of magnetic oligo(dt) beads (New England BioLab) per treatment were 
taken and were placed on a magnet for 2 minutes. The supernatant was removed. The 
beads were washed with 200μL lysis buffer. The beads were returned to the magnet 
and the lysis buffer was removed. The beads were re-suspended in 200μL lysis buffer 
and stored on ice. The cleared lysates were transferred to fresh tubes and quantified 
using the Bradford assay. Samples were normalised to the lowest one, not exceeding 
4mg protein/mL extract. The beads were placed on the magnet and the lysis buffer 
was removed. The beads were mixed with the samples and an equal volume of 2x 
binding buffer was added. The samples were incubated at room temperature, rotating 
at 10rpm, for 90 minutes. Supernatant was removed from the beads using the magnet. 
The beads were washed 5 times with 500μL 1x binding buffer (diluted with DEPC 
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water) and re-suspended in 50μL elution buffer plus 1μL PIC and 1μL RNase A. The 
samples were incubated at 37°C for 30 minutes, gently agitating the beads every 5 
minutes. On SDS-PAGE inputs and eluted protein (output) were loaded and processed 
as described before in western blot analysis section 2.1.12. 
 
2.2.15 Misfolded SOD1 and WT SOD1 Immunoprecipitation  
30µL of protein G sepharose beads (GE Healthcare) were taken as a slurry for each 
sample, cutting the tip. The beads were washed twice with 1ml of IP lysis buffer, 
centrifuged for 2 minutes at 2,000G, then the supernatant was removed. 1mL 0.5% 
BSA in IP lysis buffer was added and the tubes were left rotating at 4°C for at least 1 
hour to block the beads. The tubes containing the beads were spun down at 500g for 
1 minute at 4°C. Lysis buffer was discarded. 1µL of antibody (misfolded SOD1 or WT 
SOD1) was added to each tube, and then they were left rotating at 4°C overnight. The 
following day, on ice, the media were removed from cells, that were washed once with 
PBS. The cells were scraped and transferred to a pre-chilled 1.5mL tube. The lysate 
was passed through a 19G needle 10 times and left on ice for a further 15 minutes. 
Subsequently the preparation was centrifuged for 10min at 17,000g and 4°C the 
supernatant was transferred to a new tube, and the protein concentration was 
measured by a Bradford assay. The sample was diluted to 2mg/mL. The beads were 
centrifuged for 1min at 500g and the supernatant was removed. The same volume of 
lysate was added to the beads. The samples were incubated by rotating at 4°C 
overnight. The tubes were centrifuged for 1minute at 500g and the supernatant was 
removed. The beads were washed 5 times with IP lysis buffer. The samples were 
eluted in 2x Laemmli buffer, sonicated for 10s on ice using the Soniprep 150 (MSE) 
for 10 seconds at 25% amp and boiled 5 minutes at 95°C. SDS-PAGE inputs and 
eluted protein (output) were loaded and processed as described in section 2.1.12. 
 
2.2.16 Proximity Ligation Assay (PLA) 
The proximity ligation assay (PLA) was performed in the 96 well plate using 
Duolink® In Situ Orange Starter Kit Mouse/Rabbit (Sigma-Aldric); 7,000-10,000 cells 
were plated per well. Firstly, the medium was removed from the wells and the cells 
were gently washed with PBS. The cells were fixed with 4% formaldehyde in PBS. 
After fixing, the cells were washed twice with PBS and permeabilised with 0.5% Triton 
in PBS for 10 mins at room temperature (RT). The cells were then washed twice with 
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PBS. Secondly, droplets of PLA blocking buffer (from the PLA kit) were placed to cover 
the wells. The plate was incubated for 30 mins at 37°C. During the blocking step, the 
primary antibodies were prepared and diluted in PBS. 
The primary antibodies were incubated overnight at 4°C. The following day the PLA 
secondary probes (from the PLA kit) were prepared. After the primary antibody 
incubation, cells were washed twice with PLA wash buffer A (from the PLA kit). 40-50 
µl of PLA secondary probes were added onto each well and the secondary antibodies 
were incubated for 1 hour at 37°C. During this incubation, the PLA ligation reagents 
(from the PLA kit) were prepared. After the secondary PLA probe incubation, the cells 
were washed twice with PLA wash buffer A. 40-50 µl of the ligation mix was placed 
onto each well and incubated for 30 mins at 37°C. The PLA amplification reagents 
(from the PLA kit) were prepared. After the PLA ligation incubation, the cells were 
washed twice with PLA wash buffer A. The amplification mix was incubated for 100 
mins at 37°C. After the PLA amplification incubation, cells were washed twice in 0.01X 
wash buffer B (from the PLA kit). Hoechst reagent was diluted 1:10,000 in wash buffer 
B and incubated for 5 minutes at RT. Lastly, cells were washed twice with 0.01X wash 
buffer B to remove Hoechst from the cells. At this point, the plate was ready to be 
scanned with the Opera Phenix high content imaging system. 
 
2.2.17 Statistical Analysis 
All experiments were performed at least in triplicate. Data were analysed using 
GraphPad Prism Software (V8.4.2): one-way ANOVA with Tukey's multiple 
comparisons post-test or, two-way ANOVA with Tukey's multiple comparisons post-
test. t test was used to compare old donor samples to the young donor samples for 
qPCR and western blot and for control sample to specific patient subgroups for 
western blot.  
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 Results   
 
Characterisation of the ageing phenotype in 
directly reprogrammed astrocytes and the 






Astrocytes are the most abundant group of glial cells, necessary for homeostasis, 
defence and regeneration of the CNS. It has been reported that ageing affects glial 
cells to a greater extent than neurons in the human brain (Soreq et al., 2017). Ageing, 
in fact, provokes a reduction in the ability of glial cells, in particular astrocytes, to 
maintain a balanced and healthy CNS homeostasis. Astrocytes have preserved some 
of their roles across species, but their reaction to insults and their role in neuronal 
support make mammalian astrocytes unique. In addition, human astrocytes have 
evolved to develop a unique response to inflammatory stimuli and a finely tuned cross-
talk with neurons (Verkhratsky and Nedergaard, 2016). Thus, it is important to have a 
model of human astrocytes suitable for ageing and disease modelling, especially in 
relation to neurodegenerative disorders, in which non-cell autonomous mechanisms 
are involved.  
In my PhD project, I focused on ALS, where it is well known that astrocytes contribute 
to disease pathophysiology and ageing represents a major risk factor. This led to 
addressing the first aims of my PhD thesis: 
 
1. To determine the ability of the direct reprogramming protocol used in my 
laboratory to retain phenotypic age-related properties of donor fibroblasts in the 
induced astrocytes derived from the reprogramming. 
 
2. To determine the functional properties of induced astrocytes derived from 
donors at different ages, based on known age and disease-related functional 
changes, i.e. oxidative stress response, inflammatory response and 
nucleocytoplasmic transport changes.  
 
This first results chapter of my thesis addressing these aims is composed of the 
research article submitted for publication and currently under revision in the journal 
“Aging Cell”.  
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Directly converted astrocytes retain the ageing features of the donor 
fibroblasts and elucidate the astrocytic contribution to human CNS 
health and disease 
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Astrocytes are highly specialised cells, responsible for CNS homeostasis and neuronal 
activity. Lack of human in vitro systems able to recapitulate the functional changes 
affecting astrocytes during ageing represents a major limitation to studying 
mechanisms and potential therapies aiming to preserve neuronal health. Here we 
show that induced astrocytes from fibroblast donors in their childhood or adulthood 
display age-related transcriptional differences and functionally diverge across a 
spectrum of age-associated features, such as altered nuclear compartmentalization, 
nucleocytoplasmic shuttling properties, oxidative stress response and DNA damage 
response. Remarkably, we also show an age-related differential response of 
iAstrocytes in their ability to support neurons in co-culture upon exposure to pro-
inflammatory stimuli. These results show that iAstrocytes are a renewable, readily 
available resource of human glia that retain the age-related features of the donor 
fibroblasts, making them a unique and valuable model to interrogate human astrocyte 
function over time in human CNS health and disease. 
 
 
Keywords: direct reprogramming, astrocytes, ageing, neurodegeneration, in vitro 
model, nucleocytoplasmic transport, neuron-astrocyte crosstalk, neuroinflammation, 
oxidative stress, nuclear abnormalities.  
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Introduction  
Ageing is considered the primary risk factor for many devastating pathologies, 
including neurodegenerative diseases, which primarily affect neurons. There is robust 
evidence, however, for non-cell autonomous mechanisms in which neurodegeneration 
is influenced or even driven by glial cells (Lobsiger and Cleveland, 2007; Meyer et al., 
2014; Lee et al., 2016; Chai and Kohyama, 2019; di Domenico et al., 2019).  
Astrocytes, the most abundant non-neuronal cell population in the central nervous 
system (CNS), are known to guide brain development (Verkhratsky and Nedergaard, 
2016) and to play a crucial role in CNS homeostasis and repair (Parpura et al., 2012). 
Moreover, studies interrogating the gene expression profile of rodent and humans 
neurons, astrocytes and microglia have found that astrocytes, more than neurons, 
dramatically change their gene expression pattern with age (Soreq et al., 2017). This 
indicates that they might be significant drivers of the ageing process and preservation 
of their physiological functions over time will clearly support neuronal health. 
 
Changes in glial functions, such as reduced redox homeostasis and increased pro-
inflammatory responses, are hallmarks of the ageing brain (Lynch et al., 2010; Bellaver 
et al., 2017; Matias, Morgado and Gomes, 2019). Consistently, in vitro studies 
comparing primary astrocytes from young and old rodents have shown changes in the 
expression of the nuclear factor erythroid-derived 2-like 2 (Nrf2) (Duan et al., 2009; 
Lewis et al., 2015) and nuclear factor kappa B (NFκB) (Tilstra et al., 2011; Osorio et 
al., 2016), master regulators of the antioxidant and inflammatory responses 
respectively. A decrease in the effectiveness of the antioxidant response in the ageing 
brain leads to accumulation of oxidised nucleic acids, proteins and lipids (Gemma et 
al., 2007), while increased NFκB activity exacerbates the production of pro-
inflammatory cytokines (Lynch, 2010; Rea et al., 2018). Both processes are known to 
participate in neurodegeneration and are therefore considered appealing therapeutic 
targets.  
The lack of human in vitro models that recapitulate the functional changes affecting 
astrocytes throughout ageing represents a major limitation for studying relevant 
mechanisms and potential therapies aiming to preserve brain health, as well as 
targeting age-related neurodegenerative disorders. Studies using astrocytes isolated 
from post-mortem (PM) human samples (Blasko et al., 2000; Re et al., 2014) have 
shed light on important disease mechanisms, but the availability of these cells is 
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limited and their function might be altered by factors related to post-mortem collection, 
hence the need for widely available, reproducible human in vitro models that retain 
age-related biochemical alterations. 
So far, somatic cell reprogramming is the most commonly used methodology 
(Takahashi et al., 2007) to address the challenges of modelling human 
neurodegenerative diseases. The induction of pluripotency factors in adult fibroblasts, 
however, reverts cellular age to an embryonic status (Lapasset et al., 2011; Patterson 
et al., 2012), which is retained even after conversion into neurons, erasing ageing-
associated signatures (Miller et al., 2013). To circumvent this limitation, recent studies 
have shown that neurons directly reprogrammed from fibroblasts without the use of 
pluripotency factors, retain ageing signatures compared to induced pluripotent stem 
cells (iPSC)-derived neurons (Mertens et al., 2015; Huh et al., 2016; Tang et al., 2017; 
Victor et al., 2018). Direct conversion preserves ageing features in neurons; however, 
no study has yet achieved this goal in astrocytes. Most available protocols for 
derivation of human astrocytes utilise iPSCs, are time consuming and have low 
conversion efficiency (Almad and Maragakis, 2018). Although recent methodologies 
have made human astrocyte production from iPSCs faster (Canals et al., 2018; Tchieu 
et al., 2019), the field is still lacking an in vitro human astrocyte system able to retain 
the ageing characteristics of the donor. 
 
In 2014, we described the first human-derived astrocytes differentiated from tripotent 
induced neural progenitor cells (iNPCs) directly converted from adult fibroblasts 
(Meyer et al., 2014). This protocol is fast and highly efficient and does not involve 
clonal expansion, thus greatly reducing the variability associated with iPSCs (Ortmann 
and Vallier, 2017; Mertens et al., 2018). Induced NPCs can be expanded and stored 
for several passages and are an immediate source of neurons (Webster et al., 2016), 
oligodendrocytes (Ferraiuolo et al., 2016) and astrocytes. Induced astrocytes 
(iAstrocytes) can be obtained from iNPCs in only 7 days and have been utilised to 
study childhood (Boczonadi et al., 2018) and adult-onset neurodegenerative 
disorders, including amyotrophic lateral sclerosis (ALS) (Meyer et al., 2014; 
Hautbergue et al., 2017; Varcianna et al., 2019).  
The ability of this protocol to retain ageing features at transcriptional and functional 
level has not been interrogated previously. 
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In the present study we assess the ability of this direct conversion methodology to 
retain the ageing features of the donor’s fibroblasts. Comparing the gene expression 
profiles of iAstrocytes derived from donors in childhood or adulthood with 
transcriptomic data from adult post-mortem (PM) and fetal astrocytes revealed that 
iAstrocytes reproduce transcriptional age-related features. We then showed how 
iAstrocytes from the two different age groups diverge in relation to a spectrum of age-
associated features, such as accumulation of DNA damage, altered nuclear 
compartmentalization, oxidative stress and nucleocytoplasmic shuttling defects. 
Furthermore, we showed an age-related differential response of iAstrocytes in their 
ability to support neurons in co-culture upon stimulation with the inflammatory cytokine 
interleukin-1 beta (IL-1β). 
In conclusion, our results show that age-related features are retained in iAstrocytes 
reprogrammed from donor fibroblasts, thus making this model a reliable and 
accessible tool to interrogate human astrocyte function over the life course in health 




Efficient differentiation of iAstrocytes from young and old donor fibroblasts  
To determine whether astrocytes derived from induced neuronal progenitor cells 
(iNPCs) directly converted from fibroblasts (Meyer et al., 2014) retain the ageing 
features of the donor, we set out to directly reprogramme fibroblasts from individuals 
belonging to two distinct age groups. Fibroblast samples from three donors ranging in 
age from 42 to 56 years and three donors ranging in age from 5 months to 3 years 
(Table S1) were directly reprogrammed to iNPCs (Figure 1A), which stained positive 
for the neural progenitor markers Pax6 and Nestin (Figure 1B). Passage matched old 
and young donor-derived iNPCs were then differentiated into iAstrocytes in 7 days as 
previously described (Meyer et al., 2014). iAstrocytes from both young and old donors 
expressed typical astrocytic markers, including glial fibrillary acidic protein (GFAP), 
vimentin (VIM), CD44, as well as the glutamate transporter EAAT2, a marker of mature 
astrocytes. The cells derived from young and old donors have similar confluency rate, 
despite the difference in their size (Figure 1C). This protocol is highly efficient, yielding 
>98% cells positive for the above markers (Figure S1). 
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Figure 1. Characterization of iAstrocytes from old versus young donors 
(A) Schematic illustration of the differentiation protocol, from young and old donor 
fibroblasts to induced neuronal progenitor cell (iNPC) derived iAstrocytes. 
(B) Representative images of PAX6/Nestin staining in young and old donor derived 
iNPCs. Scale bar (10µm). 
(C) Representative images of astrocytic markers (GFAP, vimentin (VIM), CD44 and 




Transcription profile discriminates iAstrocytes from young and old donors and 
segregates them according to age-related gene expression signatures 
To interrogate the transcriptional features of fibroblast-derived iAstrocytes in relation 
to their ageing phenotype, we compared transcriptomic data from iAstrocytes obtained 
from old and young donors to bona fide human astrocytes laser captured from post-
mortem (PM) brains (Simpson et al., 2011; Waller et al., 2012) and fetal primary 
astrocytes (Table S2). After signal normalization and harmonization of the 4 datasets, 
gene expression levels of 18,357 transcripts were imported into the bioinformatics 
software Qlucore. The data were then visualised using a principal component analysis 
(PCA) plot (Figure 2A), with application of stringent multi-group comparison statistics 
(p-value ≤ 1x10e-4). This analysis identified 16,284 differentially expressed transcripts 
that determined sample grouping on the PCA plot (Figure 2A). Using the same 
parameters, we also visualised the sample groups based on transcript levels in a 
hierarchical cluster heat-map (Figure 2B). Both data representation plots showed that 
iAstrocytes from the two different age groups have distinct transcription profiles, which 
group closely with their bona fide astrocyte counterpart. In fact, individuals in their 5th-
6th decade of life (old donor) group closely with astrocytes taken at post-mortem from 
older individuals, while iAstrocytes from individuals in their 1st decade of life (young 
donor), although clearly separate from fetal astrocytes, group more closely to these 
samples. In order to determine whether the transcripts described age-related features, 
we downloaded a human dataset of 307 genes commonly altered during ageing, from 
the Human Genomic Resources (HAGR), GenAge database 
(https://genomics.senescence.info/genes/index.html). From this list of 307 genes, 285 
genes were present in the list of 16,284 transcripts that determined the sample sub-
grouping. Consistently, the PCA plot (Figure S2A) and the hierarchical clustering 
(Figure S2B) of the 4 groups in relation to these 285 age-related transcripts confirmed 
the separation between PM and fetal astrocytes and iAstrocytes in the two age groups 
(Figure S2). We also performed two-group comparison analysis (p-value ≤ 0.05, fold 
change > 1.5), between bona fide astrocytes from different age groups, PM and fetal 
astrocytes, as well as iAstrocytes from young and old donors. The first comparison 
(PM vs fetal astrocytes) reported 7,875 differentially expressed transcripts, while the 
second (young vs old iAstrocytes) reported 1,639. We then proceeded to interrogate 
how many of these differentially expressed transcripts were common to both 
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comparisons, and almost 80% of the transcriptional differences between young and 
old iAstrocytes matched the corresponding comparison between PM and fetal primary 
human astrocytes (Figure 2C). Pathway analysis of these 1,298 transcripts (Table S3) 
via Panther (http://www.pantherdb.org/) identified several physiological and 




Figure 2. Old donor iAstrocytes and post-mortem (PM) astrocytes have 
distinctly different transcriptomes compared to fetal astrocytes and young 
donor iAstrocytes. 
(A) Principal component analysis (PCA) plot of fetal astrocytes, PM astrocytes and old 
and young donor derived iAstrocytes. Multi-group comparison, p≤1x10e-4. 
(B) Hierarchical cluster heat-map of fetal astrocytes, PM astrocytes and old and young 
donor iAstrocytes. Multi-group comparison, p≤1x10e-4. 
(C) Venn diagram representing two-group comparison analysis (p-value ≤ 0.05; fold 
change > 1.5) between PM and fetal astrocytes as well as iAstrocytes from young and 
old donors. PM vs fetal astrocyte comparison reported 7,875 differentially expressed 
transcripts, while young and old donors iAstrocytes reported 1,639. 1,298 differentially 
expressed transcripts were common to both comparisons. Approximately 80% of the 
transcriptional differences between young and old iAstrocytes matched the 
corresponding comparison between PM and fetal primary human astrocytes. See also 
Figure S2 and Table S3.  
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Table 1 Table illustrating the pathways identified by the 1,298 transcripts intersecting 
the comparisons between PM vs fetal astrocytes as well as iAstrocytes from young vs 
old donors. 
Pathway name % 
transcripts 
Integrin signalling pathway 4.50% 
Wnt signaling pathway 4.20% 
Huntington disease 3.40% 
Inflammation mediated by chemokine and cytokine signalling 
pathway 
3.40% 
EGF receptor signalling pathway 3.20% 
DNA damage signalling pathway 2.20% 
Alzheimer disease-amyloid secretase and presenilin pathway 2% 
Cytoskeletal regulation by Rho GTPase 1.90% 
Parkinson disease 1.90% 
p53 pathway 1.80% 
Ubiquitin proteasome pathway 1.80% 
TGF-beta signalling pathway 1.60% 
Oxidative stress response 1.60% 
Heterotrimeric G-protein signalling pathway-Gi alpha and Gs alpha 
mediated pathway 
1.50% 
Axon guidance mediated by semaphorins 1.40% 
PI3 kinase pathway 1.30% 
VEGF signalling pathway 1.30% 
Glutamate receptor pathway 1% 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP 
kinase cascade 
0.90% 
Protein biosynthesis 0.70% 
p38 MAPK pathway 0.60% 
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iAstrocytes from older donors recapitulate nuclear ageing features 
In order to determine whether the expression of specific age-associated transcripts 
was preserved between iAstrocytes and their fibroblasts of origin, we interrogated the 
expression of 3 transcripts that have been previously identified as consistently 
decreasing with ageing in various tissues (Martínez et al., 2014; Mertens et al., 2015; 
Godin et al., 2016). RAN binding protein 17 (RANBP17) and laminin subunit alpha 3A 
(LAMA3A) were identified by Mertens et al when comparing the transcriptomes of 
human fibroblasts and brain samples from a broad range of aged donors. Their change 
in expression was shown to be maintained between fibroblasts and derived directly 
reprogrammed neurons (iNeurons), but not iPSC-derived neurons. RANBP17 is a 
nuclear pore-associated transport receptor, a member of the importin-β family, 
involved in the transport of nuclear localisation signal (NLS)-containing cargo proteins 
through the nuclear pore complex (NuPC) (Koch et al., 2000; Lee, Zhou and Smas, 
2010), while LAMA3, also reported to decrease with age in other in vivo studies (Godin 
et al., 2016), encodes an extracellular matrix protein. In addition, we also assessed 
the expression of telomeric repeat-binding factor 2 (TERF2), a component of shelterin 
that together with TERF1 is responsible for telomerase maintenance (Martínez et al., 
2014). It is well known that telomerase activity is crucial in determining telomere length 
in ageing cells and that telomere length can be considered as a biomarker of 
chronological ageing (Rizvi, Raza and Mahdi, 2015; Fasching, 2018). In agreement 
with previous reports, our results show that TERF2, RANBP17 and LAMA3 mRNA 
levels decrease significantly with age in fibroblasts and we show here that iAstrocytes 
retain this decline in expression levels after reprogramming (Figures 3A, 3B and 3C). 
In addition to assessment of transcriptional features, we interrogated cellular 
parameters that have previously been reported to change with age, including nuclear 
size and shape (Pienta, Getzenberg and Coffey, 1992; Haithcock et al., 2005; Scaffidi 
and Misteli, 2006; Brandt, Krohne and Grohans, 2008), as well as histone methylation 
(Miller et al., 2013).  
DNA is contained in the nucleus and it is well documented how nuclear structure is 
affected during ageing (Haithcock et al., 2005; Scaffidi, Gordon and Misteli, 2005). 
Heterochromatin organization and nuclear shape were assessed via immunostaining 
using the heterochromatin-associated trimethylated 'Lys-9' on histone H3 marker 
(H3K9me3) and the nuclear lamina marker lamin A/C. H3K9me3 is the hallmark of 
constitutive heterochromatin (Maleszewska, Mawer and Tessarz, 2016), whilst Lamin 
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A/C coded by the gene LMNA, is part of the lamin protein family, which form 
components of the nuclear lamina (Liu and Zhou, 2008). 
Consistent with previous reports describing an overall decrease in H3K9me3 in cells 
and tissues (Miller et al., 2013) iAstrocytes from older donors displayed a significant 
global reduction of H3K9me3 staining (Figures 3E and 3H). Immunostaining of lamin 
A/C also confirmed that iAstrocytes from older donors displayed significant nuclear 
morphology alterations, with increased nuclear folding and blebbing. Lamin staining is 
clearly localized in the nuclear membrane and defines nuclear shape in young 
iAstrocytes, while it displays fragmented and less spherical staining in iAstrocytes from 
older donors (Figures 3F and 3I). In addition, we report a significant increase in nuclear 
size assessed by Hoechst staining in old iAstrocytes (Figures 3D and 3G). Similar 
findings have been reported in in vitro and in vivo fibroblasts (Mitsui and Schneider, 
1976; Mukherjee and Weinstein, 1986; Pienta, Getzenberg and Coffey, 1992).  
Taken together, these results demonstrate that iAstrocytes reprogrammed from 
donors of different age groups retain some of the ageing features of their parental 




Figure 3. Young and old iAstrocytes retain the ageing phenotype of their 
fibroblasts of origin.  
(A) Quantification of RANBP17 mRNA levels in young and old donor fibroblasts and 
derived iAstrocytes. Results are expressed as the means ± SD. Unpaired t-test, 
*P<0.05, **P<0.01 (n=3). 
(B) Quantification of LAMA3A mRNA levels in young and old donor fibroblasts and 
derived iAstrocytes. Results are expressed as the means ± SD. Unpaired t-test, 
*P<0.05 (n=3). 
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(C) Quantification of TERF2 mRNA levels in young and old donor fibroblasts and 
derived iAstrocytes. Results are expressed as the means ± standard deviation (SD). 
Unpaired t-test, *P<0.05 (n=3). 
(D) Representative images of Hoechst staining in young and old donor derived 
iAstrocytes. Scale bar (10µm). 
(E) Representative images of H3K9me3 staining in young and old donor derived 
iAstrocytes. Scale bar (10µm). 
(F) Representative images of Lamin A/C staining in young and old donor derived 
iAstrocytes. Scale bar (10µm). 
(G) Quantitative image analysis of nuclear sizes in young vs old donor derived 
iAstrocytes. Nuclear size (µm2) was assessed using Columbus Software. Results are 
expressed as the means ± SD. Unpaired t-test, ****P<0.0001 (n=3). 
(H) Quantitative image analysis of H3K9me3 in young vs old donor derived 
iAstrocytes. H3K9me3 intensity was assessed using Columbus Software. Results are 
expressed as the means ± SD. Unpaired t-test, **P<0.01 (n=3). 
(I) Quantitative image analysis of Lamin A/C in young vs old donor derived iAstrocytes. 
Lamin A/C roundness was assessed using Columbus Software. Results are 
expressed as the means ± SD. Unpaired t-test, **P<0.01 (n=3). 
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iAstrocytes reveal age-related nuclear permeability and nucleocytoplasmic 
transport defects  
In order to examine further the nuclear envelope abnormalities detected via lamin A/C 
staining, we set out to interrogate the overall integrity of another nuclear component, 
the nuclear pore complex (NucPC). Seminal work (D’Angelo et al., 2009) has 
previously revealed that the NucPC is highly affected by age in post-mitotic cells, 
leading to nuclear “leakiness”. This phenomenon has also been recently highlighted 
as critically important also in age-related diseases, such as amyotrophic lateral 
sclerosis (ALS) and Alzheimer’s disease (AD) (Kim and Taylor, 2017; Eftekharzadeh 
et al., 2018). 
In intact nuclei, molecules of up to 40-50 kDa can pass through the NucPC via passive 
diffusion, while molecules larger than 60 kDa are excluded from intact nuclei (Lénárt 
and Ellenberg, 2006). Thus, we analysed the overall nuclear permeability in young 
and old donor iAstrocytes, by isolating nuclei from both groups of iAstrocytes and 
incubating them with a 70 kDa fluorescently-labelled dextran (Figure 4A). Nuclei were 
then stained for Hoescht and imaged using a confocal microscope. We found that 
influx of the 70 kDa dextran was observed only in the old donor-derived iAstrocyte 
nuclei (Figure 4B), and not in young donor-derived iAstrocyte nuclei. This confirms 
that direct conversion of fibroblasts into iNPCs and subsequently iAstrocytes retains a 
key characteristic of ageing that is often associated with neurodegenerative conditions 
(D’Angelo et al., 2009) and so far has been primarily associated with neuronal ageing. 
Further, we assessed the levels of three proteins involved in active nucleocytoplasmic 
transport, i.e. Ran binding protein 17 (RANBP17), Importin 5 (IPO5) and Exportin 1 
(XPO1). Importin 5 is a member of the importin-β family of nuclear transport receptors 
that mediates transport of proteins carrying a nuclear localisation signal (NLS), 
RANBP17 serves as nuclear import receptor, whilst Exportin 1 (XPO1) mediates the 
nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) 
and of some non-coding RNA molecules including snRNAs and rRNAs. 
Consistent with reports that nucleocytoplasmic transport becomes impaired with age 
and in neurodegeneration (Ribezzo, Shiloh and Schumacher, 2016; Kim and Taylor, 
2017; Ferreira, 2019; Hutten and Dormann, 2019), our results show that RANBP17, 
IPO5 and XPO1 protein levels are significantly decreased in older compared to young 




Figure 4. Old and young iAstrocytes show differential nuclear permeability and 
nucleocytoplasmic shuttling/export.  
(A) Schematic illustration of the nuclear isolation protocol for dextran application 
(B) Representative images of TRITC-labelled dextran influx in young vs old donor 
derived iAstrocytes.  
(C) Representative images of western blot analysis of RANBP17, IPO5 and XPO1. 
Protein from young and old donor derived iAstrocytes was separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting.  
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(D) Densitometric quantification of RANBP17 normalised to GAPDH. Values are 
expressed as means ± SD. Unpaired t-test, **P<0.01 (n=3). 
(E) Densitometric quantification of XPO1 normalised to GAPDH. Values are expressed 
as means ± SD. Unpaired t-test, *P<0.05. (n=3). 
(F) Densitometric quantification of IPO5 normalised to GAPDH. Values are expressed 
as means ± SD. Unpaired t-test, **P<0.01 (n=3). 
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Older donor-derived iAstrocytes display lower anti-oxidant defences 
A key hallmark of ageing is rising levels of oxidative stress and accumulation of 
reactive oxygen species (ROS) that leads to nucleic acid, protein and lipid oxidation. 
Astrocytes are the principal cell type in the CNS responsible for counteracting the 
increase in oxidative stress through the anti-oxidant response and non-cell 
autonomous support of neurons (Bell et al., 2011). To test the hypothesis that 
reprogrammed iAstrocytes from donors of different ages can model this central aspect 
of astrocyte function, we quantified the endogenous levels of ROS in iAstrocytes from 
naïve young and old donors, using the CellROX® Oxidative Stress Reagent, a 
fluorogenic probe designed to measure reactive oxygen species (ROS) in live cells. 
We found that ROS levels were significantly higher in old compared to young donor-
derived iAstrocytes under basal conditions (Figures 5A and 5B). To test how 
iAstrocytes respond to stressors that increase oxidative stress over time, we also 
performed a time-course experiment. We measured intracellular levels of ROS in 
young and old donor iAstrocytes at baseline before subjecting the cells to 12h of serum 
starvation. After 12h we measured the levels of intracellular ROS in both groups of 
iAstrocytes, and then following a change to full iAstrocyte medium assessed how long 
it took the cells to return to baseline levels of ROS. Our measurements show that both 
young and old donor-derived iAstrocytes display an increase in intracellular ROS after 
serum starvation and recover after removing the stimulus, going back to baseline 
levels (Figure 5C). Remarkably, iAstrocytes from younger individuals recovered to 
their baseline levels after only 4 hours, while iAstrocytes from older individuals 
required a longer time-period of 6 hours (Figure 5C).  
To understand what changes may underlie the increased levels of ROS seen in old 
iAstrocytes at baseline, and the delayed recovery from oxidative stress following 
serum starvation, we investigated the levels of NRF2, the master regulator of 
antioxidant defences, and superoxide dismutase 1 (SOD1), a major antioxidant 
enzyme responsible for the breakdown of superoxide radicals. Both NRF2 and SOD1 
are present in the list of ageing genes that are down-regulated in both PM and old 
iAstrocytes versus fetal astrocytes and young iAstrocytes in our microarray analysis 
(Figure 2 and S2B). Consistent with in vivo data (Zhang, Davies and Forman, 2015; 
Paladino et al., 2018) and our transcriptomic data, we found that NRF2 and SOD1 
baseline levels are significantly lower in old as opposed to young donor-derived 
iAstrocytes (Figures 5D, 5E and 5F). The lowered antioxidant defences present in old 
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iAstrocytes may explain the increased levels of baseline ROS species observed 
(Figures 5A and 5B). Considering the ability of both young and old donor iAstrocytes 
to respond to the oxidative stress generated by serum starvation treatment (Figure 
5C), we set out to evaluate the protein levels of NRF2 and SOD1 in response to this 
stressor. As suggested by our time-course experiments (Figure 5C), we observed a 
significant increase in NRF2 protein level in iAstrocytes from both age groups, thus 
showing that both groups can respond to acute oxidative stress insults. However, the 
total levels of NRF2 and SOD1 were still lower in old compared to young iAstrocytes 
in the serum starved conditions, giving a potential explanation for the decreased and 
slower response to counteract oxidative stress after the insult (Figures 5D, 5E and 
5F). 
Oxidative stress is known to affect cell function in many ways through protein, lipid 
and nucleic acid oxidation. In particular, DNA damage has been recognised as a 
causal factor in the ageing process and its markers are hallmarks of aged tissues, 
especially in the CNS, where cell turnover is limited (Lu et al., 2004). The current 
hypothesis is that DNA damage accumulation with ageing causes loss of key cellular 
functions leading to degeneration (Ribezzo, Shiloh and Schumacher, 2016). In order 
to repair these lesions, in particular DNA double strand breaks (DSBs), the DNA 
damage response (DDR) starts at the damage site with the phosphorylation of the C-
terminal of the core histone protein H2AX (γH2AX). Consistent with the increase in 
ROS and concomitant decrease in the anti-oxidant response, we detected an increase 




Figure 5. Altered oxidative stress capacities in old donor derived astrocytes. 
(A) Representative immunofluorescence images of ROS in young and old donor 
derived iAstrocytes. Cellular ROS levels were assessed in iAstrocytes by CellROX® 
Reagent, Scale bar (10µm). 
(B) Quantitative image analysis of ROS detected by CellROX® Reagent in young and 
old donor derived iAstrocytes. Fluorescence intensity was assessed using Columbus 
Software. Results are expressed as means ± SD. Unpaired t-test, ****P<0.0001 (n=3).  
(C) Quantitative imaging analysis of ROS time course detected by CellROX® Reagent 
in young and old donor derived iAstrocytes. Fluorescence intensity was assessed 
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using Columbus Software. Results are expressed as means ± SD. Unpaired t-test 
between young and old iAstrocytes at each timepoint, **P<0.01, *P<0.05 (n=3). 
(D) Representative images of western blot analysis of NRF2 and SOD1. Cells were 
incubated in serum-free media for 24h and harvested (UT=untreated, SF=Serum free 
media). Protein from young and old donor derived iAstrocytes was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by 
immunoblotting.  
(E) Densitometric quantification of NRF2 protein levels, normalised to GAPDH. Values 
are expressed as means ± SD. Two-way ANOVA, ****P<0.0001, *P<0.05, **P<0.01 
(n=3) 
(F) Densitometric quantification of SOD1 protein levels, normalised to GAPDH. Values 
are expressed as means ± SD. Two-way ANOVA, *P<0.05 **P<0.01 (n=3). 
(G) Representative images of yH2AX staining in young and old donor derived 
iAstrocytes, Scale bar (10µm). 
(H) Quantitative imaging analysis of yH2AX Foci/cell in young vs old donor derived 
iAstrocytes. yH2AX foci were assessed using Columbus Software. Results are 
expressed as the means ± SD. Unpaired t-test, ****P<0.0001 (n=3). 
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Older donor-derived iAstrocytes are less supportive to MNs upon pro-
inflammatory stress 
So far, our results demonstrate that iAstrocytes derived from fibroblasts of donors from 
different age groups successfully recapitulate important transcriptional and functional 
age-related features. To probe the ageing astrocyte phenotype in more depth we 
wanted to assess one of the most important functions fulfilled by astrocytes in vivo, 
i.e. their ability to support neurons throughout the ageing process and under stressful 
conditions. In particular, recent studies have shown that, as astrocytes are exposed to 
microglia-secreted pro-inflammatory cytokines in the ageing brain (Liddelow et al., 
2017), they become less supportive to neurons. Therefore we tested the effect of IL-
1β treatment, as this pro-inflammatory cytokine is released by microglia in the CNS 
during ageing (Clarke et al., 2018) and after injury (Pineau and Lacroix, 2007). 
To functionally test our cell model, both young and old donor-derived iAstrocytes were 
exposed to IL-1β for 6 hours, washed to remove any residual cytokine and were then 
co-cultured with human iPSC-derived motor neurons (Figures S3 and S4) to test their 
ability to support neurons when challenged with inflammatory stress. 
Caspase-3, a master regulator of apoptosis, that catalyses the cleavage of many key 
cellular proteins, was used to assess neuronal health in co-culture. Immunostaining 
data showed that both young and old donor-derived iAstrocytes are equally able to 
support neuronal survival under basal conditions (Figures 6A and 6B). Treatment of 
iAstrocytes with IL-1β, however, led to a significant 3-fold increase of caspase-3 and 
apoptotic nuclear fragmentation in MAP2+ cells cultured with old donor iAstrocytes 
(Figures 6A and 6B). In contrast, neurons cultured with young donor iAstrocytes did 
not show any difference between conditions, i.e. iAstrocytes untreated or pre-treated 
with IL-1β (Figures 6C and 6D). In order to understand the causes of this differential 
response, we assessed the effect of IL-1β treatment on iAstrocytes, with a particular 
focus on NFκB. NFκB is a transcription factor that regulates multiple aspects of innate 
and adaptive immune functions and represents a central mediator of inflammatory 
responses. Our results show that in IL-1β-stimulated old donor-derived iAstrocytes, 
nuclear activation of NFκB is four times higher than in young donor iAstrocytes 
(Figures 6D). Furthermore, old donor iAstrocytes become more reactive, displaying 
higher levels of GFAP and Vimentin, resulting in a significant increase in cell size 




Figure 6. Old donor-derived iAstrocyte are less supportive to MNs after pro-
inflammatory stress with IL-1β 
(A) Representative images of human MN and young or old donor derived astrocytes 
co-culture. Scale bar (10µm). 
(B) Quantitative imaging analysis of percentage of caspase-3 in MAP2+ cells. Results 
are expressed as the means ± SD. Two-way ANOVA, ****P<0.0001 (n=3). 
(C) Representative images of NfκB staining in untreated and treated with IL-1β 
(20ng/mL) young and old donor derived iAstrocytes. Scale bar (10µm). 
(D) Quantitative imaging analysis of NfκB nuclear activation. Results are expressed 
as the means ± SD. Two-way ANOVA, ****P<0.0001 (n=3). 
(E) Representative images of Vimentin staining in untreated and treated with IL-1β 
(20ng/mL) young and old donor derived iAstrocytes. Scale bar (10µm). 
(F) Quantitative imaging analysis of Vimentin intensity. Results are expressed as the 
means ± SD. Two-way ANOVA, ****P<0.001 (n=3). 
(G) Representative images of GFAP staining in untreated and treated with IL-1β 
(20ng/mL) young and old donor derived iAstrocytes. Scale bar (10µm). 
(H) Quantitative imaging analysis of GFAP intensity. Results are expressed as the 




Astrocytes are the largest group of glial cells in the CNS and are responsible for vital 
homeostatic functions. Several studies have reported that glial cells are potentially 
more affected by the ageing process than neurons. In particular, astrocytes present 
dramatic transcriptional (Soreq et al., 2017) and functional changes during ageing 
(Gemma et al., 2007; Lynch et al., 2010; Rea et al., 2018) that hinder their ability to 
maintain homeostasis in the CNS and support neurons throughout their life-course. 
Ageing is a leading risk factor for multiple neurodegenerative diseases, so it is 
fundamental to recapitulate age-related characteristics in cells that contribute to and 
are actively involved in diseases. It is well known that ageing and neurodegeneration 
share common mechanisms including increased oxidative stress, excitotoxicity and 
inflammation. Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic 
lateral sclerosis (ALS) are three common adult-onset neurodegenerative diseases 
known to involve astrocyte dysfunction (Haidet-Phillips et al., 2011; Meyer et al., 2014; 
Booth, Hirst and Wade-Martins, 2017; González-Reyes et al., 2017). As a 
consequence, lack of human in vitro models that mimic the functional features of 
astrocytes in young and old age is a limitation to studying mechanisms and potential 
therapies involved not only in maintaining brain health, but also in combatting 
neurodegenerative diseases and other neurological conditions.  
In this study, we successfully derived iAstrocytes from young donors (5 months-3 
years) and compared them to iAstrocytes derived from older donors (42 years-56 
years). Comparative transcriptomic analysis demonstrated that the transcription profile 
of iAstrocytes from old donors recapitulates transcriptional features of laser-captured 
post-mortem (PM) astrocytes from adults of a similar age. Strikingly, the transcriptional 
differences between iAstrocytes from young and old donors display ~80% overlap with 
the differences discriminating between PM and fetal primary human astrocytes. This 
indicates that iAstrocytes derived from directly converted iNPCs retain astrocyte-
relevant ageing transcriptomic features. When we specifically looked at the pathways 
described by these transcriptional changes, we identified multiple pathways involved 
in ageing and senescence, i.e. p53 signalling, oxidative stress, DNA damage and 
inflammatory response. Indeed, we confirmed these transcriptional changes at a 
functional level. We show here that direct conversion of fibroblasts to iNPCs and 
differentiation to iAstrocytes retains key age-related cellular characteristics. TERF2, 
an enzyme involved in telomere organization, decreases significantly with age in 
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fibroblasts and derived iAstrocytes recapitulate this decrease in expression level 
following reprogramming. Moreover, our model reproduces the global loss of the 
heterochromatin marker (H3K9me3) and nuclear organisation abnormalities reported 
in ageing and neurodegenerative conditions (Miller et al., 2013; Tang et al., 2017). 
Major Lamin A disruption occurs in Hutchinson-Gilford progeria syndrome (HGPS), as 
a consequence of mutations in the gene encoding for this protein, i.e. LMNA. HGPS 
is a rare genetic condition that leads to accelerated ageing and brain development 
abnormalities (Gonzalo, Kreienkamp and Askjaer, 2017), demonstrating the link 
between nuclear envelope integrity, ageing and neurodegeneration. At a cellular level, 
HGPS displays a number of characteristics typical of ageing cells including loss of 
heterochromatin, nuclear lobulation and increased DNA damage (Ghosh and Zhou, 
2014). Expression of progerin, a truncated form of LMNA, is used to induce ageing in 
iPSC models (Miller et al., 2013). Although this approach recapitulates some aspects 
of cellular ageing, it still carries the substantial limitation of introducing a pathogenic 
mutation to model a physiological process. In addition, this strategy might create 
confounding phenotypes when applied in the study of neurodegenerative conditions 
other than HGPS. 
Without inserting any mutation, our data show that iAstrocytes derived from directly 
reprogrammed iNPCs from older individuals display decreased histone H3K9 
trimethylation, accumulation of DNA damage and mild Lamin A/C disruption with 
associated loss of nuclear integrity, leading to nuclear “leakiness”. This phenotype has 
been reported in several ageing studies and is associated with loss of integrity of the 
nuclear pore complex (D’Angelo et al., 2009; Lord et al., 2015), thus favouring 
uncontrolled protein diffusion and loss of the normal compartmentalization between 
the nucleus and the cytoplasm. 
In addition to this impairment, the present report reveals a significant decrease in three 
nucleocytoplasmic transporters, RANBP17, Importin 5 and Exportin 1, which play 
major roles in regulating nuclear import and export. Mertens et al (Mertens et al., 2015) 
have previously reported that RANBP17 expression decreases in ageing cells and 
directly reprogrammed neurons from old donor fibroblasts, but not in iPSCs. Our data 
reveal that the age-related decrease in nucleocytoplasmic transport is bidirectional 
and is not limited to RANBP17. Nucleocytoplasmic transport has recently emerged as 
a key dysregulated pathway in neurodegenerative disorders. Several studies have 
shown how mutations in genes causing amyotrophic lateral sclerosis and 
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frontotemporal dementia (ALS/FTD) lead to aberrant nucleocytoplasmic partitioning of 
ALS-causing gene products and that this dysregulation includes both subcellular mis-
localisation and cytoplasmic inclusions (Ferreira, 2019). For instance, it has been 
reported how mutations in TARDBP and FUS lead to accumulation of these proteins 
within the cytoplasm and mis-localisation from the nucleus, thus affecting 
nucleocytoplasmic transport (Neumann et al., 2006; Dormann et al., 2010; Mackenzie, 
Rademakers and Neumann, 2010). More recently, studies also revealed that the 
GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport 
(Freibaum et al., 2015; Jovičić et al., 2015). Further evidence revealed that this 
pathway is also impaired in AD (Eftekharzadeh et al., 2018) and Huntington’s disease 
(HD) (Gasset-Rosa et al., 2017; Grima et al., 2017). Specifically, exportin 1 (XPO1, 
also known as XPO1) has been identified as an important transporter for many 
proteins involved in neurodegenerative diseases (Chan et al., 2011a; Zhong et al., 
2017; Ederle et al., 2018). XPO1 is an essential nuclear export receptor (Stade et al., 
1997) which recognizes cargoes with the leucine-rich nuclear export sequence (NES) 
(Dong et al., 2009). Recently, a study in C. elegans showed that ALS-linked mutant 
SOD1, when misfolded, exposes a normally buried NES-like sequence, leading to 
XPO1-dependent nuclear export. This has been proposed as a potential protective 
mechanism against misfolded SOD1 proteotoxicity (Zhong et al., 2017), which, our 
data suggest, is likely to decrease with age, thus shifting the balance between 
accumulation of toxic proteins and neuroprotective cellular defences. A similar 
mechanism has also been reported for CAG repeat expansions associated with 
polyglutamine (polyQ) diseases, in which exportin 1 regulates the nucleocytoplasmic 
distribution of the expanded polyQ protein (Chan et al., 2011b). Decreased expression 
of XPO1 protein levels in vivo contributes to the accumulation of the expanded polyQ 
protein in the nucleus of symptomatic polyQ transgenic mice. This process drives the 
nuclear accumulation of the disease protein, thus the cell nucleus becomes an 
important site of pathology in polyQ diseases, where transcription is affected.  
Additional stress that can significantly affect transcription, and also translation, is 
represented by accumulation of ROS that damage lipids, protein and nucleic acids, 
which are commonly detected as biochemical footprints in aged tissue (Brawek et al., 
2010; Lukiw et al., 2012). Oxidative stress is caused by an imbalance in the redox 
state of the cell, by overproduction of ROS, or by impairment of the antioxidant defence 
system. In particular, the CNS is vulnerable to the effects of ROS due to its high 
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demand for oxygen, and its abundance of substrates highly susceptible to oxidative 
modification. Neurons are post-mitotic and have a very high energy demand, and thus 
are vulnerable to oxidative insults. Consistently, it has been shown that Nrf2 levels 
and activity are significantly higher in the longest-lived rodents compared to short-lived 
mice (Lewis et al., 2015). Surprisingly, however, neurons have weak endogenous 
antioxidant defences, as the main antioxidant pathways such as the Nrf2 pathway are 
silenced during development within neurons (Bell et al., 2015). Therefore, neurons rely 
heavily on non-cell autonomous antioxidant support from astrocytes. Antioxidant 
defences, however, have been shown to significantly decrease during ageing in 
astrocytes themselves, with consequent accumulation of ROS (Ishii et al., 2017). A 
recent study showed that Nrf2 overexpression in astrocytes protects against cerebral 
hypoperfusion, thus suggesting that Nrf2 overexpression specifically in astrocytes is 
protective, exerting beneficial effects through repression of inflammation (Sigfridsson 
et al., 2018). In neurodegenerative diseases such as multiple sclerosis (MS), for 
example, astrocytes in active lesions display an increase of cytoplasmic accumulation 
of oxidized proteins and lipids (van Horssen et al., 2008) and nuclear accumulation of 
oxidized DNA (Haider et al., 2011). As the antioxidant defences of astrocytes decrease 
with age, they are unable to provide optimal support to neighbouring neurons, which 
start accumulating oxidative DNA damage, thus leading to an increased susceptibility 
to a number of age-related diseases and cognitive decline (Oksanen et al., 2019). 
Because of its crucial role in ageing and neurodegeneration, it is important that human 
in vitro models of astrocytes can recapitulate this age-dependent functional decline. 
Strikingly, in the present report, we found that old iAstrocytes exhibited a higher 
baseline level of ROS and DNA damage compared to young iAstrocytes. Furthermore, 
when iAstrocytes were stressed by serum starvation, old iAstrocytes required more 
time to recover to baseline ROS levels, as the levels of both NRF2 and SOD1 were 
lower in old iAstrocytes compared to young iAstrocytes, both at baseline and following 
acute stress. Thus, our model recapitulates the age-related decrease in antioxidant 
defences reported from in vivo studies and, provides an explanation for the increased 
level of ROS seen in these cells.  
It is well known that oxidative stress plays a central role in the pathophysiology of 
neurodegenerative diseases, such as ALS, AD, HD and PD (J. Li et al., 2013; 
Niedzielska et al., 2016) where the antioxidant response has been proposed as a 
potential therapeutic target (Barber, Mead and Shaw, 2006). Oxidative stress may 
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provoke cellular damage, dysregulation of DNA damage repair and mitochondrial 
dysfunction, all hallmarks of the ageing process as well as neurodegenerative 
disorders (Shibata and Kobayashi, 2008; Allen et al., 2019).  
Toxicity from free radicals also contributes to inflammation, another major component 
in neurodegeneration. In our study, we showed the age-related differential responses 
of iAstrocytes in their ability to support neurons in co-culture upon acute stimulation 
with the inflammatory cytokine interleukin-1 beta (IL-1β). Our data suggest that this is 
due to an exaggerated response of old donor-derived iAstrocytes to IL-1β stimulation, 
resulting in stronger nuclear activation of NFκΒ and higher levels of expression of 
GFAP and Vimentin. Although already at baseline old and young iAstrocytes differ in 
the activation of several stress defence mechanisms, we did not detect a significant 
difference in their ability to support neuronal survival, measured as caspase 3 
activation. Other more subtle parameters, however, could be compromised in neurons 
cultured with older non stimulated astrocytes. Recent studies in post-mortem brains 
and C. elegans, in fact, have reported that dendrite restructuring, neuronal sprouting, 
and synaptic deteriorations are subtle changes commonly detected in physiological 
brain ageing, rather than neurodegeneration (Henstridge et al., 2015; Hess et al., 
2019) 
GFAP and vimentin are classical astrocytic markers that increase in expression as 
astrocytes become more reactive with age (Wu, Zhang and Yew, 2005; Boisvert et al., 
2018; Clarke et al., 2018). Moreover, increased astrocyte reactivity has been reported 
in several neurodegenerative disorders. For example, studies in AD brain samples and 
mouse models detected amyloid plaques surrounded by reactive astrocytes, with 
higher expression of GFAP (Li et al., 2011). Interestingly, the increased number of 
reactive astrocytes frequently correlates with the extent of cognitive decline (Kashon 
et al., 2004). In patients with PD, astrocyte reactivity has been seen in the substantia 
nigra pars compacta (Hirsch and Hunot, 2009), whilst in ALS patients, it has been 
observed in susceptible regions and the degree of reactivity correlates with the 
severity of neurodegeneration (Haim et al., 2015). 
In conclusion, the present study demonstrates that direct conversion of fibroblasts to 
iNPCs and subsequent differentiation into iAstrocytes results in an in vitro model able 
to retain key hallmarks of the ageing process. Although not investigated in this study, 
it is likely that the iNPCs themselves and all cells derived from them would preserve 
ageing features through this reprogramming methodology, bypassing the epigenetic 
 97 
landscape toward the pluripotent state of the IPSCs. This is of extreme importance, as 
this in vitro tool allows for more accurate and physiologically relevant modelling of 
ageing and disease, without the need to introduce age-inducing genetic mutations or 
insults. 
In particular, the ability to model the behaviour of human astrocytes throughout the 
process of ageing as well as the cross-talk with age-matched neurons has the unique 
and unprecedented potential to answer important questions about the physiology and 
the pathophysiology of the CNS and to provide a powerful tool for novel therapeutic 






Human skin fibroblast samples were obtained from different sources (Table S1). Prof. 
Pamela Shaw (PJS) and Dr Daniel Blackburn (DB) provided the fibroblast samples 
from the University of Sheffield (Study number STH16573, Research Committee 
reference 12/YH/0330 and MODEL-AD research study number STH19080 Research 
and Ethics Committee number: 16/YH/0155 respectively). Human skin fibroblast 
samples from donors below the age of consent were from established tissue banks 
(Coriell Institute) as shown in Table S1. Informed consent was obtained from all 
subjects before sample collection.  
 
The human induced pluripotent stem cells (iPSC) line used in this study named control 
MIFF1 (Desmarais JA et al., 2016) was kindly provided by Professor Peter Andrews 
and Dr. Ivana Barbaric (Centre for Stem Cell Biology, The University of Sheffield). 
iPSCs were maintained in complete mTeSR™-Plus™ Medium (StemCell 
Technologies) in  Matrigel® growth factor reduced-coated plates (Corning®) according 
to the manufacturer’s recommendations. Cultures were replenished with fresh medium 
every alternate day.  The passage of cells was performed when the cells reached 
around 70% of confluence, every four to six days as clumps using ReLeSR™ an 
enzyme-free reagent for dissociation (StemCell Technologies) according to the 
manufacturer’s recommendations. For all the experiments in this study, iPSCs were 
used between passage 20 and 28, all iPSCs were cultured in 5% O2, 5% CO2 at 37°C.  
 
Direct Reprogramming of Skin Fibroblasts to iNPCs 
Direct conversion was conducted with a modified version of the protocol described 
previously in Meyer et al., 2014. Fibroblasts were seeded in a well of a six-well plate 
and treated with retroviral vectors for OCT3, SOX2, KLF4 and c-MYC (Meyer et al., 
2014). The medium was switched to NPC conversion medium, consisting of 
DMEM/F12, 1% N2, 1% B27, EGF (40ng/ml) and FGF (20 ng/mL). After 2-4 days the 
cells changed shape and created sphere-like structures or started growing into 
rosettes. These were collected or lifted using Accutase (StemPro® Accutase® Cell 
Dissociation Reagent, Gibco) and, depending on the density and their growth rate, 
they were expanded in multiple wells of a six-well plate or a 10cm dish coated with 
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human fibronectin (5 μg/mL; Millipore). Cells were then stained for Nestin and PAX6 
to establish successful iNPC conversion. 
 
Differentiation of iNPCs into iAstrocytes 
To induce astrocyte differentiation, the iNPCs were plated in medium composed of 
DMEM, 10% fetal bovine serum (FBS) (Life Science Production), 1% penicillin-
streptomycin (Lonza Biowhittaker), 0.2% N2-supplement (Gibco Life Tech) in a 10cm 
dish coated with human fibronectin (Millipore). Astrocytes were allowed to differentiate 
for 7 days.  
 
Differentiation of iPSCs into motor neurons (MNs) 
Motor neuron differentiation (Figure S3) of iPSCs was performed using the modified 
version dual SMAD inhibition protocol (Du et al., 2015). To induce differentiation, 
iPSCs were transferred for matrigel-coated plate (Corning® Matrigel® Growth Factor 
Reduced). On the day after plating (day 1), after the cells had reached ∼100% 
confluence, the cells were washed once with PBS and then the medium was 
replaced with neural medium (50% of KnockOut™ DMEM/F-12, 50 % of Neurobasal 
(ThermoFisher), 0.5× N2 supplement (ThermoFisher), 1x Gibco® GlutaMAX™ 
Supplement (ThermoFisher), 0.5x B-27 (ThermoFisher), 50 U ml−1 penicillin and 50 
mg ml−1 streptomycin, supplemented with DMH-1 2 μM (Tocris), SB431542-10 μM 
(Tocris) and CHIR99021 3 μM (CHIR, Tocris). The medium was changed every day 
for 6 days.  On day 7, the medium was replaced with neural medium supplemented 
with SB431542-10 μM, and CHIR 1 μM, DMH-1 2 μM, all-trans retinoic acid 0.1 μM 
(RA, StemCell Technologies), and  purmorphamine 0.5 μM (PMN, Tocris). The 
medium was changed every day until day 12 when was possible to see a uniform 
neuroepithelial sheet. On day 12 the cells were split 1:6  with accutase (StemPro® 
Accutase® Cell Dissociation Reagent, Gibco), onto a matrigel-coated plate in the 
presence of 10 µM of  rock inhibitor (Y-27632 dihydrochloride, Tocris), giving rise to 
a sheet of neural progenitor cells (NPC). After 24 hours of incubation, the medium 
was changed for neural medium supplemented with RA 0.5 μM and PMN 0.1 μM.  
The medium was changed every day until day 19 when the motor neuron 
progenitors (MNP) can be visualized. On day 20 MNP were split with accutase onto 
to matrigel-coated plates and the medium was replaced with neural medium 
supplemented with compound E 0.1 µM (Cpd E, Tocris), retinoic acid 0.5 μM, PMN 
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0.1 μM, BDNF 10ng/mL (ThermoFisher), CNTF 10ng/mL (ThermoFisher) and IGF 
10ng/mL (ThermoFisher) - (this medium is named as neuronal medium). At this stage 
the cells were fed every other day with neuronal medium until day 40. 
 
Co-culture of iAstrocytes and MNs 
Motor neuron progenitors were plated onto matrigel-coated 96 well plates in the 
presence of 10 µM of rock inhibitor (1x104 cell/well) on day 20 of differentiation. The 
MNPs were differentiated into MN until day 40 when the astrocytes (0.8x104 
cell/well) were added on the top of the motor neurons. The co-cultures were cultured 
for three days, and then the cells were fixed and processed for immunofluorescence 
staining (Figure S4). 
 
Microarray analysis 
Microarray analysis of human fetal astrocytes (purchased from Sciencell), post-
mortem (PM) astrocytes laser-captured from brain and iAstrocytes reprogrammed 
from fibroblast donors was performed at SITraN, University of Sheffield (Table S2). 
Fetal astrocytes were run on GeneChip™ Human Gene 2.0 ST Array; while post-
mortem astrocytes and iAstrocytes were run on GeneChip™ Human Genome U133 
Plus 2.0 Array. All the included studies obtained relevant ethical approval. The quality 
of array data CEL files was assessed using the Affymetrix Expression Console 
software. Normalisation, with all the transcripts normalised by beta-tubulin and 
GAPDH, and harmonisation across Chip files was obtained using the Robust Multi-
Array (RMA) algorithm. Differential gene expression between samples was 
determined using Qlucore Omics Explorer after normalisation. The software was used 
also for Principal Component Analysis (PCA) and hierarchical clustering. To access 
the functions of genes found in the meta-analysis, the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) and Panther 
(http://www.pantherdb.org/). The website Human Genomic Resources (HAGR, 






RNA Isolation and quantitative real-time polymerase chain reaction (qPCR) 
RNA was harvested using the RNAeasy Mini kit (Qiagen), and total RNA was reverse-
transcribed with the High Capacity cDNA Reverse Kit (Applied Biosystem) according 
to the manufacturer’s instructions.  
Primers were designed using Primer-BLAST to assess transcriptional changes in a 
number of selected genes reported by microarray analysis identified through HAGR 
and validated ageing markers (Table S4). Samples were loaded at a concentration of 
12.5 ng/μl per well. qPCR was performed using 2x SYBR Green/Rox PCR Master Mix 
(Bimake.com) and forward and reverse primers (final concentration 250nM), to a total 
volume of 20µL. After initial denaturation at 95°C for 10 minutes, templates were 
amplified by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute, using the 
Stratagene MX300P machine. At the end, a dissociation curve was created to ensure 
amplification of a single product and the absence of primer dimers. 
GAPDH was tested against other housekeeping genes, including B-actin, RLP13A and 
U1. GAPDH showed the most consistent and stable expression across samples of 
different ages as well as between fibroblasts and astrocytes. Hence, GAPDH was 
amplified on each plate to normalize expression levels of target genes between 
different samples using the ΔΔCt calculation (ABI) and to assess assay reproducibility. 
 
iAstrocyte treatment for stress response assessment and cell collection 
Serum starvation experiments were carried out by washing the cells with PBS twice 
and changing the culture medium to fresh media without FBS at day 6.  
On day 7 iAstrocytes were washed twice with PBS to remove medium residuals and 
harvested by cell scraping. The cell pellets were stored at -80°C until processed for 
RNA or protein extraction. 
 
IL-1β treatment to induce inflammation in iAstrocytes and CC 
Astrocyte activation was stimulated by the addition of fresh medium containing IL-1β 
(20 ng/ml, R&D Systems) and incubated for 20 minutes for evaluation of NF-
κB translocation, for 24 and 72 hours and for reactive gliosis. 
For the co-culture experiments, young and old astrocytes were stimulated with IL-1β 
(20 ng/ml), for 6 hours and then gently washed X 3 with warm PBS to fully eliminate 
residual IL-1β in the culture. After that the astrocytes were seeded on the top of the 
MNs in the presence of neuronal medium. The co-cultures were maintained at 37°C 
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in a humidified atmosphere with 5% CO2 for 3 days when the analyses of cell death 
were performed. Young and old untreated astrocytes were used as controls. 
 
Immunocytochemistry (ICC) iAstrocytes 
10,000 iAstrocytes were plated per well in 96-well plates at day 6 of differentiation and 
fixed 24h after seeding with 4% paraformaldehyde (PFA) for 10 min. Cells were 
washed 3 times with phosphate-buffered saline (PBS) following which blocking 
(PBS,5% horse serum and 0.05% Triton X-100) was applied for 1 hour. All primary 
antibodies were diluted in blocking solution and their dilution and suppliers are listed 
in Table S5. Incubation of the primary antibody was performed overnight at 4°C. The 
next day, cells were washed 3 times in PBS before the secondary antibody (Table S6) 
in blocking solution was applied for 1 h at room temperature. Hoechst (Hoechst 33342, 
Trihydrochloride, Trihydrate, Life tech) diluted 1:6,000 was added for 5 minutes to 
visualise the nucleus. Cells were then washed twice with PBS and imaged using the 
Opera Phenix high-content imager (PerkinElmer).  
 
Immunocytochemistry (ICC) MNs and CC 
For immunostaining, after three days of co-culture (CC), cells were washed with PBS 
and fixed with 4% paraformaldehyde for 15 min at room temperature. After fixation 
samples were washed three times with PBS, incubated with 0.3% Triton X-100 in PBS 
(Sigma) for 5 min then blocked by incubation with PBS containing 5% donkey serum 
(DS) (Millipore) for 1 hour. After blocking, cell cultures were incubated with primary 
antibodies diluted in PBS containing 1% of DS overnight. Cells were washed with PBS 
three times. Then, secondary antibodies were added to cells and incubated for 1 hour. 
The samples were washed with PBS three more times and incubated with 1.0 mg/mL 
4,6-diamidino-2-phenylindole (DAPI) for nuclear staining. The primary and secondary 
antibodies were used at the dilutions indicated in tables S5 and S6. All experiments 
included cultures where the primary antibodies were not added, and non-specific 
staining was not observed in these negative controls.  
 
Oxidative-stress assay  
7,000 iAstrocytes were plated per well in 96-well plates at day 5 of differentiation in 
complete astrocyte medium. On day 6, medium was replaced either with complete or 
with serum-free astrocyte medium for 12 hours. After 12h, medium was replaced in all 
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conditions with complete astrocyte medium and CellROX baseline measurements 
were collected, using the Opera Phenix Imaging System. A time-course experiment 
was also performed, in which CellROX measurements were collected every 2 hours 
for 6 hours. CellROX® Reagent (Life Technologies) was used at a final concentration 
of 2.5 μM as per manufacturer’s instructions and incubated with cells for 30 minutes 
at 37°C. CellROX® Reagent was then removed, cells were washed three times with 
PBS before imaging.  
 
Nuclear isolation and dextran influx assay 
Two 10cm dishes of iAstrocytes (2 million cells) were used for isolation of nuclei. After 
two washes with PBS, accutase was added and the plates were incubated at 37°C for 
3 minutes. Accutase was diluted with 3ml PBS and the cells were collected in a tube 
and spun at 1,000rpm for 4 minutes. The pellet was washed twice with PBS and then 
left to dry. 400µL of hypotonic lysis buffer (10mM HEPES, 1.5mM MgCl2, 10mM KCl, 
0.5mM DTT, 20µL/mL PIC) was added to the pellet. The lysate was passed through a 
19g needle 5 times, left for 10 minutes on ice and then spun down at 4,000rpm for 3 
minutes at 4°C to separate the nuclear from the cytoplasmic fraction. The supernatant 
was discarded (cytoplasmic fraction), while 250µL of IP lysis buffer (150mM NaCl, 
50mM HEPES, 1mM EDTA, 1mM DTT, 0.5% (v/v) Triton™ X-100, 20µL/mL PIC, pH 
8.0) with 60µL of PMSF (phenylmethanesulfanyl) was added to the nuclear pellet. The 
lysate was passed through a 25g needle 5 times and then left for 30 minutes on ice. It 
was spun at 13,300rpm for 4 minutes at 4°C and the supernatant was kept as the 
nuclear fraction. Nuclei were stained with Hoechst (Hoechst 33342, Trihydrochloride, 
Trihydrate, Life tech) diluted 1:6,000 in PBS. Tetramethylrhodamine isothiocyanate-
dextran was added to the nuclear fraction. The nuclei were mounted with ProLong™ 
Gold Antifade Mountant (Invitrogen) on cover slips and imaged with the confocal 
microscope Leica TCS SP5 II. 
Western Blot (WB) Analysis  
iAstrocyte samples were lysed using lysis buffer (150mM NaCl, 50mM HEPES, 1mM 
EDTA, 1mM DTT, 0.5% (v/v) Triton™ X-100, PIC, pH 8.0). Samples were then 
centrifuged at 13,300 rpm for 5 min at 4°C and the supernatant was collected. Lysates 
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
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PAGE) on 12% polyacrylamide gels. Resolved proteins were transferred to 
nitrocellulose membranes and processed for immunoblot analysis.  
Membranes were blocked for 1 hour in 5% milk/tris-buffered saline and tween 20 
(TBS-T). Primary antibodies (Table S5) were diluted in 5% milk/TBS-T and incubated 
with the membrane overnight at 4°C. After primary antibody incubation, the membrane 
was washed for 3 × 5 minutes each in TBS-T buffer. Secondary horseradish 
peroxidase (HRP) antibodies (Table S6) were diluted in 5% milk/TBS-T and incubated 
with the membrane for 1 hour at room temperature. After secondary antibody 
incubation, the membrane was washed for 3 × 5 minutes each in TBS-T buffer. Protein 
bands were visualized using EZ-ECL reagent (Geneflow) and the G-Box imaging 
system (Syngene). Densitometric analysis of protein bands was carried out using 
GeneTools Software (Syngene). 
Image and statistical analysis 
Columbus Software was used in the image analysis setting to measure different 
parameters including nuclei numbers, nuclear size (μm2) (mean per well), CellROX 
intensity/Cell area, Lamin A/C distribution and H3K9me3 intensity.  
To investigate whether IL-1β interferes with the translocation of NF-κB, young and old 
astrocytes were stained for NF-κB, untreated cells were used as a control for each 
line. Reactive gliosis was determined by GFAP and Vim staining intensity, which was 
quantified using Harmony software (Perkin Elmer). After the treatment the cells were 
fixed and stained for NF-κB and vimentin was used as a marker that define the 
boundary of cells and DAPI for nuclear staining.  Quantitative image analysis of the 
astrocytes was conducted through the Opera Phenix™ High Content Screening 
System at 40× magnification using the Columbus™ Image analysis system. The 
following morphological features were assessed for both treated and control 
astrocytes: cell area and the intensity of GFAP and vimentin staining per cell. At 
least 20 fields were randomly selected and scanned per well of a 96-well plate in 
triplicate. To identify and remove any false readings generated by the system, three 
random treated and untreated wells were selected and counted manually (blind to 
group). 
 
All experiments were performed at least in triplicate with a minimum of 3 technical 
repeats in each independent experiment. Data were analysed using GraphPad Prism 
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Software (V7.02): one-way ANOVA with Tukey's multiple comparisons post-test or, 
two-way ANOVA with Tukey's multiple comparisons post-test. Two-tailed t-test was 
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Table S1. Summary of the information on the astrocytes and fibroblast lines used in 
this study 
  
ID Cell line Age Gender Biobank 
Young 1(Y1) GM08680 5 months Male Coriell 
Young 2 (Y2) GM00498 3 years Male Coriell 
Young 3 (Y3) GM03813 3 years Male Coriell 
Old 1 (O1) MAD14 56 years Male Blackburn 
Old 2 (O2) 3050 55 years Male Shaw 




Figure S1 related to Figure 1 Characterization of iAstrocytes from old versus 
young donors 
(A) Quantitative imaging analysis of astrocytic markers (GFAP, Vimentin (VIM), CD44 
and EAAT2) in young and old donor derived iAstrocytes (n=3). 
  
 109 
Table S2. Summary of the information on microarray data used in this study  
ID Origin Age Gender GEO accession 
number 
Fetal_1 Sciencell - M/F pending 
Fetal_2 Sciencell - M/F pending 
Fetal_3 Sciencell - M/F  pending 
PM_1 Laser-captured from brain 72 years F GSE83670 
PM_2 Laser-captured from brain 75 years M GSE83670 
PM_3 Laser-captured from brain 78 years F GSE83670 
PM_4 Laser-captured from brain 78 years F GSE83670 
Old 
iA_1 
Direct reprogramming from 
skin fibroblasts 





Direct reprogramming from 
skin fibroblasts 















Direct reprogramming from 
skin fibroblasts 
3 years F  pending 
Young 
iA_2 
Direct reprogramming from 
skin fibroblasts 














Figure S2 related to Figure 2 Old donor iAstrocytes and post-mortem (PM) 
astrocytes have distinctly different transcriptomes to fetal astrocytes and young 
donor iAstrocytes. 
(A) Principal component analysis (PCA) plot of fetal astrocytes, PM astrocytes and old 
and young donor derived iAstrocytes. Multi-group comparison, p≤1x10e-4. 
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(B) Hierarchical cluster heat-map of fetal astrocytes, PM astrocytes and old and young 
donor iAstrocytes. Multi-group comparison, p≤1x10e-4. 
 
Table S3 Related to Figure 2 Genes in the intersection between the two comparisons 




Figure S3. MN differentiation. 
(A) Schematic illustration of the differentiation protocol for human MN derived from 
hiPSCs. 
(B) Representative images of characterisation of MN with cell-specific markers Tuj1, 




Figure S4 Human co-culture system workflow. 
(A) Schematic illustration of the co-culture representing the differentiation of human 
astrocytes derived from iNPCs from young and old donors. After the differentiation, 
astrocytes were exposed to human IL-1β (20ng/mL) for 6 hours. After this treatment, 
the cells were washed and then seeded on to MNs. MN progenitors were seeded and 
on day 40 astrocytes were added on the MNs. The co-culture was kept for 72 hours. 
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Table S4. Primer sequences used for qPCR, Forward (Fw) and Reverse (Rv) 
















Table S5 Primary antibodies used in this study  
Primary 
Antibody 





Rabbit WB 1:2,000 
NRF2 Abcam  Rabbit WB 1:1,000 
SOD1  Cell 
Signalling  
Rabbit WB 1:1,000 
XPO1 Abcam  Rabbit WB 1:2,000 
RANBP17 Abcam  Rabbit WB 1:2,000 
VIMENTIN Millipore  Chicken ICC 1:1,000 
GFAP Dako Rabbit ICC 1:1,000 
CD44 Abcam Rabbit ICC 1:200 
EAAT2                                                                                                                                                                                                                                                                                             SantaCruz Goat ICC 1:100
Histone H3  
(tri methyl K9)  
Abcam Rabbit ICC 1:800 
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Lamin A/C Abcam Mouse ICC 1:800 
Nestin Abcam Mouse ICC 1:200 
Nestin Biolegend Rabbit ICC 1:500 
PAX6 Abcam Rabbit ICC 1:1,000 
PAX6 Millipore Mouse ICC 1:200 
Beta III Tubulin Millipore Chicken ICC 1:1,000 
Beta III Tubulin Biolegend Mouse ICC 1:1,000 
NeuN Biolegend Mouse ICC 1:1,000 
CHAT Millipore Goat ICC 1:100 
SMI32 Biolegend Mouse ICC 1:500 
MAP2 Synaptic 
systems 
Guinea pig ICC 1:1,000 







Table S6. Secondary antibodies used in this study 
Secondary antibody  Source Assay Dilution used 
Alexa Fluor 488 donkey a-
mouse IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:400 
Alexa Fluor 488 donkey a-
rabbit IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:400 





Alexa Fluor 488 goat a-
rabbit IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:1,000 





Alexa Fluor 568 donkey a-
mouse IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:400/1000 
Alexa Fluor 568 donkey a-
rabbit IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:400 
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Alexa Fluor 586 goat a-
rabbit IgG(H+L) 
Invitrogen,ThermoFisher ICC 1:1,000 
Alexa Fluor 594 donkey a-




Alexa Fluor 647 goat a-




a-Rabbit IgG (H+L), HRP 
Conjugate 
Promega WB 1:5,000 
a-mouse IgG (H+L), HRP 
Conjugate 
Promega WB 1:5,000 
a-chicken IgGY (H+L), 
HRP Conjugate 
Invitrogen,ThermoFisher WB 1:5,000 
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 Results  
 
SOD1 aberrantly accumulates in the nucleus 
due to altered interaction with 
nucleocytoplasmic transporters in ALS derived 
astrocytes  
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4.1 Introduction  
 
In chapter 3, I showed that directly induced astrocytes retain functional age-related 
features, such as altered nuclear compartmentalization, nucleocytoplasmic shuttling 
properties, oxidative stress response and DNA damage response. Remarkably, 
nucleocytoplasmic transport emerged as a pathway commonly altered in ALS with 
subsequent protein mis-localisation and aggregation.  
Nucleocytoplasmic defects have been brought to light and explored with interest due 
to the identification of mutations in TARDBP and C9orf72, where aberrant transport of 
proteins and RNA between nucleus and cytoplasm seem to play a pivotal role in 
disease pathophysiology. 
The presence of TDP-43 proteinopathy in >97% of ALS cases is one of the strongest 
indications of the central role played by nucleocytoplasmic dysregulation in the 
disease. Beyond the disruption in RNA processing caused by TDP-43 nuclear loss 
and cytoplasmic aggregation described in section 1.1.2.6., recent elegant studies have 
highlighted how TDP-43 pathology can disrupt nuclear pore complexes and 
nucleocytoplasmic transport. Using a proximity-dependent biotin identification system 
termed BioID, Chou and colleagues interrogated the interactome of detergent-
insoluble cytoplasmic TDP-43 aggregates, identifying components of the nuclear pore 
complex (NuPC) and nucleocytoplasmic transport machinery as a major group of 
proteins present in pathological TDP-43 aggregates (Chou et al., 2018). Interestingly, 
in this study, aggregated and disease-linked mutant TDP-43 caused the sequestration 
and/or mis-localisation of nucleoporins and transport factors and impaired the nuclear 
membrane and NuPC, affecting nuclear protein import and RNA export in mouse 
primary cortical neurons, human fibroblasts and iPSC–derived neurons (Chou et al., 
2018). Next, it has been demonstrated how transient stress induces long-lasting 
separation of cytoplasmic TDP-43 in multiple cell types. Remarkably, the phase-
separated TDP-43 compromises nuclear transport by de-mixing importin-α and Nup62 
and inducing mis-localisation of RanGap1, Ran, and Nup107, and leads to clearance 
of nuclear TDP-43 and eventually, cell death (Gasset-Rosa et al., 2019). These 
findings indicate that TDP-43-mediated nucleocytoplasmic transport disruption is a 
common disease mechanism.  
Similarly, C9orf72 repeat expansions as well as mutant PFN1 are also able to affect 
the nuclear pore (Giampetruzzi et al., 2019). In 2015 a Drosophila transgenic fly, able 
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to express 8, 28 or 58 G4C2 repeat-containing transcripts that do not have a 
translation start site (AUG) but contain an open-reading frame for green fluorescent 
protein (GFP) to detect repeat-associated non-AUG (RAN) translation, was generated. 
This model was used for a genetic screen that identified 18 genetic modifiers that 
encode components of the NuPC as well as the machinery implicated in the export of 
nuclear RNA and in the import of nuclear proteins (Freibaum et al., 2015). 
Consistently, morphological changes in the architecture of the nuclear envelope in 
cells expressing expanded G4C2 repeats  were found in vitro and in vivo. Furthermore, 
alterations in RNA export resulting in retention of RNA in the nucleus were observed 
in Drosophila cells expressing expanded G4C2 repeats and also in aged iPSC-derived 
neurons from C9orf72 patients (Freibaum et al., 2015). This and further studies (Fallini 
et al., 2020) have demonstrated that the disruption of nucleocytoplasmic transport 
through the nuclear pore is a primary consequence of G4C2 repeat expansion. 
Importantly, depletion of the nuclear export adaptor SRSF1 prevents 
neurodegeneration and locomotor deficits in a Drosophila model of C9orf72-related 
disease (Hautbergue et al., 2017), suggesting the importance of nucleocytoplasmic 
transport in regulating pathology. Furthermore, nuclear pore pathology is present also 
in brain tissue from sporadic ALS patients (Fallini et al., 2020), thus indicating that 
dysregulation of nucleocytoplasmic shuttling and disruption of the nuclear membrane 
and NuPCs may be a common mechanism in both sALS and fALS cases displaying 
TDP-43 proteinopathy. 
 
SOD1 and nucleocytoplasmic transport  
Mutations in SOD1 were first identified in 1993 (Rosen et al., 1993) and a few years 
later, it was determined that mutant SOD1-linked ALS was related to a toxic gain of 
function (Wong et al., 1995). Nearly 30 years later, we still do not fully understand the 
mechanisms related to this gain of toxicity and, for some aspects, we are still 
investigating the role of wild-type SOD1 beyond its anti-oxidant function. Several 
pieces of evidence indicate that misfolded wild-type SOD1 may be pathogenic in ALS 
through various processes summarised in section 1.3.2. Moreover, there is evidence 
indicating that SOD1 could function as a transcription factor, responding to oxidative 
stress and probably being regulated by endogenous ROS (Tsang et al., 2014). 
Since the other potential roles of wild-type SOD1 have been thoroughly investigated 
in ALS, the focus of this chapter is to interrogate SOD1 nuclear localisation and its 
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potential role. This still under-investigated localisation and physiological role of SOD1 
might lead to a better understanding of ALS pathology and the link between SOD1 
and the other major genes associated to ALS and involved in DNA or RNA binding, 
i.e. C9orf72, TARDBP and FUS. 
Following on from the hypothesis of SOD1 as a transcription factor or potentially as a 
transcription regulator, SOD1 nuclear localisation has been reported in the literature 
(Chang et al., 1988; Crapo et al., 1992; Sau et al., 2007). Furthermore, human SOD1 
nuclear localisation was confirmed in transgenic mice expressing mutated forms of 
hSOD1 (Sau et al., 2007; Gertz, Wong and Martin, 2012). Thus, the nuclear presence 
of SOD1 posed the question of how it enters into the nucleus and its subcellular 
function in this location. Inside the cell, movement of small proteins happens via 
passive diffusion through the nuclear pore complex (NuPC), while proteins bigger than 
~40 kDa normally require specific transporters (Terry, Shows and Wente, 2007). The 
size of the native SOD1 dimer is 32 kDa, and it should be capable of moving 
spontaneously between the nuclear and the cytosolic compartments, via nuclear 
pores. Additionally, also misfolded SOD1 was detected in the nucleus of motoneurons 
and glial cells in spinal cord tissue from ALS patients, highlighting the nucleus as a 
potential site of SOD1 toxicity (Forsberg et al., 2010, 2011, 2019).  
It has been shown that misfolded mutant SOD1 and wtSOD1 expose a normally buried 
NES-like sequence that is then recognised by the nuclear export carrier protein XPO1 
which binds the NES sequence and exports misfolded SOD1 to the cytoplasm. 
Removal of this NES-like domain leads to nuclear accumulation of mutant SOD1 in 
cell models and C. elegans, thus resulting respectively in cell death and locomotor 
defects. This study shows that SOD1 is removed from the nucleus by XPO1 as a 
defence mechanism against toxicity of nuclear misfolded SOD1 (Zhong et al., 2017). 
A year later, Israelson et al., revealed that macrophage inhibitory factor (MIF), a 
multifunctional protein with cytokine/chemokine activity and cytosolic chaperone-like 
properties inhibits mutant SOD1 nuclear clearance when overexpressed in motor 
neuron-like NSC-34 cells and reduces the toxicity of misfolded SOD1 by directly 
interacting with it (Shvil et al., 2018). MIF was shown to act as a chaperone for 
misfolded SOD1 in vivo, in fact eliminating MIF in a mutant SOD1 mouse model 
increased the accumulation of misfolded SOD1, accelerated disease onset and late 
disease progression, and shortened the lifespan of mice expressing mutant SOD1 
(Leyton-Jaimes et al., 2016). 
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These findings indicate that MIF might exert its beneficial effect by correctly folding 
SOD1, therefore restoring SOD1 physiological role into the nucleus. These findings 
indicate how nucleocytoplasmic transport could have an important role also in SOD1-
linked ALS. Consistent with the literature reporting that nucleocytoplasmic shuttling 
becomes disrupted with physiological ageing and in neurodegenerative disorders 
(Ribezzo, Shiloh and Schumacher, 2016; Kim and Taylor, 2017; Ferreira, 2019; Hutten 
and Dormann, 2019), in the previous chapter I showed that several transporters such 
as RANBP17, IPO5 and XPO1 decrease with age. This decline in transporter proteins 
with age might account for the late onset of ALS symptoms, when neuroprotective 
cellular mechanisms fail to compensate for pathological events.  
This evidence led to the formulation of the hypothesis that in all forms of fALS, caused 
by mutations in SOD1 or other genes, as well as in sALS, misfolded SOD1 
accumulates in the nucleus of astrocytes and contributes to toxicity. 
 
Therefore, the aims of this chapter are: 
 
1. To determine mutant and wild-type SOD1 localisation within induced 
astrocytes; 
 
2. To confirm the direct interaction between SOD1 and XPO1; 
 
3. To determine the mechanisms involved in SOD1 accumulation in the nucleus 
in sALS and fALS cases and the role of XPO1 in this process. 
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4.2 ALS patient derived astrocytes recapitulate typical pathological features 
observed in ALS 
In the previous chapter, we demonstrated how directly reprogrammed astrocytes 
retain the ageing features of the donor fibroblasts. As in this chapter I set out to 
interrogate pathological mechanisms occurring in ALS, my first step was to determine 
whether iNPC-derived astrocytes retain known ALS pathological features. With the 
same procedure described in sections 2.2.1 and 2.2.2, iNPC were differentiated into 
iAstrocytes, and immunostaining was used to validate the successful cell 
differentiation using CD44, glial fibrillary acid protein (GFAP), EAAT2 and vimentin 
antibodies, identifying typical glial markers (Figure 4.1 A). Hoechst was used to stain 
the nuclei in all immunocytochemistry experiments. CD44 identifies astrocyte-
restricted precursors (Schnitzer, Franke and Schachner, 1981) and is a cell-surface 
glycoprotein involved in cell-cell interactions, cell adhesion and migration. GFAP and 
vimentin are both intermediate neurofilaments. Vimentin is not astrocyte specific, but 
within the neural lineage, is a marker of astrocytes (Ribezzo, Shiloh and Schumacher, 
2016; Kim and Taylor, 2017; Ferreira, 2019; Hutten and Dormann, 2019). EAAT2 is 
an astrocyte specific glutamate transporter and, with GFAP, is a marker of mature 
astrocyte identity. Hence, co-staining of all these markers confirms both successful 





Figure 4.1 Representative images of astrocytic markers  
A CD44, GFAP, EAAT2 and Vimentin (VIM) in derived iAstrocytes, Scale bar (10µm). 
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Subsequently, I focused on the characterisation of the disease phenotype in ALS 
iAstrocytes.  
TDP43 (43kDa) proteinopathy is a hallmark of ALS. The TDP-43 protein was identified 
as a major component of the ubiquitinated neuronal cytoplasmic inclusions both in 
FTD and in spinal motor neurons in ALS (Liu et al., 2004) as well as in glia cells 
(Nishihira et al., 2008; Zhang et al., 2008). TDP-43-positive inclusions are common in 
97% of ALS cases. The main exceptions are cases caused by mutations in SOD1 or 
FUS (Neumann et al., 2006).  
TDP-43 protein levels were evaluated through western blot in our iAstrocytes, using a 
C-terminal TDP43 antibody. Although TDP-43 total levels show a certain degree of 
variability between different cell lines (Figure 4.2 B) grouped analysis reveals that 
sALS and SOD1 patients display significantly lower protein levels compared to healthy 
controls (Figure 4.2 D). The reduction in TDP-43 found in SOD1 patients could be 
representative of alteration in TDP-43 turnover. In addition, it was possible to observe 
a second band of 35kDa, which is a cleavage product of TDP-43, only present in sALS 
and C9orf72 patients (Figure 4.2 A,C). It has been demonstrated that this C-terminal 
cleavage fragment of 35kDa is prone to aggregate, forming cytoplasmic inclusions. 
Moreover, TDP-35 is able to sequester TDP-43 from nuclear localisation into 
cytoplasmic inclusions, that leads to alterations of RNA processing (Mackenzie, 
Rademakers and Neumann, 2010). Indeed, it was possible to observe the TDP-43 
cytoplasmic inclusions also in iAstrocytes (Figure 4.2 E). Then the expression of p62 
was analyses, as marker of protein homeostasis, using western blotting in order to 




Figure 4.3 A). As expected due to its role in autophagy, as well as proteasomal protein 
degradation, and the reported impairment of these pathways in SOD1 and C9orf72 
cases (Che et al., 2011) p62 western blot showed a higher level of expression of this 
protein in patients compared to controls (Figure 4.3 B,C). Moreover, with 
immunostaining, it was possible to observe the typical p62-punctate pattern of staining 































































































































































































































Figure 4.2 TDP-43 proteinopathy in iAstrocytes 
A Representative images of TDP-43 and  b-actin western blot. B Western blot TDP-
43 quantification graph (n≥3 per line). C Western blot TDP-35 quantification graph 
(n≥3 per line). D Quantification graph (n=3) of TDP-43 in ALS patient subgroups. 
Unpaired t-test CTR vs PAT subgroup, **P<0.01; One-way ANOVA, multiple 
comparisons ## P<0.01, ### P<0.001 (n=3). Results are expressed as the means ± 
SD. E Representative images of TDP-43 (rabbit antibody) cytoplasmic inclusions 
(indicated by white arrows) in iAstrocytes derived from a C9orf72 patient (PAT 
C9orf72) compared to control (CTR). Co-stained with Vimentin (chicken antibody) to 






Figure 4.3 p62 as a marker of ALS pathology 
A Representative images of p62 and b-actin blot. B Quantification graph with each 
single cell line (n≥3). C Quantification graph with patient subgroups. Unpaired t-test 
CTR vs PAT subgroup, *P<0.05, **P<0.01; One-way ANOVA, multiple comparisons # 
P<0.05 (n=3). Results are expressed as the means ± SD. D Representative image of 
p62-puncta (mouse antibody) in iAstrocytes derived from a sALS patient (PAT sALS) 
compared to control (CTR). Co-stained with CD44 (rabbit antibody) to discriminate the 


























































































4.3 SOD1 localisation and quantification in derived iAstrocytes 
After confirming that the direct reprogramming method used for this study is able to 
recapitulate some aspects of the disease phenotype observed in ALS post-mortem 
tissue, I focused on assessing the expression levels and distribution of the wild-type 
and misfolded SOD1 protein. Initially, a staining for wild-type and misfolded SOD1 was 
performed. Staining for total wild-type SOD1 showed that SOD1 is abundantly present 
in iAstrocytes, also with nuclear localisation (Figure 4.4 A). Several manuscripts have 
identified misfolded SOD1 as another pathological marker, usually located in protein 
inclusions in post-mortem samples from SOD1 familial cases, as well as other genetic 
and sporadic forms (Gal et al., 2009; W. J. Liu et al., 2016; Webster et al., 2018). To 
identify misfolded SOD1 localisation via immunostaining, the B8H10 antibody was 
used, which was raised in the SOD1 G93A mouse model and that recognises 
misfolded forms of mutant human SOD1 protein (Gros-Louis et al., 2010). The staining 
revealed misfolded SOD1 protein in the nucleus of patient derived astrocytes, and also 
misfolded SOD1 cytoplasmic aggregation in SOD1 patient astrocytes (Figure 4.4 B). 
Due to the qualitative nature of immunostaining, western blotting was used to quantify 
the total levels of SOD1 protein without discrimination between the misfolded and wild-
type form. In order to demonstrate that the antibody (Cell Signalling #2770) used 
specifically recognises SOD1, the protein was knocked-down through an adenovirus 
expressing an shRNA against SOD1 (Figure 4.4 C). SOD1 (~16kDa) levels decrease 
with age, as reported in Chapter 3 (Figure 5, Chapter 3) and display some degree of 
variability within each patient and control cell line, however, without showing any 
further expression change in any patient subgroup (Figure 4.4 D-F). Remarkably, in 
ND, a patient with SOD1 D90A mutation, another band was detected below 16kDa 
that has been reported before in the literature and might represent a subunit truncated 



































































































Figure 4.4 SOD1 levels are variable in derived astrocytes 
A Representative images of wild-type SOD1 (Cell Signalling #2770) in iAstrocytes, 
Scale bar (10µm), . B Representative images of misfolded SOD1 (B8H10 antibody) in 
iAstrocytes, Scale bar (10µm). C Representative images of complete knock-down 
through adenovirus expressing a shRNA against SOD1. D Representative images of 
SOD1 and b-actin blot. E Quantification graph with each single cell line (n≥3). F 
Quantification graph with patient subgroups (n=3). Unpaired t-test CTR vs PAT 
subgroup; One-way ANOVA, multiple comparisons, no significance. Results are 
expressed as the means ± SD.  
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4.4 Nuclear and cytoplasmic fractionation revealed higher SOD1 nuclear levels 
in sALS and C9orf72 astrocytes 
Due to the qualitative data obtained with the B8H10 antibody, showing the presence 
of misfolded SOD1 predominantly in sALS, the amount of SOD1 that was localised in 
the nucleus was assessed. As indicated in the materials and methods section, the 
fractionation protocol had to be optimised specifically for human iAstrocytes (2.2.13 
Nuclear and Cytoplasmic Fractionation). b-tubulin was used as a cytoplasmic marker, 
even though there are reports of its localisation in the nuclear compartment (Walss-
Bass et al., 2002; Akoumianaki et al., 2009). In the experimental conditions,  b-tubulin 
was overall a good cytoplasmic marker with low level of nuclear contamination. SSRP1 
(Structure Specific Recognition Protein 1) was used as nuclear marker. To confirm 
that there is no contamination between cell compartments after fractionation, the 
presence of b-tubulin and SSRP was examined in all compartments. Thereafter SOD1 
was quantified by using the cell compartment-specific loading control. This protocol 
(Figure 4.5 A) was applied to the iAstrocytes (Figure 4.5 B) (ND was excluded because 
it was not confluent enough to perform fractionation) and the graphs were produced 
(Figure 4.5 C). The resulting western blots confirmed the presence of SOD1 in the 
nucleus, as well as in the cytoplasm, where it is more abundant. Interestingly, sALS 
and C9orf72 displayed significantly higher nuclear levels of SOD1, while SOD1 lines 
did not, although this was tested only in two SOD1 samples (Figure 4.5 C). The results 
of the nuclear and cytoplasmic fractionation experiments are in line with the finding 
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Figure 4.5 Fractionation showed higher SOD1 nuclear levels in sALS and C9orf72 
astrocytes 
A Schematic illustration of fractionation protocol: SSRP1 (Structure Specific 
Recognition Protein 1) was used as nuclear marker, while b-tubulin was used as 
cytoplasmic marker. B Representative image of fractionation in most of the lines. C 
Quantification of SOD1 in the cellular fractions in sALS, C9orf72 and SOD1 
iAstrocytes. Unpaired t-test, CTR Nuclear vs PAT Nuclear, * P<0.05, ** P<0.01, **** 






4.5 SOD1 does not directly bind RNA in iAstrocytes 
In order to determine the role of SOD1 in the nucleus, the hypothesis that SOD1 might 
act as an RNA-binding protein, like several other mutant proteins causing ALS, was 
investigated. To answer this question RNA pull-down was performed using an 
antibody against oxidised RNA (8-OHG, Abcam) and poly dT beads to pull down total 
polyadenylated RNA. A crosslinking step by UV was performed to strengthen the 
protein interaction with RNA in order to be able to detect them via western blotting. 
Since the oxidised RNA pull down relied on an antibody that gave high variability, the 
protocol for the total RNA pull-down was optimised. This experiment was repeated 
three times in a SOD1 patient cell line with a control, and once in C9orf72 patient with 
a control. In none of these experiments I was able to detect SOD1 in the output (Figure 
4.6 A), thus indicating that SOD1 does not bind RNA. TDP-43, on the contrary, was 
consistently detected in the output. Interestingly, the ratio between the 35kDa and 
43kDa changed within different patients depending as to whether they carried a SOD1 
or C9orf72 mutation. In fact, although preliminary, my results show the TDP-35/43 
ratio is half of the control level in the SOD1 patients, while it is 4 times higher in the 
C9orf72 patient (Figure 4.6 B, C), consistent with the literature, indicating an alteration 
in RNA metabolism in C9orf72 patients, while SOD1 patients are not affected by the 
same TDP-43 proteinopathy (Robertson et al., 2007; Turner et al., 2008). Interestingly, 
in the no UV cross-linked samples (-) it is possible to see the 35kDa fragment of TDP-






Figure 4.6 SOD1 does not bind directly RNA  
A Poly-A RNA pull down output with control and SOD1 patient, blotted for SOD1. B 
Poly-A RNA pull down output with control and SOD1 patient, blotted for TDP-43 and 
the relative TDP-35/TDP-43 ratio. C Poly-A RNA pull down output with control and 
C9orf72 patient, blotted for TDP and the relative TDP-35/TDP-43 ratio. (-) No UV 
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4.6 XPO1 levels decrease in sALS patient derived astrocytes 
After discarding the hypothesis that SOD1 might bind RNA, I proceeded with a series 
of experiments to determine the mechanisms leading to SOD1 accumulation in the 
nucleus of sporadic and C9orf72 patients. I started with evaluating the expression of 
XPO1 through western blotting (Figure 4.7 A), since a recent paper (Zhong et al., 
2017) showed that this carrier protein is responsible for misfolded and mutant SOD1 
export from the nucleus to the cytoplasm as a defence mechanism to avoid 
accumulation of misfolded SOD1 in the nucleus. It is reported that this 
nucleocytoplasmic transporter recognises a nuclear export signal (NES)-like 
sequence in SOD1 that is only accessible when the protein is misfolded (Zhong et al., 
2017). Relevant in this context, my data showed that XPO1 levels decrease with age 
in iAstrocytes (Figure 4, Chapter 3), suggesting a potential role of ageing in affecting 
the balance between accumulation of toxic proteins and neuroprotective cellular 
defences. Interestingly, the resulting western blot showed a significant lower level of 
XPO1 in sALS iAstrocytes, but not in the other patient subgroups, compared to age-
matched controls (Figure 4.7 B,C), indicating that this transporter is even more 
affected in sALS which might explain the higher level of SOD1 in the nucleus in this 




Figure 4.7 XPO1 decreases in sALS patient derived astrocytes 
A Representative images of XPO1 and b-actin blot. B Quantification graph of XPO1/b-
actin with each single cell line shown separately (n≥3). C Quantification graph with 
patients pooled together by genetic subgroup. Unpaired t-test CTR vs PAT subgroup 
**P<0.01; One-way ANOVA, multiple comparisons, no significance (n=3). Results are 
















































































4.7 XPO1 displays differential interaction with misfolded or mutant SOD1  
Next, I wanted to confirm whether there is a direct interaction between SOD1 and 
XPO1. To achieve this goal, immunoprecipitation technique was used to demonstrate 
the interaction between both misfolded SOD1 (B8H10 antibody) and wild-type SOD1 
(Cell Signalling #2770) with XPO1 (Figure 4.8 A). SOD1 was knocked down through 
shRNA as a control in this experiment.  
The obtained results showed in both cases a direct interaction. This procedure was 
repeated in one control line, one sALS and one SOD1 line (Figure 4.8 B, C). This 
experiment represents a proof of concept, demonstrating the interaction of XPO1 with 
both forms of SOD1 and not with misfolded SOD1 only as previously reported (Zhong 





Figure 4.8 Immunoprecipitation confirms the interaction between XPO1 with 
misfolded and wild-type SOD1 
A Schematic illustration describing the immunoprecipitation protocol. B 
Representative images of WB blot showing the direct interaction between XPO1 and 
misfolded SOD1; input on the left shows the protein levels loaded before the 
immunoprecipitation procedure. SOD1 KD=SOD1 knock-down through shRNA as a 
control, no binding with XPO1; POST-IP eluted on the right shows the output of the 
immunoprecipitation, after the final step of elution. C Representative images of WB 
blot showing the direct interaction between XPO1 and wild type SOD1, input on the 
left shows the protein levels loaded before the immunoprecipitation procedure. SOD1 
KD=SOD1 knock-down through shRNA as a control no binding with XPO1; POST-IP 
eluted on the right shows the output of the immunoprecipitation, after the final step of 
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Considering the qualitative nature of the immunoprecipitation assay, I next wanted to 
assess the level of interaction and the affinity of misfolded SOD1 and wild-type SOD1 
for XPO1. To assess these parameters, a proximity ligation assay (PLA) was 
performed in the astrocyte lines. This assay allows detection of protein interaction in 
fixed cells and consists of a pair of PLA probes (one PLUS and one MINUS) with hosts 
corresponding to those of the primary antibodies, in this case mouse and rabbit, 
detection reagents and wash buffers. The two primary antibodies from different 
species that recognise two target epitopes were selected before the assay and 
validated in immunocytochemistry. In this assay, it was included as positive control, a 
separate sample with known protein interaction, p62-LC3, previously reported in the 
literature (Pankiv et al., 2007), while as negative control, one of the two primary 
antibodies by itself or no antibodies at all (Figure 4.9 A). Then, the nuclear interaction 
between XPO1 and both forms of SOD1 was evaluated, quantifying the nuclear spots 
per number of cells (Figure 4.9 B, D), and the misfolded SOD1-XPO1 interaction as a 
percentage of the total wtSOD1-XPO1 interaction (Figure 4.9 C, E), observing a 
reduction in the sALS and C9orf72 patients. This suggests that XPO1, further 
decreased in sALS cases (Figure 4.7) might not recognise the misfolded form of SOD1 





Figure 4.9 Proximity ligation assay (PLA) results show a reduction in the interaction between 
misfolded SOD1 and XPO1 in sALS and C9orf72 derived astrocytes 






















































































































































































































































































































































































A Representative images of the positive control p62-LC3 interaction, SOD1-XPO1 
interaction, misfolded SOD-XPO1 interaction, negative control (No Ab). B 
Quantification of nuclear spots normalised by number of cells to evaluate the 
interaction between wtSOD1 and XPO1, and misfolded SOD1 and XPO1 (n=2-3, n=1 
for 201). C Quantification of nuclear interaction as percentage of wtSOD1 (100%), 
between misfolded SOD1 and XPO1 per cell line (n=2-3, n=1 for 201). D Quantification 
of nuclear spots normalised by number of cells to evaluate the interaction between 
wtSOD1 and XPO1 (n=3, 2 SOD1 patients). E Quantification of nuclear interaction as 
percentage of wtSOD1, between misfolded SOD1 and XPO1 per patient subgroups, 
One-way ANOVA, multiple comparisons *P<0.05, **P<0.01 (n=3, 2 SOD1 patients). 
Results are expressed as the means ± SD.   
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4.8 Discussion: SOD1 aberrantly accumulates in the nucleus due to altered 
interaction with nucleocytoplasmic transporters in ALS derived astrocytes 
 
Mutations in the SOD1 gene were first identified in 1993 (Rosen et al., 1993). Since 
then, several other ALS-causing mutations have been identified in more than 30 genes 
(Al Sultan et al., 2016). Unfortunately, however, little progress has been made on the 
aetiology of the vast majority (90%) of sALS cases. Interestingly, several pieces of 
evidence indicate that misfolded wild-type SOD1 may also be pathogenic in sALS, 
through different processes, such as post-translational modifications, misfolding, 
aggregation and prion-like pathogenic behaviour. Moreover, there is evidence 
indicating that SOD1 could function as a transcription factor or potentially as a 
transcription regulator responding to oxidative stress and probably being regulated by 
endogenous ROS (Tsang et al., 2014). 
Mutant SOD1 exerts its neurotoxic effects via multiple mechanisms. It has been shown 
that age or environmental-dependent post-translational alterations lead to 
conformational rearrangements in the configuration of wild-type SOD1, that mimic the 
alterations observed in mutant SOD1 in fALS (Ezzi, Urushitani and Julien, 2007). In in 
vitro models, oxidized wild-type SOD1 forms protein aggregates that cause cell death 
(Kabashi et al., 2009). Wild-type SOD1, depleted of zinc, induces death and metal-
deficient SOD1 forms, like mutated SOD1, an unstable and aggregation-prone 
structure (Banci et al., 2008). Furthermore, the use of specific antibodies has led to 
the detection of uncommon wild-type SOD1 species in a subgroup of sALS (Rakhit et 
al., 2007; Bosco, Morfini, et al., 2010). In vitro, these mutated SOD1-specific 
antibodies also have recognised the oxidized form of recombinant wild-type SOD1, 
suggesting that the wild-type SOD1 detected in sALS patients may also be oxidized 
(Bosco, Morfini, et al., 2010). Therefore, it is possible that, in a cellular environment 
with chronic high levels of oxidative stress as in ALS cells, oxidised wild-type SOD1 
might develop toxic properties, thus identifying a common SOD1-dependent 
mechanism linking mutant SOD1 fALS and a subgroup of sporadic ALS cases.  
In agreement with this hypothesis, misfolded SOD1 has been reported in post-mortem 
CNS tissues of sporadic ALS patients (Rakhit et al., 2007; Bosco, Morfini, et al., 2010) 
and recent evidence showed misfolded SOD1 inclusions in patients with mutations in 
C9orf72 and other ALS/FTD-associated genes (Forsberg et al., 2019). In addition, in 
vitro data using astrocytes from post-mortem spinal cords from sporadic ALS patients 
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showed that reducing the expression levels of wtSOD1 was a successful strategy to 
dampen astrocyte toxicity (Haidet-Phillips et al., 2011). Similar data were obtained 
using oligodendrocytes reprogrammed from sporadic ALS patients (Ferraiuolo et al., 
2016), where reducing the levels of SOD1 improved oligodendrocyte function in SOD1 
and sALS cases, but not in C9orf72 samples. This indicates that SOD1 misfolding 
might not be the main contributor to C9orf72 pathology in this cell type.  
Since the pathogenicity of mutant SOD1 can be dampened by decreasing its 
expression levels, silencing SOD1 may also be relevant to sALS cases. Recently, 
different strategies to silence gene expression have been developed, such as anti-
sense oligonucleotides (ASO) and RNA interference (RNAi) that enhance degradation 
of RNA or small inhibitory RNA (siRNA), short hairpin RNA (shRNA) and microRNA 
(miRNA) that are capable of permeating the central nervous system (CNS) and 
silencing genes (van Zundert and Brown, 2017). Indeed, a single injection of an adeno-
associated virus serotype 9 (AAV9) encoding an shRNA decreases the production of 
ALS-causing human SOD1 mutants, penetrating the blood brain barrier and 
successfully transducing motor neurons and astrocytes (Foust et al., 2013). This 
results in a slowdown of disease onset and of disease progression in SOD1 G93A and 
G37R models. This intravenous administration of AAV9-SOD1-shRNA is safe and 
tolerated in wild-type mice, with no adverse effects. This approach was successful in 
non-human primates as well. The authors determined that infusion directly into the 
CSF at the lumbar level in a non-human primate produces extensive SOD1 reduction, 
targeting MN and non-neuronal cells (Foust et al., 2013). Another study, using ASO 
ISIS 333611 delivered to the CSF reduced SOD1 levels in spinal cord tissue of SOD1 
G93A rat ALS model and prolonged survival. Moreover, its safety, tolerability an 
pharmacokinetics after intrathecal administration was assessed in patients with SOD1 
fALS, showing no serious adverse events (Miller et al., 2013). In conclusion, reducing 
the production of the aberrant misfolded protein could be a strategic therapy, as it can 
attenuate its toxicity and its aggregation, and also, the downstream intracellular and 
extracellular pathophysiological pathways.  
 
In this context and motivated by the availability of therapeutic approaches aimed at 
targeting wild-type as well as mutant SOD1, we set out to interrogate the role of SOD1 
in our patient-derived in vitro model. Firstly, astrocytes derived from patients and 
controls were characterised phenotypically for disease hallmarks. Patient-derived 
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astrocytes, in fact, showed TDP-43 proteinopathy as reported in the literature, and 
higher levels of p62. Furthermore, other members of the group are looking at other 
ALS characteristics within these cells, such as DNA damage accumulation, abnormal 
glutamate uptake and motor neuron survival in co-culture of astrocytes and motor 
neurons. 
 
We then focused on SOD1 expression to determine whether the levels of this protein, 
which decrease with age, are further affected in ALS. However, we did not observe 
significant changes between the patient subgroups. Remarkably, in one patient with 
SOD1 D90A mutation another band was detected below 16kDa, that has been 
reported before in literature (Jacobsson, 2001). This might be due to an additional 
truncation mutation affecting even further SOD1 function. This specific cell line was 
acquired through Coriell and was not genotyped in house, therefore the presence of 
additional mutations cannot be excluded. Sanger sequencing of the SOD1 exons 
could exclude an additional second variant causing the truncated protein. The 
behaviour of this cell line in all assays, however, was comparable to the behaviour of 
the other two mutant SOD1 lines analysed.  
Subsequently, misfolded SOD1 was evaluated through staining in control and patient 
cell lines. Interestingly, this experiment showed presence of misfolded SOD1 in the 
nucleus of sALS patient. In this regard, it has been demonstrated by Tsang et al., that 
in response to elevated endogenous and exogenous reactive oxygen species (ROS), 
in yeast cells, SOD1 relocates into the nucleus and could function as a transcription 
factor, elucidating the regulatory mechanism for its localisation. 
The presence of SOD1 was confirmed in the nucleus of human iAstrocytes through 
cellular fractionation. A complete screen of all the lines confirmed accumulation of 
higher levels of nuclear SOD1 in sALS and C9orf72, but not SOD1 derived astrocytes. 
Since all the major genes associated with ALS encode for proteins involved in RNA 
binding and transport, we also tested our own hypothesis that SOD1, like most ALS-
associated proteins, might bind RNA. However, in our pull-down experiments on total 
or oxidised RNA, I was unable to detect SOD1 in the RNA-bound fraction, leading to 
the conclusion that SOD1 does not bind RNA.  
Remarkably, total RNA pull-down preliminary data showed a different TDP-35 
fragment/TDP-43 full-length protein ratio in SOD1 and C9orf72 patient cell lines. The 
ratio between TDP-35 and TDP-43 was 4 times higher than the control in C9orf72 
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samples, while in the SOD1 patient the ratio was the half the level of the control. These 
findings confirm that the TDP-35 fragment could bind RNA and lead to alteration in 
RNA metabolism in C9orf72 patients, while SOD1 patients do not display and are not 
affected by TDP-43 proteinopathy (Robertson et al., 2007; Turner et al., 2008). 
Due to technical challenges with chromatin immunoprecipitation, however, I was 
unable in the timescale of the PhD programme to test the possibility that SOD1 could 
bind DNA, as suggested by previous studies (Tsang et al., 2014).  
In this regard, Barbosa et al. evaluated DNA damage, p53 activity and apoptosis in 
SH-SY5Y human neuroblastoma cells transfected with wild-type or mutant G93A 
SOD1. Their experiments, using different techniques, such as Western blot, FACS and 
confocal microscopy analysis, showed that mutant SOD1 is present in the nucleus in 
association with DNA. Additionally, G93A SOD1 present in the nucleus has identical 
superoxide dismutase activity but shows increased peroxidase activity, compared to 
wild-type SOD1. The authors hypothesised that SOD1 association with DNA might 
induce DNA damage and trigger the apoptotic response by activating the p53 pathway 
(Barbosa et al., 2010).  
The presence of SOD1 in the nucleus was demonstrated in in vivo models as well. 
Transgenic mice expressing hSOD1-G93A, hSOD1-G37R, and hSOD1-wild-type 
were used to investigate a new subcellular pathology involving mutant hSOD1 protein  
localizing to the nuclear compartment. Consistently, Gertz et al., reported a prominent 
nuclear accumulation of hSOD1-G93A, -G37R and -wild-type in transgenic mice. 
These data suggest new mechanisms involving hSOD1 accumulation in the cell 
nucleus and mutant hSOD1-specific perturbations in survival motor neuron protein 
(SMN) localisation, with disruption of the nuclear SMN complex in the ALS model mice 
(Gertz, Wong and Martin, 2012). Hence, further investigation should address the role 
of SOD1 in the nucleus and its link with DNA damage. 
 
Due to our interest in WT misfolded SOD1, I focused on the abnormal and previously 
unreported accumulation of WT SOD1 in the nucleus of sALS and C9orf72 patients. 
SOD1 lacks a nuclear localisation sequence, however it might enter the nucleus 
through co-transport or passive diffusion. Data from my own research (Chapter 3) and 
the literature show nuclear lamina disruption and nuclear pore degradation occurring 
with age, indicating that passive protein transport is facilitated with age.  
 148 
Hence, multiple age-related and pathology-driven mechanisms might be responsible 
for increased SOD1 nuclear localisation. However, only sALS and C9orf72 
iAstrocytes, which do not carry SOD1 mutations, but are affected by the disease, 
display abnormal protein accumulation. A possible explanation for high levels of 
nuclear SOD1 in sALS and C9orf72 could be the accumulation of DNA damage or 
oxidative stress, as we observed in iAstrocytes derived from old donors (Chapter 3). 
Indeed, a body of evidence reported increased DNA damage and oxidative stress in 
C9orf72 cases (Lopez-Gonzalez et al., 2016; Farg et al., 2017; Walker et al., 2017; 
Konopka and Atkin, 2018). Elevated levels of DNA/RNA hybrids (R-loops) and double-
strand breaks (DSBs) have been observed in rodent neurons, human cells, and in 
C9orf72-ALS patient spinal cord tissues. Moreover, high levels of DNA damage are 
associated with impairment of ATM-mediated DNA repair signalling and accumulation 
of protein-linked DNA breaks (Walker et al., 2017). This suggests that genomic 
instability partially drives C9orf72-linked neurodegeneration. Additionally to increased 
DNA damage, a study reported increased levels of oxidative stress by poly-GR in 
C9orf72 iPSC derived-neurons in an age-dependent manner (Lopez-Gonzalez et al., 
2016). Thus, poly-GR preferentially binding to mitochondrial ribosomal proteins and 
disrupting mitochondrial function, leading to increased oxidative stress in neurons, 
represents another pathogenic mechanism in C9orf72-associated ALS.  
 
As regards the sALS cases, various studies have indicated increased oxidative 
damage and DNA damage (Ferrante et al., 2002; Murata, Ohtsuka and Terayama, 
2008; Riancho et al., 2020). However, based on unpublished data from my laboratory, 
iAstrocytes derived from sALS cases have similar levels of DNA damage and oxidative 
stress as samples from patients with SOD1 mutations, so higher SOD1 nuclear levels 
might be not related to an increase increased oxidative damage and DNA damage. 
 
Recently, it has been reported that Chromosomal Maintenance 1 (CRM1) or Exportin 
1 (XPO1) recognizes a NES-like sequence that is usually hidden in wild-type SOD1 
(Zhong et al., 2017). When SOD1 is misfolded, however, the authors reported that this 
NES-like domain is revealed and can bind XPO1 for protein export to the cytoplasm. 
So, disruption of the NES consensus sequence or downregulation of XPO1 would lead 
to misfolded and mutant SOD1 accumulation to the nucleus (Zhong et al., 2017). 
Consistently, our data showed that iAstrocytes also express XPO1 and, interestingly, 
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its level is lower in sALS patient- derived cells compared to controls and the other ALS 
genotypes assessed in this study. This downregulation of XPO1 could explain the 
SOD1 accumulation observed in the nucleus of sALS iAstrocytes, as opposed to 
controls, SOD1 and C9orf72 cases, which all express similar XPO1 levels. 
Nevertheless, C9orf72, like sALS, iAstrocytes displayed high levels of nuclear SOD1, 
but not lower levels of XPO1. 
 
Another potential explanation for SOD1 nuclear accumulation could be lack of 
exposure of the NES-like domain that is recognised by XPO1. To confirm the 
interaction between SOD1 and XPO1, immunoprecipitation was performed with both 
wild-type SOD1 and misfolded SOD1 in our astrocytes. In both cases co-
immunoprecipitation was observed. To further investigate this interaction, a proximity 
ligation assay (PLA) was performed, which enabled me to detect the interaction 
between both wild-type and misfolded SOD1 and XPO1. Interestingly, there was a 
reduction in the interaction between misfolded SOD1 and XPO1 in sALS and C9orf72 
cases, in agreement with the higher SOD1 nuclear levels in these patient subgroups. 
This decreased interaction observed between wild-type misfolded SOD1 and mutant 
misfolded SOD1 could be due to a different misfolding/conformation of SOD1 in the 
presence or absence of mutations. 
 
In conclusion, further studies are required in order to investigate the physiological and 
pathological relevance of SOD1 nuclear localisation. Importantly, SOD1 misfolding in 
the nucleus could have important pathological implications and it is still unclear what 
signals lead to SOD1 nuclear localisation and what functions this protein performs in 
this cell compartment.  
 
Finally, my results show that wild-type SOD1 and mutant SOD1 are expressed at 
similar levels in controls and patients, however, they localise in different cellular 
compartments in ALS patients, with wild-type SOD1 accumulating in the nucleus in 
sALS and C9orf72 cases, while mutant SOD1 remains mainly cytoplasmic in SOD1 
cases. This different localisation might be due to different misfolding conformations 
that might reduce wild-type SOD1 interaction with XPO1 compared to mutant SOD1, 
as opposed to what has been shown in overexpressing and stress-driven systems 
(Zhong et al., 2017). Additionally, XPO1 levels are lower in sALS cases, thus 
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suggesting another mechanism for misfolded SOD1 accumulation in the nucleus of 
sALS patients and confirming the important role of nucleocytoplasmic dysregulation in 




Astrocytes are the largest group of glial cells in the brain, having vital roles in the 
pathogenesis of ageing and neurodegenerative diseases. Indeed, they are involved in 
several functions of the brain, such as regulation of synapse formation and pruning, 
being part of the tripartite synapse, as well as the regulation of neuroinflammation 
together with microglia. Moreover, astrocytes provide metabolic support to neurons, 
play a crucial role in the antioxidant response of the CNS and maintain the integrity of 
the blood brain barrier (Oksanen et al., 2019). 
 
Remarkably, various studies have reported that glial cells, including microglia and 
astrocytes, are potentially more affected by the ageing process than neurons. In 
particular, astrocytes present dramatic transcriptional (Soreq et al., 2017) and 
functional changes during ageing (Gemma et al., 2007; Lynch et al., 2010; Rea et al., 
2018), thus affecting their ability to maintain homeostasis in the CNS. 
 
It is well known that ageing is a risk factor for several neurodegenerative diseases, so 
it is crucial to recapitulate age-related characteristics in human cells that contribute to 
and are actively involved in diseases. In fact, Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS) are three common adult-onset 
neurodegenerative diseases which demonstrate astrocyte dysfunction (Haidet-Phillips 
et al., 2011; Meyer et al., 2014; Booth, Hirst and Wade-Martins, 2017; González-
Reyes et al., 2017). Moreover, it has been observed that human astrocytes are more 
complex than their rodents counterparts, thus creating the need for a human astrocytic 
model (Oberheim et al., 2009). 
 
In this context, human iPSCs are an invaluable model to study the pathogenic 
mechanisms occurring in neurodegenerative diseases while maintaining physiological 
expression levels of pathogenic proteins (Ziff and Patani, 2019; Chang et al., 2020). 
However, they fail in retaining ageing features from the fibroblasts donor.  
 
In this study, this limitation was overcome by performing direct conversion of skin 
fibroblasts into induced neural progenitor cells, which then allows for the generation of 
human astrocytes that recapitulate many aspects of ageing that have great relevance 
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in the context of ALS (Meyer et al., 2014). For example, working with a cell model that 
reproduces the functional changes characteristic of ageing is likely to have a massive 
impact on the ability of the model to recapitulate pathological hallmarks related to 
protein homeostasis, oxidative stress and other pathways affected by age. As a matter 
of fact, iPSC-derived neurons and astrocytes from ALS patients display a milder 
pathological phenotype compared to the iAstrocyte model used in this study when 
assessing TDP-43 proteinopathy and p62 accumulation without the addition of 
stressors (Seminary, Sison and Ebert, 2018). 
 
In addition, iAstrocytes from older cases exhibited a higher baseline level of ROS and 
DNA damage compared to young iAstrocytes. Furthermore, when exposed to serum 
starvation, old iAstrocytes required more time to return to baseline ROS levels. This is 
likely to be due to the lower levels of both NRF2 and SOD1 in old iAstrocytes compared 
to young iAstrocytes, both at baseline and following acute stress. Thus, the model 
used in this study recapitulates the age-related decrease in antioxidant defences 
reported from in vivo studies and, provides an explanation for the increased level of 
ROS seen in these cells. These low levels of SOD1 in iAstrocytes from older donors 
are a consistent feature in the age-matched iAstrocytes from ALS patients, where we 
did not observe any further significant decrease or increase. Interestingly, it is has 
been widely reported that both fALS and sALS cases display high levels of oxidative 
stress (Ferrante et al., 2002; Lopez-Gonzalez et al., 2016) and our own unpublished 
data have confirmed this observation in the ALS iAstrocytes used in this study. 
Increased levels of ROS would lead to an increase in the anti-oxidant response, hence 
SOD1, as it was shown in aged healthy iAstrocytes. However, the steady levels of 
SOD1 in ALS iAstrocytes indicate that patient cells might be unable to upregulate the 
anti-oxidant response, thus exacerbating this pathophysiological process. On the 
contrary, rejuvenated ALS models, like iPSCs, might fail to demonstrate an increase 
in oxidative stress. In fact, a recent study showed oxidative stress and astrocyte 
toxicity, only after ageing the cells in vitro for 80 days (Birger et al., 2019).  
Further, it is known that increased oxidative stress, such as toxicity of ROS, 
contributes to neuroinflammation. In my study, neuronal survival in co-culture 
decreases in the presence of old Astrocytes after IL-1β treatment. It is known that 
astrocytes are strictly involved in neuroinflammation, and play a major role in ALS 
pathogenesis. Our data indicate that inflammation might be one of the factors that, in 
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association with old age, can lead to neuronal death. Of relevance in this context, it 
has been seen that partial loss of function of TBK1, a major genetic cause for ALS and 
FTD, leads to age-dependent neurodegeneration (Xu et al., 2018). TBK1 is a 
suppressor of RIPK1, that plays a crucial role in mediating neuroinflammation by 
promoting the activation of microglia and apoptosis (Geng et al., 2017; Xu et al., 2018). 
Normally, in the ageing human brain RIPK1 is inhibited by phosphorylation by TAK1, 
that decreases its expression with age. In Tbk1 +/- mice, reducing the expression of 
TAK1 induced all the key features of ALS, including neuroinflammation. Ageing then 
facilitates RIPK1 activation by reducing TAK1 expression, cooperating with genetic 
risk factors to promote the disease onset (Xu et al., 2018). This suggests a strong link 
between ageing and neuroinflammation, leading to the conclusion that is important to 
preserve this aspect when modelling astrocytes pathophysiology.  
 
Indeed oxidative stress, inflammation and DNA damage all are potential factors 
leading to SOD1 translocation into the nucleus. Although, as discussed in Chapter 4, 
further studies are needed in order to determine how specifically SOD1 enters into the 
nucleus, there is clear evidence that SOD1 has a physiological role in this cellular 
compartment. A study in peripheral blood mononuclear cells (PBMCs) of sALS and 
SH-SY5Y cells, in fact, has demonstrated that during oxidative stress SOD1 is 
phosphorylated by Chk2, guiding its translocation in the nucleus, where SOD1 protects 
DNA from oxidative damage (Bordoni et al., 2019). However, the function of SOD1 in 
this compartment also still requires clarification and validation in a more physiological 
system, where protein levels are physiological.  
 
Another aspect captured from the iAstrocytes is the dysfunction in nucleocytoplasmic 
transport, an emerging theme in physiological ageing and other related 
neurodegenerative diseases (Kim and Taylor, 2017). Of relevance in this context, a 
decrease in the expression of nucleocytoplasmic transporters occurred with age in 
iAstrocytes. In contrast to the levels of SOD1, where it was not observed any further 
expression change driven by disease, a significant down-regulation of XPO1 was 
observed only in sALS derived astrocytes. This might suggest that XPO1 is actually 
affected at transcriptional or post-transcriptional levels in some sALS cases. So, it 
would be ideal to test whether reducing or overexpressing XPO1 leads to the same 
accumulation of SOD1 in the nucleus of sporadic ALS cases.  
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Moreover, the downregulation of pathways related to protein homeostasis might 
impact on SOD1 misfolding. So, it would be interesting to test various antibodies 
against different conformations of misfolded SOD1 and determine if SOD1 misfolds in 
different ways in different ALS patient genotypes. In particular, it will be important to 
evaluate SOD1 misfolding in the nuclear compartment, potentially performing 
fractionation on a native gel. Evidence has demonstrated that protein homeostasis is 
subject to age-related decline (Koga, Kaushik and Cuervo, 2011; Hipp, Kasturi and 
Hartl, 2019). Alterations in proteostasis lead to protein misfolding and aggregation, 
strongly associated with neurodegeneration (Douglas and Dillin, 2010). In the case of 
SOD1, for example it has been seen how MIF, an ATP-independent protein folding 
chaperone, inhibits mutant SOD1 misfolding (Israelson et al., 2015). Another important 
chaperone is Copper Chaperone for SOD1 (CCS). It transiently interacts with SOD1 
and promotes its correct maturation by transferring copper and catalysing disulfide 
bond formation (Luchinat, Barbieri and Banci, 2017). Therefore, an aspect that must 
be studied in depth is how ageing affects components of proteostasis in old donor 
derived astrocytes and in ALS astrocytes.  
This study presented some limitations, such as the sex ratios of the samples used in 
the ageing study, but also the number of samples in the patient subgroups, for example 
in the SOD1 group. Moreover, the use of additional antibodies for SOD1 in Chapter 4 
would be beneficial to support our hypothesis and also it will be important to measure 
the amount of misfolded SOD1 in the nucleus of patient derived astrocytes. 
In conclusion, the novelty of my study consists firstly, in the retention of ageing features 
in a human in vitro model of astrocytes. Indeed no study has assessed this aspect yet. 
Using a rejuvenated model might mask alteration of a lot of these pathways. Hence, 
iPSCs could be more relevant for the early phases of the disease, rather than the later 
ones. It was shown the nuclear function of SOD1 can have an important role in disease 
pathogenesis. In ALS research it is still controversial whether in a human non-
overexpressing model wtSOD1 misfolds without adding any additional stressor. Thus, 
some evidence was added that wtSOD1 does misfold in human iAstrocytes and 
accumulates in the nucleus of ALS patients that do not carry a SOD1 mutation. This 
implies that if SOD1 is misfolded it may not function correctly, may propagate between 
cells and it may represent a potential therapeutic target. 
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CDC42BPB 1,20E-06 
CDC42EP1 5,36E-05 
CDK17 0,000790571 
CDK19 0,000757551 
CDKAL1 2,07E-07 
CDKN2AIPNL 3,65E-08 
CDON 0,000374995 
CDR1 0,036162455 
CDV3 0,000228985 
CENPF 7,74E-05 
CEP95 1,45E-06 
CEPT1 3,93E-06 
CFAP97 1,93E-08 
CFLAR 0,000636061 
CGGBP1 0,00105565 
CHD3 5,86E-05 
CHD6 4,84E-08 
CHM 7,12E-05 
CHML 1,36E-07 
CHMP1B 0,000534986 
CITED2 0,011252769 
CKAP2 3,15E-07 
CLDN11 0,001057743 
CLEC2B 0,0048632 
CLN6 4,12E-09 
CLTA 0,000115388 
CMPK1 7,08E-07 
CMTM3 1,30E-05 
CMTM6 3,84E-05 
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CMTM7 6,05E-05 
CNKSR3 2,19E-05 
CNOT1 1,67E-06 
CNOT6L 5,80E-11 
CNOT7 3,81E-05 
CNTNAP3 0,005763783 
COA1 2,42E-05 
COG3 6,65E-07 
COL1A2 0,017663554 
COL6A1 0,001721466 
COL8A1 0,011649949 
COLGALT1 0,00021785 
COPA 4,48E-07 
COPS3 6,30E-05 
COQ10B 5,59E-05 
COTL1 0,000197953 
COX1 5,42E-05 
COX17 3,43E-05 
COX2 4,96E-07 
COX20 0,000107915 
COX8A 0,000558713 
CPPED1 3,06E-05 
CRKL 1,90E-06 
CRNDE 0,001860954 
CRTAP 0,000131318 
CSDE1 1,20E-07 
CSF1 0,009674138 
CSNK1A1 8,73E-06 
CSNK2A2 0,000242359 
CTNNA1 0,003075046 
CTNNB1 2,59E-06 
CTSA 7,05E-05 
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CTSC 2,15E-05 
CTSZ 0,009407338 
CTTN 2,62E-05 
CUL3 0,000260906 
CYB5R1 1,34E-05 
CYB5R3 0,000152287 
CYBRD1 0,000528905 
CYHR1 1,10E-05 
CYS1 3,86E-05 
CYYR1 0,005867621 
DAB2 1,46E-05 
DAD1 0,000169281 
DCAF13 8,32E-06 
DCAF5 0,000309049 
DCAKD 0,009521252 
DCBLD2 0,002834703 
DCTN5 2,61E-05 
DDR2 0,002036466 
DDX10 1,67E-07 
DDX17 4,93E-05 
DDX19A 3,95E-06 
DDX19B 2,33E-05 
DDX3X 1,32E-05 
DDX42 3,77E-11 
DDX50 0,000419401 
DDX52 7,11E-05 
DDX6 0,000236922 
DEK 0,000425755 
DESI2 0,00036109 
DHX30 3,18E-06 
DHX36 0,000780826 
DHX8 5,42E-05 
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DIAPH1 4,34E-09 
DIAPH3 1,18E-05 
DIP2B 1,05E-05 
DMTF1 0,000157227 
DNAJC13 1,80E-05 
DNAJC2 0,000105007 
DNAJC4 4,33E-09 
DNAJC7 2,12E-05 
DOCK10 0,002707755 
DOCK5 0,006689282 
DPY19L1 7,35E-05 
DPY19L4 0,000136336 
DPYD 0,000824645 
DR1 4,30E-06 
DSE 3,31E-05 
DST 0,000108967 
DTD1 3,57E-07 
DTWD1 0,000174021 
DVL2 1,32E-05 
DVL3 1,76E-06 
DYM 2,71E-05 
DYNC1H1 0,000143298 
DYNC2H1 9,26E-05 
DYNLRB1 6,31E-05 
E2F4 5,89E-05 
ECH1 0,000642061 
EDNRA 0,015881254 
EEF1A1 3,06E-08 
EEF1G 5,33E-07 
EEF2 1,28E-05 
EFEMP2 0,00334949 
EFNA5 0,000395781 
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EFTUD2 1,42E-06 
EGFL7 0,000344088 
EGR1 0,000852326 
EHD2 7,83E-06 
EHD4 0,000312045 
EIF1 2,71E-05 
EIF2AK1 1,92E-06 
EIF2AK2 1,04E-05 
EIF2S2 0,000115531 
EIF2S3 4,82E-07 
EIF3K 0,000151821 
EIF4A1 4,88E-06 
EIF4B 1,52E-05 
EIF4EBP2 5,70E-06 
EIF4G2 1,04E-05 
EIF4G3 1,61E-05 
EIF5 5,74E-05 
ELAC2 2,49E-06 
ELK4 6,87E-06 
ELL2 0,00333085 
ELOVL5 5,84E-06 
ELP3 1,65E-05 
EMC10 1,80E-05 
EMC3 9,21E-06 
EMD 9,69E-05 
EML2-AS1 2,24E-05 
EML4 2,15E-06 
EMP1 8,47E-07 
EMP2 0,00253193 
EMSY 0,000403532 
ENAH 0,001616579 
ENG 0,000248319 
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ENPP1 0,002637033 
EPB41L2 0,005798544 
EPHA7 0,014730959 
ERGIC3 1,72E-06 
ERO1A 5,97E-05 
ERP44 0,000654947 
ERRFI1 0,006846282 
ESYT2 6,09E-05 
EXOSC1 3,59E-05 
EXOSC10 1,17E-05 
EZR 0,004807015 
F2RL2 0,006615736 
F2RL3 1,35E-07 
FADS2 0,001458405 
FAF2 0,0006083 
FAM117B 0,000508662 
FAM120A 2,30E-05 
FAM120AOS 0,001352645 
FAM160B1 5,97E-06 
FAM49B 0,000252921 
FAM98B 0,000985349 
FAR2 0,011724668 
FARP1 0,000730041 
FARP2 2,24E-06 
FARSB 7,42E-06 
FASTKD2 5,15E-05 
FBL 3,42E-05 
FBXL14 0,000232374 
FBXO18 0,001691953 
FBXO22 4,21E-06 
FBXO4 1,92E-05 
FBXW2 4,21E-07 
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FCF1 8,41E-05 
FCHSD2 0,001779789 
FERMT2 4,47E-05 
FFAR1 2,32E-06 
FGD6 6,67E-05 
FGF8 3,46E-06 
FGFR1OP2 3,95E-05 
FILIP1L 0,01328783 
FIP1L1 7,55E-07 
FKBP10 0,001123935 
FKBP15 2,46E-07 
FKBP4 2,03E-06 
FKBP7 0,000210886 
FKBP8 7,53E-05 
FKBP9 0,000547876 
FLT1 0,001195278 
FN1 0,047182143 
FNDC3B 1,14E-05 
FNIP1 1,82E-06 
FOS 0,000248335 
FOXN2 0,000215987 
FOXP1 0,001214978 
FRRS1 4,54E-05 
FSCN1 0,001059919 
FTL 0,000334773 
FUS 5,86E-07 
FUT10 4,41E-09 
FXR1 0,000680238 
G3BP1 1,13E-05 
G3BP2 6,24E-06 
G6PC3 0,000533888 
G6PD 3,60E-05 
 214 
GAB1 0,000857676 
GABARAP 0,000816617 
GAL 0,00023883 
GANAB 1,08E-05 
GARS 0,003299642 
GART 5,59E-06 
GBF1 6,70E-06 
GFI1 7,86E-09 
GFM1 0,000177862 
GGNBP2 9,94E-10 
GHITM 1,22E-05 
GIGYF2 0,000124048 
GIT2 1,12E-06 
GLG1 6,02E-05 
GLI4 1,88E-05 
GLRX3 0,000862385 
GLS 0,000410609 
GNA13 1,71E-05 
GNB1 6,59E-07 
GNB4 0,000219398 
GNG12 0,000136477 
GNS 1,56E-05 
GOLGA8A 9,35E-06 
GOLIM4 4,66E-10 
GOLM1 4,80E-09 
GOSR1 1,48E-08 
GPBP1L1 2,04E-05 
GPNMB 0,001066195 
GPR157 3,08E-08 
GPR89B 7,14E-07 
GPRIN3 7,76E-05 
GRIK2 2,64E-05 
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GRSF1 4,79E-05 
GSK3B 0,002012045 
GSTP1 1,14E-05 
GTF2A1 3,85E-06 
GTF2H1 0,000116505 
GTF2H5 0,00015419 
GTF2I 4,73E-06 
GTF3C3 1,58E-05 
GTPBP10 4,24E-07 
GVQW2 3,06E-07 
H2AFJ 1,17E-05 
H2AFY 4,02E-06 
HAT1 0,000374804 
HBP1 1,43E-05 
HEATR1 1,06E-05 
HEATR5B 7,03E-05 
HECTD1 8,43E-05 
HERC2P3 2,85E-08 
HERC4 1,44E-06 
HERPUD1 0,000106023 
HES1 0,0149001 
HEXA 2,77E-06 
HGSNAT 0,00032737 
HINT1 0,000376959 
HIPK1 8,14E-06 
HIPK3 0,000229609 
HIST1H1E 7,37E-05 
HIST1H2AE 0,000795951 
HIST1H2AL 9,08E-09 
HIST1H2BG 0,000242074 
HIST1H2BH 9,37E-05 
HIST1H2BK 0,000201661 
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HIST1H2BM 2,20E-05 
HIST1H3A 2,35E-05 
HIST1H3F 1,54E-05 
HIST1H3I 2,99E-09 
HIST1H4C 0,003257339 
HIST1H4D 2,53E-05 
HIST1H4E 1,13E-06 
HIST1H4H 0,000492837 
HIST1H4J 1,23E-06 
HIST1H4L 3,08E-05 
HM13 8,79E-08 
HMGA1 0,001444852 
HNRNPC 4,17E-07 
HNRNPDL 0,000346852 
HNRNPF 0,000401397 
HNRNPH3 6,93E-05 
HNRNPK 1,53E-06 
HNRNPM 1,60E-09 
HNRNPR 2,41E-06 
HNRNPUL1 2,39E-05 
HNRNPUL2 1,99E-05 
HOOK3 8,01E-05 
HP1BP3 0,000674336 
HPRT1 3,08E-06 
HSD17B12 5,35E-05 
HSD17B4 3,41E-07 
HSDL2 6,41E-07 
HSP90AB1 6,73E-06 
HSP90B1 0,000970976 
HSPA1B 1,16E-08 
HSPA4 7,39E-05 
HSPA5 1,13E-05 
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HSPA8 3,95E-05 
HSPA9 4,86E-06 
HSPB1 0,000390142 
ICK 8,75E-05 
IDH3G 4,69E-05 
IER3 0,003319151 
IFI16 0,000598898 
IFI44 0,004259609 
IFI44L 0,025343849 
IFIH1 0,004748935 
IFT122 0 
IGF2BP3 2,10E-05 
IGF2R 7,06E-05 
IL6ST 0,000862788 
ILF2 0,000111641 
IMMP2L 2,97E-06 
IMPAD1 0,000505403 
INIP 3,46E-09 
INTS10 1,14E-07 
INTS4 1,21E-05 
INTS6 0 
IPO11 5,35E-06 
IPO7 0,000246227 
IPO9 0,000157437 
IREB2 2,46E-07 
IST1 6,03E-05 
ITFG2 0,000150851 
ITGB1 0,001576931 
ITGBL1 0,001163866 
ITM2B 0,000982523 
ITM2C 0,000372353 
ITSN1 0,00011373 
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IVD 4,39E-06 
IWS1 1,08E-06 
JRK 2,97E-07 
KANSL3 6,78E-05 
KAT6B 7,99E-06 
KCNQ5 0,000153039 
KDM1B 6,34E-09 
KDM5B 9,82E-13 
KDSR 4,37E-05 
KHSRP 6,74E-07 
KIAA0100 0,000142972 
KIAA0513 5,62E-06 
KIAA1109 9,08E-11 
KIF13A 2,59E-06 
KLF12 3,01E-06 
KLF3 0,001495684 
KLHDC3 2,76E-07 
KMT2A 7,15E-05 
KMT2C 0,000178731 
KPNA4 1,55E-06 
KRIT1 0,000192226 
LAMC1 6,05E-05 
LANCL1 0,000305662 
LAPTM4A 2,23E-05 
LARP1 3,46E-05 
LATS1 0,000232988 
LCORL 3,12E-07 
LDB1 0,000149258 
LGALS1 0,007019296 
LGALS3 0,001574969 
LIFR 0,000548809 
LIMS1 1,02E-07 
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LINC00337 4,69E-07 
LINC01521 7,84E-11 
LLPH 8,83E-05 
LMAN1 3,15E-05 
LMAN2 8,62E-06 
LMO7 0,000109636 
LOX 0,004190145 
LPP 0,000533279 
LRCH3 1,80E-05 
LRIG3 0,002610927 
LRP1 9,10E-05 
LRPPRC 0,00025137 
LRRC16A 5,53E-05 
LRRC59 9,19E-08 
LSAMP 0,000952706 
LSG1 0,000121963 
LSM12 0,000165538 
LTBR 4,36E-06 
LUC7L 7,76E-06 
LY6E 0,001282538 
LYST 0,000192725 
M6PR 4,36E-06 
MACF1 0,001309394 
MACROD1 2,59E-06 
MAF 0,000240031 
MAGEA8 1,01E-07 
MAGT1 1,45E-05 
MAN1A2 0,001158233 
MANEA 4,41E-06 
MAP3K11 4,18E-06 
MAP3K2 4,14E-06 
MAPK1 2,41E-05 
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MAPK1IP1L 0,000841234 
MAPKAP1 1,13E-05 
MAPKAPK5 2,40E-06 
MAPRE1 2,66E-07 
MARCKS 0,000250088 
MATR3 0,000613776 
MAX 4,76E-07 
MBNL1 7,99E-05 
MBNL2 0,000444172 
MBTD1 4,18E-05 
MBTPS2 1,33E-05 
MCCC2 7,61E-06 
MCFD2 9,11E-05 
MCL1 1,90E-05 
MCM9 1,26E-05 
MDFIC 0,009698921 
MDM2 1,58E-07 
MDM4 0,000287496 
MECOM 9,89E-05 
MED14 1,06E-09 
MEN1 7,06E-05 
METAP1D 0,00017255 
METTL15 2,79E-05 
METTL2B 7,38E-05 
METTL5 0,000359112 
MEX3C 0,0001424 
MFAP3 2,27E-05 
MFGE8 8,20E-05 
MFN2 1,29E-05 
MGA 1,90E-09 
MGST1 0,002380026 
MINA 0,010669636 
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MIR99AHG 2,40E-06 
MKLN1 8,59E-05 
MKRN2 1,61E-07 
MKX 4,11E-05 
MLF2 0,003780194 
MLLT1 0,000881243 
MLLT3 1,28E-06 
MOCS1 4,11E-05 
MORN1 9,57E-09 
MPDU1 1,73E-07 
MRC2 0,000214708 
MRPS18A 6,94E-05 
MRPS2 0,000139042 
MRPS21 0,000230365 
MRPS27 3,77E-10 
MTA1 2,01E-05 
MTA2 4,53E-08 
MTCH2 8,93E-05 
MTDH 9,91E-05 
MTHFD1L 4,36E-06 
MTHFSD 1,59E-06 
MTMR10 0,000343137 
MYEOV2 0,005095489 
MYL12A 3,35E-05 
MYL9 0,000259406 
MYNN 4,66E-05 
MYSM1 0,000123051 
mar-06 7,59E-05 
mar-07 6,84E-07 
N4BP1 5,26E-05 
N4BP2L2 2,37E-05 
NAA35 2,26E-05 
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NAALADL2 1,56E-05 
NABP1 0,002227939 
NACA2 0,002346033 
NADSYN1 1,92E-07 
NBR1 1,86E-08 
NCBP1 5,63E-08 
NCLN 2,59E-10 
NCOA2 1,12E-08 
NCOA3 9,60E-10 
NCOA7 6,90E-05 
ND6 0,00013798 
NDUFA2 0,000526343 
NDUFA6 0,001123259 
NDUFA7 0,000276175 
NDUFAF5 0,000106489 
NDUFB6 8,39E-05 
NDUFS4 5,37E-05 
NEK1 9,34E-06 
NF2 0,00015984 
NFATC3 1,57E-05 
NFE2L2 1,68E-05 
NFIA 0,007824577 
NFIX 0,00052036 
NFKBIZ 0,001623063 
NFYC 0,000216061 
NID1 0,001540191 
NIFK 0,0001219 
NIN 2,97E-05 
NKTR 8,76E-06 
NLN 6,33E-06 
NOB1 1,16E-07 
NOMO3 2,62E-06 
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NOP10 0,000396168 
NOP56 3,52E-05 
NR2C2 0,000143604 
NRAS 0,000130112 
NREP 0,00285635 
NRG1 0,001249443 
NRP1 0,001624211 
NSF 0,000253998 
NSL1 3,28E-06 
NSMAF 0,00083506 
NSUN4 9,92E-06 
NT5DC2 6,69E-05 
NT5E 0,032188202 
NUB1 0,000459363 
NUCB1 2,52E-06 
NUDT14 3,25E-08 
NUDT21 0,000833342 
NUDT3 7,82E-07 
NUMA1 2,73E-06 
NUMB 0,000208222 
NUP153 5,68E-06 
NUP54 3,13E-06 
NUPR1 0,003987999 
OSBP 2,38E-05 
OSBPL1A 1,25E-05 
OSMR 7,12E-05 
OST4 0,002198127 
OTUD4 0,000267355 
OXSR1 0,000832966 
P4HA2 0,000198762 
P4HB 2,27E-05 
PABPC1 0,00119381 
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PACS1 0,001198644 
PAFAH1B1 0,000632354 
PAFAH1B2 5,04E-05 
PAICS 0,000126887 
PAIP2 8,44E-06 
PALLD 0,014187339 
PAPD4 2,83E-05 
PAPOLA 7,03E-07 
PAPOLG 3,47E-05 
PARP14 0,001874086 
PARVA 2,13E-05 
PCCB 8,25E-12 
PCNX 9,67E-06 
PCNXL4 0,000134835 
PCOLCE 0,002820903 
PCYOX1 0,000129917 
PDCD4 2,79E-05 
PDIA4 3,14E-05 
PDIA6 0,000149287 
PDK1 4,05E-06 
PDLIM5 0,00013448 
PDLIM7 0,000240616 
PDS5B 2,50E-08 
PDXDC1 5,62E-08 
PEA15 0,000788255 
PER3 0,000184695 
PEX2 9,57E-08 
PFDN4 0,00259628 
PFDN6 8,15E-06 
PFKL 0,000397264 
PFN1 0,000261912 
PGD 0,000162226 
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PGK1 1,16E-05 
PGLS 6,21E-05 
PGRMC1 0,00510746 
PGRMC2 0,000213661 
PHAX 0,004089741 
PHC3 0,000801497 
PHF14 0,000141895 
PHF20 0,000811672 
PHF20L1 3,10E-05 
PHF3 2,69E-06 
PHF6 0,000321228 
PHKG2 1,59E-09 
PHLPP1 3,85E-05 
PIAS1 0,000275609 
PICALM 0,000111701 
PIGK 0,000373838 
PIGT 0,000356187 
PIK3C3 5,76E-05 
PIKFYVE 3,70E-08 
PITHD1 0,000243515 
PKD1 0,000148315 
PKM 6,62E-08 
PKN2 2,30E-06 
PLAA 0,001193323 
PLD3 9,64E-05 
PLK1 0,000261445 
PLOD1 3,35E-05 
PLOD2 0,008629701 
PLP2 0,006665136 
PLPP3 0,000684027 
PLXDC2 0,045315209 
PLXNA1 5,75E-05 
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PLXND1 8,78E-05 
PMP22 0,000140697 
PMPCB 4,59E-06 
PMS1 7,00E-06 
PNN 0,000116406 
PNRC1 5,52E-05 
POFUT1 3,62E-09 
POLDIP3 1,50E-09 
POLK 3,19E-06 
POLR1E 0,000743278 
POLR2B 2,21E-05 
POLR2J3 2,28E-05 
POLR2L 0,004460716 
POLR3A 1,59E-05 
POLR3B 1,30E-06 
POLR3H 5,41E-09 
POM121 0,000124816 
POMK 3,02E-06 
PPFIBP1 0,001419712 
PPHLN1 4,75E-06 
PPIB 1,58E-07 
PPP1CA 1,38E-05 
PPP1R11 1,38E-05 
PPP1R7 0,00038389 
PPP2CB 0,000829375 
PPP2R2B 0,000345744 
PPP2R3C 2,33E-06 
PPP2R5A 1,68E-05 
PPP2R5C 0,000128338 
PPP4R3B 1,41E-05 
PPP5C 7,20E-06 
PRCP 2,66E-05 
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PRDX1 1,46E-05 
PRDX2 1,73E-05 
PRIM2 4,06E-05 
PRKAA1 1,13E-06 
PRKAG1 0,000147754 
PRKAR1A 2,24E-05 
PRKCI 0,000405738 
PRKCSH 2,69E-05 
PRKD3 0,000233059 
PRMT1 3,14E-05 
PRR14L 0,000110837 
PRRX1 0,028361829 
PRSS12 0,001856109 
PSAP 0,000218242 
PSEN1 5,20E-06 
PSENEN 0,000840298 
PSIP1 0,00030139 
PSMC2 1,10E-06 
PSMD11 2,29E-05 
PSMD6 4,38E-05 
PSMD8 9,92E-05 
PSMF1 5,46E-05 
PTBP1 0,001592908 
PTBP3 2,05E-06 
PTCH1 0,000101989 
PTK2 6,92E-06 
PTK7 2,89E-05 
PTMS 2,34E-05 
PTP4A1 0,00031864 
PTPN11 6,47E-05 
PTPRG 0,000510779 
PTPRS 1,16E-06 
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PUM3 0,000196043 
PWWP2A 2,31E-05 
PXK 7,58E-05 
QKI 0,000538395 
QPRT 0,009441879 
QSER1 0,001088556 
QTRTD1 8,93E-08 
RAB11B 1,79E-09 
RAB1A 0,000464725 
RAB5A 0,000330183 
RAB5C 0,000311446 
RAB6A 1,70E-07 
RAB7A 0,0001297 
RAB8A 1,66E-07 
RAC1 6,40E-05 
RAD23B 9,02E-05 
RALGAPA1 4,85E-06 
RAN 3,76E-06 
RANBP1 1,23E-05 
RAP1A 0,00025375 
RAP2A 0,000104012 
RAPH1 0,001257664 
RARA 1,68E-07 
RASAL2 9,81E-05 
RASSF8 3,73E-05 
RAVER2 2,72E-07 
RBAK 6,55E-05 
RBL1 2,37E-08 
RBM17 6,56E-05 
RBM18 4,94E-05 
RBM26 0,002414929 
RBM34 5,03E-07 
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RBM8A 3,39E-05 
RBMS3 2,39E-05 
RBMX 6,32E-05 
RBSN 1,23E-06 
RC3H1 1,46E-05 
RCN1 1,13E-05 
RDH11 0,001293247 
RECK 1,11E-06 
REPS1 5,63E-05 
RERE 4,09E-07 
REXO1 4,32E-06 
RFTN1 3,31E-06 
RHNO1 0,004636814 
RHOA 0,001269402 
RHOQ 5,15E-05 
RIC1 4,66E-07 
RIPK2 0,00025959 
RMND5A 0,000367796 
RNF130 0,001221887 
RNF141 1,11E-05 
RNF168 1,09E-06 
RNF180 0,00082573 
RNF216 1,85E-05 
RNF5 2,32E-07 
RNH1 1,80E-05 
ROCK1 0,000368501 
RP2 1,37E-07 
RPARP-AS1 0,000139872 
RPE 2,29E-10 
RPL10 3,70E-06 
RPL11 6,93E-06 
RPL13 6,88E-05 
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RPL3L 4,07E-05 
RPL4 9,49E-05 
RPL5 2,02E-05 
RPLP2 2,50E-05 
RPN1 6,13E-07 
RPN2 0,000406619 
RPRD1A 3,35E-05 
RPS11 1,39E-06 
RPS13 0,000686298 
RPS15 7,88E-05 
RPS19 1,44E-07 
RPS2 6,93E-05 
RPS24 6,72E-05 
RPS28 7,71E-06 
RPS6KB2 9,01E-06 
RPS9 1,52E-06 
RQCD1 4,82E-05 
RRM1 0,002226811 
RSU1 3,87E-06 
RUFY2 9,12E-06 
RUNX1T1 5,29E-05 
RUNX2 0,000654759 
RUVBL2 3,44E-08 
SAE1 7,60E-05 
SAFB 0,000144638 
SAMD4B 3,05E-05 
SAMD5 0,00144421 
SAMHD1 4,61E-05 
SAP18 0,001003216 
SAP30 1,44E-05 
SART3 5,15E-09 
SAXO2 3,74E-07 
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SBNO1 1,69E-05 
SBNO2 7,14E-05 
SCAF11 0,000367103 
SCAF4 9,14E-06 
SCML1 3,59E-05 
SCPEP1 2,46E-06 
SEC22B 0,000397909 
SEC23B 0,000146054 
SEC23IP 3,92E-07 
SEC62 3,35E-05 
SELT 0,000923499 
SEMA3C 0,003391508 
SEMA5A 0,003542697 
SEMA6D 0,00218908 
SERBP1 9,71E-07 
SERINC3 6,45E-05 
SERPINB6 0,000110375 
SERPINE1 0,011419873 
SESN3 3,52E-08 
SF3A2 7,34E-06 
SF3B6 3,25E-05 
SFPQ 0,000834491 
SHC1 0,000346115 
SHISA3 1,21E-06 
SIAE 2,04E-05 
SIKE1 1,57E-08 
SIRT5 2,28E-07 
SKIV2L2 4,84E-05 
SKP1 0,000327406 
SLAIN2 0,000105959 
SLC16A1 3,81E-07 
SLC19A1 3,98E-05 
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SLC25A11 1,17E-05 
SLC2A1 0,001116384 
SLC30A5 2,09E-05 
SLC30A9 0,000277249 
SLC31A1 0,001294061 
SLC35F5 0,000230343 
SLC38A10 1,70E-06 
SLC38A2 0,000126342 
SLC39A14 0,001492749 
SLC39A7 0,000455659 
SLC39A9 6,47E-08 
SLC3A2 2,19E-05 
SLC4A7 0,001163787 
SLC6A9 0,000224285 
SLC7A1 0,001552372 
SLK 6,56E-06 
SMAD4 8,24E-05 
SMAD5 2,62E-05 
SMARCA1 1,33E-06 
SMARCA4 5,16E-05 
SMARCC2 0,000140421 
SMARCD1 6,03E-06 
SMC1A 3,02E-05 
SMC3 2,02E-07 
SMC4 0,003536256 
SMCHD1 0,00025143 
SMG1 0,000195344 
SMIM14 8,71E-05 
SMIM7 1,30E-05 
SMYD2 5,14E-07 
SNAI2 7,07E-05 
SND1 6,15E-07 
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SNRK 1,53E-07 
SNRPB2 2,60E-05 
SNRPN 9,85E-05 
SOCS4 5,02E-05 
SORT1 0,006127788 
SOS1 2,05E-06 
SOX13 7,68E-05 
SOX4 9,29E-06 
SP1 1,96E-05 
SPAG16 2,44E-05 
SPAG9 5,39E-10 
SPARC 3,14E-05 
SPATS2 8,24E-07 
SPATS2L 0,001430214 
SPCS3 1,41E-05 
SPDL1 0,000382169 
SPG11 3,98E-05 
SPICE1 1,03E-05 
SPIN1 4,13E-05 
SPTBN1 0,000160294 
SRC 1,43E-08 
SRD5A3 0,000643027 
SREBF1 0,001021468 
SREK1 0,000148942 
SRGAP1 0,002825332 
SRGAP2 5,31E-05 
SRI 0,000249972 
SRPR 2,64E-05 
SRRM2 5,46E-05 
SRSF1 5,75E-05 
SRSF11 0,00113903 
SRSF6 0,003558389 
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SSB 0,000236685 
SSBP1 3,48E-05 
SSBP2 0,004501609 
SSH2 6,03E-07 
SSR1 0,001272092 
SSR2 9,43E-05 
SSR3 0,000111963 
ST7L 0,000530691 
STAG2 1,22E-06 
STAT1 0,002365171 
STAU2 3,49E-06 
STIM1 1,09E-05 
STMN1 0,000162171 
STOML2 3,29E-05 
STRADA 4,92E-05 
STRAP 0,000202237 
STRN 4,35E-05 
STT3A 4,31E-06 
STT3B 0,000371964 
STX8 0,000214917 
STXBP3 0,000259384 
SULF1 0,044210723 
SUPT20H 2,25E-06 
SUPT6H 1,42E-07 
SUPT7L 0,003729721 
SUZ12 5,81E-05 
SVEP1 7,63E-06 
SYF2 0,00097763 
SYNCRIP 2,68E-05 
SYNRG 2,10E-05 
SYT11 0,000661055 
SYTL2 0,001450259 
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set-07 3,16E-05 
set-09 3,03E-06 
TAB2 6,94E-05 
TAB3 4,77E-07 
TADA3 5,52E-06 
TAF13 0,005877353 
TAF15 7,05E-05 
TAF8 9,08E-06 
TAF9B 0,001637318 
TAOK1 2,28E-05 
TAPT1 4,66E-08 
TBC1D1 1,74E-05 
TBC1D7 7,33E-09 
TBL2 4,25E-05 
TCAIM 2,62E-05 
TCEA1 1,46E-05 
TEAD1 9,71E-05 
TECR 2,20E-07 
TENM3 7,98E-05 
TERF2 2,33E-09 
TEX10 4,97E-05 
TFB2M 0,000161625 
TFDP1 4,60E-05 
TFPI2 0,004573959 
TGFB1 0,000778286 
TGFBR1 0,006983234 
THADA 1,07E-07 
THBS1 0,000921386 
THRAP3 2,57E-06 
TIA1 3,60E-05 
TIMM17B 2,60E-05 
TIMM23 7,05E-05 
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TIMM50 4,10E-06 
TIMP1 0,002080945 
TKTL1 1,05E-06 
TM2D1 6,35E-05 
TM9SF4 0,000120341 
TMBIM4 3,61E-05 
TMED4 0,000168265 
TMED5 5,82E-07 
TMEM109 0,001035154 
TMEM126B 3,42E-05 
TMEM135 0,001674461 
TMEM138 5,78E-06 
TMEM19 0,000172637 
TMEM230 0,000590968 
TMEM30A 0,00218319 
TMEM50A 2,30E-05 
TMEM59 2,70E-05 
TMEM64 0,000174995 
TMSB10 0,000117828 
TMTC3 6,92E-05 
TMTC4 0,000692106 
TMX3 2,01E-05 
TNFRSF10B 5,13E-05 
TNPO1 1,99E-07 
TNPO2 4,82E-06 
TNRC6A 7,50E-06 
TOP1MT 2,32E-06 
TOR1A 6,33E-06 
TOR1AIP1 3,18E-06 
TOR1AIP2 8,10E-06 
TP53 0,000398378 
TPM1 0,020267013 
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TPM4 3,28E-06 
TPMT 4,93E-05 
TPP2 0,000136302 
TPT1 5,03E-05 
TRA2B 9,59E-05 
TRAF3IP2 0,001807614 
TRAM1 6,87E-05 
TRAM2 0,000141472 
TRAPPC1 4,02E-05 
TRAPPC2 3,04E-06 
TRIM16L 0,00043845 
TRIM24 0,000160822 
TRIM25 0,000232479 
TRIM44 5,76E-06 
TRIQK 5,93E-07 
TROVE2 0,000112495 
TSPAN3 2,65E-05 
TSPYL1 2,07E-05 
TTC3 3,93E-05 
TTC37 6,00E-07 
TTC9C 2,76E-06 
TTF2 3,93E-05 
TTLL5 9,01E-10 
TUBA1B 2,84E-06 
TUBB 0,000630172 
TUBG1 1,09E-05 
TUSC3 0,00027249 
TXLNA 1,61E-07 
TXN 0,000571264 
TXNL4A 0,002103734 
TXNRD1 9,44E-06 
TYMS 0,004837732 
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U2AF2 3,65E-05 
UACA 5,63E-05 
UBA1 0,001014754 
UBA3 6,82E-07 
UBA52 8,88E-06 
UBA6 0,000311258 
UBAP2L 7,38E-07 
UBE2H 0,000867514 
UBE2I 2,41E-05 
UBE2W 4,33E-08 
UBE3C 1,45E-06 
UBE4B 3,01E-05 
UBIAD1 8,73E-05 
UBQLN1 2,48E-05 
UBR2 3,61E-05 
UBR4 3,14E-05 
UBXN4 8,13E-07 
UCHL1 0,000584487 
UCHL5 9,33E-06 
UGGT1 5,25E-08 
UGGT2 4,62E-05 
UHMK1 0,000124113 
UHRF1BP1L 0,000405436 
UQCRC2 0,000116579 
URI1 6,77E-08 
USO1 0,000126419 
USP10 4,92E-05 
USP25 4,74E-05 
USP36 2,53E-06 
USP42 5,18E-05 
USP48 1,34E-08 
USP53 7,18E-05 
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USP9X 0,000939577 
USPL1 1,05E-06 
UTP15 0,003370513 
VAPB 3,01E-05 
VCL 1,62E-08 
VCP 0,000125433 
VDAC3 4,49E-06 
VEGFC 0,002026642 
VEZT 4,03E-07 
VGLL3 0,010527075 
VIM 2,03E-05 
VKORC1 0,000236257 
VPS13B 3,28E-11 
VPS29 2,74E-05 
VPS35 1,38E-06 
VPS41 6,01E-06 
VPS45 2,32E-05 
VPS8 4,10E-05 
VRK3 7,27E-09 
VWA9 2,20E-08 
WARS 0,000929962 
WARS2 4,93E-05 
WBSCR16 6,01E-07 
WDR19 0,000480292 
WDR3 3,32E-05 
WDR33 3,21E-08 
WDR43 9,20E-05 
WHSC1L1 1,25E-06 
WIPI2 4,46E-09 
WNK1 7,57E-06 
WNT9B 3,02E-06 
WRNIP1 2,81E-06 
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WSB1 0,002103153 
WTAP 2,21E-05 
XPO4 2,24E-06 
XRN1 2,38E-05 
YBX1 2,35E-05 
YIPF3 9,16E-05 
YTHDF3 7,94E-06 
YWHAE 4,52E-06 
YWHAZ 8,40E-07 
ZAK 0,000248382 
ZBED6 9,20E-06 
ZBTB1 8,32E-06 
ZBTB33 1,88E-05 
ZBTB38 2,38E-05 
ZC2HC1A 0,000529013 
ZC3HAV1L 4,38E-05 
ZCCHC7 2,89E-05 
ZDHHC2 9,82E-06 
ZFC3H1 2,68E-06 
ZFP36L2 6,55E-05 
ZFYVE16 4,07E-07 
ZGRF1 2,10E-09 
ZKSCAN8 1,08E-07 
ZMYND11 2,54E-05 
ZMYND8 5,21E-05 
ZNF100 0,00024536 
ZNF134 1,92E-06 
ZNF138 0 
ZNF17 4,89E-06 
ZNF207 5,41E-05 
ZNF236 1,31E-05 
ZNF24 3,56E-09 
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ZNF254 1,73E-05 
ZNF264 2,40E-13 
ZNF277 2,96E-05 
ZNF283 9,02E-06 
ZNF292 3,98E-07 
ZNF33A 9,56E-10 
ZNF362 1,69E-05 
ZNF37A 0,001314646 
ZNF407 0,001142262 
ZNF417 1,39E-06 
ZNF460 1,25E-09 
ZNF461 7,82E-10 
ZNF507 2,04E-06 
ZNF605 5,12E-09 
ZNF611 1,11E-05 
ZNF639 0,000783434 
ZNF664 0,000356571 
ZNF674 0,000534431 
ZNF740 0,000152483 
ZNF780B 5,78E-08 
ZNF808 2,66E-06 
ZNF814 4,69E-06 
ZNF880 3,77E-06 
 
